Syracuse University

SURFACE
Dissertations - ALL

SURFACE

August 2020

EXPANDING THE POTENTIAL PRENYLOME: PRENYLATION OF
SHORTENED TARGET SUBSTRATES BY FTASE AND
DEVELOPMENT OF FRET-BASED SYSTEM FOR DETECTING
POTENTIALLY “SHUNTED” PROTEINS
Sudhat Ashok
Syracuse University

Follow this and additional works at: https://surface.syr.edu/etd
Part of the Physical Sciences and Mathematics Commons

Recommended Citation
Ashok, Sudhat, "EXPANDING THE POTENTIAL PRENYLOME: PRENYLATION OF SHORTENED TARGET
SUBSTRATES BY FTASE AND DEVELOPMENT OF FRET-BASED SYSTEM FOR DETECTING POTENTIALLY
“SHUNTED” PROTEINS" (2020). Dissertations - ALL. 1185.
https://surface.syr.edu/etd/1185

This Dissertation is brought to you for free and open access by the SURFACE at SURFACE. It has been accepted for
inclusion in Dissertations - ALL by an authorized administrator of SURFACE. For more information, please contact
surface@syr.edu.

ABSTRACT
Protein prenylation is a posttranslational modification involving the attachment of a C15
or C20 isoprenoid group to a cysteine residue near the C-terminus of the target substrate by
protein farnesyltransferase (FTase) or protein geranylgeranyltransferase type I (GGTase-I),
respectively. Both of these protein prenyltransferases recognize a C-terminal "CaaX" sequence in
their protein substrates, but recent studies in yeast- and mammalian-based systems have
demonstrated FTase can also accept sequences that diverge in length from the canonical fouramino acid motif, such as the recently reported five-amino acid C(x)3X motif. In this work, we
further expand the substrate scope of FTase by demonstrating sequence-dependent farnesylation
of shorter three-amino acid "Cxx" C-terminal sequences using both genetic and biochemical
assays. Surprisingly, biochemical assays utilizing purified mammalian FTase and Cxx substrates
reveal prenyl donor promiscuity leading to both farnesylation and geranylgeranylation of these
sequences. The work herein expands the substrate pool of sequences that can be potentially
prenylated, further refines our understanding of substrate recognition by FTase and GGTase-I
and suggests the possibility of a new class of prenylated proteins within proteomes.
To identify potential new Cxx substrates in human proteomes, we explored a FRETbased system using phosphodiesterase delta subunit (PDE) as the acceptor protein for
potentially prenylated Cxx sequences. While not conclusive, this work lays the foundation for an
assay not dependent on membrane localization as a signal for prenylation inside cells and
suggests future studies to improve upon the utility of this assay. Lastly, this work demonstrates
FTase’s flexibility in accepting a prenyl donor analogue with an azobenzene moiety that can be
modulated with light. This establishes a potential new avenue for mediating membrane
localization behavior of prenylated proteins.
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Chapter 1: Introduction

Portions of this chapter including figures have been previously published and are reprinted with
permission from the publisher, reference 104, Blanden, M. J.; Ashok, S. A.; Hougland, J. L.,
Mechanisms of CaaX Protein Processing: Protein Prenylation by FTase and GGTase-I,
Reference Module in Chemistry, Molecular Sciences and Chemical Engineering, Elsevier, 2020.
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1.1 Protein Post-Translational Modifications
The central dogma of molecular biology dictates that each organism’s genetic code
determines its proteome. That is, DNA is transcribed to RNA, and RNA is translated to proteins
that are essential for proper functioning and development of every organism. However, many
organisms have proteomes that are far more diverse and complex than would be simply predicted
from its genome. For example, the human genome is estimated to have 20,000-25,000 open
reading frames while the total number of molecularly distinct protein forms in the human
proteome is estimated to be more than a million.1, 2 These numbers show that a single gene can
code for distinct protein forms. This diversity can be attributed to two phenomena in a cell. First,
at the transcriptional level, use of multiple promoter and termination sites, alternate mRNA
splicing, and/or recombination yields protein variation. Second, protein modifications at the cotranslational and post-translational levels result in distinct forms as well.3
Post-translational modifications (PTMs) refer to covalent chemical modifications of
target proteins, with these modifications influencing protein structure, localization, stability, and
protein-protein interactions.4-7 Protein lipidation is one class of PTMs in which proteins are
altered by attachment of various lipid groups such as fatty acids, isoprenoids, sterols,
phospholipids and glycosylphosphatidylinositol (GPI) anchors.8, 9 While lipidation commonly
serves to enhance protein affinity for cell membranes, this modification has been found to both
facilitate protein-protein interactions and play a role in protein stability.8, 9
Protein lipidation modifications can be broadly classified into two categories: those that
occur in the luminal compartments of the endoplasmic reticulum (ER) and Golgi bodies as part
of secretory pathways, directing the modified proteins to targets outside the cell or the
extracellular face of the plasma membrane; and those that occur on the cytoplasmic face of
2

membranes, targeting the modified proteins to the inner membrane leaflet or membranous
compartments in cells. Glycosylphosphatidylinositol (GPI) anchors and cholesterol attachments
represent the former of the two categories of lipid modifications that occur in the ER and Golgi
lumen (Figure 1.1). The GPI moiety is composed of a phospholipid, sugars, and ethanolamine
and is attached to the C-terminal carboxylate of a protein through its ethanolamine functional
group. This attachment is involved in cell signaling, prion disease pathogenesis, and protein
incorporation into lipid rafts.10-16 Similarly, cholesterol attachment occurs at the C-terminus of
target proteins via an ester linkage.17-21 This modification is predominantly found in the
Hedgehog protein family with the modified proteins playing roles in tissue repair and
regeneration, organ development and stem cell maintenance.17, 22-25
Protein myristoylation, palmitoylation, and prenylation belong to the second class of lipid
modifications that occur on the cytoplasmic face of organelles or in the cytoplasm itself,
targeting the modified proteins to the inner leaflet of the plasma membrane in addition to
facilitating associations with other cellular compartments such as the Golgi, ER, and lipid
vesicles (Figure 1.2).8, 9, 26 Protein myristoylation is the attachment of a 14-carbon myristic acid
moiety to an N-terminal glycine residue on the target protein through an amide linkage. This
modification plays a key role in cellular signaling pathways and is also known to act as a
regulatory switch for proteins’ spatial distribution inside cells.9, 10, 26-33 Palmitoylation usually
involves the reversible addition of a 16-carbon palmitic acid moiety to a cysteine residue via a
thioester bond, however, serine and threonine resides are also found to be palmitoylated on select
proteins.8-10, 34, 35 The reversible nature of this modification via thioester hydrolysis allows
modified proteins to shuttle between a membrane-bound or membrane-unbound state.36-42 This
modification is known to serve important roles in protein-protein interactions, protein trafficking
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and stability.10, 43-50 Lastly, prenylation is the irreversible attachment of a 15-or 20-carbon
isoprenoid chain to a cysteine residue near the C-terminus of a target protein. Prenylation plays
an important role in cell signaling by aiding the localization of modified proteins to the plasma
membrane and protein-protein interactions.51-55

4

Figure 1.1: Types of post-translational lipidations targeting proteins to the extracellular
environment of a cell. A) Glycophosphatidylinositol (GPI) anchors consist of an ethanolamine
group, a sugar chain (D-mannose and D-glucosamine), and a phosphatidylinositol group.
Mannose hydroxyl groups can also consist of various substitutions of long chain fatty acids.13 B)
A protein-cholesterol ester bond.56

5

Figure 1.2: Types of post-translational lipidations targeting proteins to membrane-bound
organelles and/or the inner leaflet of the plasma membrane. Myristoylation forms an amide
bond to the N-terminal amino group of proteins; Palmitoylation occurs on a cysteine residue
through a thioester linkage; Prenylation (farnesylation or geranylgeranylation) involves the
formation of a thioether bond on a cysteine reside near the C-terminus.

6

1.2 Prenylation and its enzymes
Prenylation is a post-translational modification wherein a hydrophobic isoprenoid group,
either a farnesyl or geranylgeranyl group, is transferred to a cysteine residue near the C-terminus
of a target protein.7, 52, 53 This modification is necessary for membrane localization of many
proteins which play important roles in signaling pathways and cellular processes. Prenylation can
be catalyzed by protein farnesyltransferase (FTase) or protein geranylgeranyltransferase type I
(GGTase-I), which differ in amino acid sequence recognition and the isoprenoid substrate to be
attached.52 FTase catalyzes the addition of a 15-carbon isoprenoid group from farnesyl
pyrophosphate (FPP), while GGTase-I catalyzes the addition of a 20-carbon isoprenoid group
from geranylgeranyl pyrophosphate (GGPP, Figure 1.3).7, 52-55 GGTase-II is a third enzyme
responsible for addition of a 20-carbon isoprenoid chain. It requires a Rab escort protein (REP)
for substrate recognition, with REP binding to the substrate to be prenylated and presenting it to
the catalytic site of GGTase-II for prenylation.57 The target sequence for GGTase-II is also
distinct from FTase and GGTase-I, with this enzyme modifying a variety of motifs from the Rab
family of proteins including CC, CXC, CCXX, CCXXX, where C is a cysteine that undergoes
modification.58-61 Recently, a fourth protein prenyltransferase GGTase3 was identified as a novel
human enzyme that modifies a ubiquitin ligase, FBXL2, with a 20-carbon geranylgeranyl
isoprenoid group.62 This discovery expands our appreciation for the potential extent of
prenylation within the proteome.
FTase and GGTase-I are both heterodimeric metalloenzymes comprising of an identical α
subunit with differing  subunits.63, 64 The active site for both enzymes lies at the interface of the
 and  subunits and is mainly composed of residues in the  subunit.65 Both enzymes follow an
ordered sequential mechanism wherein the isoprenoid binds first followed by binding of the
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peptide or protein substrate. A subsequent conformational change in the first two units of the
prenyl donor (FPP or GGPP) brings C1 of the prenyl donor near the cysteine side chain thiol to
be modified.7, 66-70 In FTase, the negatively charged diphosphate group of the isoprenoid is
stabilized during catalysis through interaction with a bound Mg2+ ion (Figure 1.4).70, 71 GGTase-I
does not require a magnesium ion for reaction with GGPP, with lysine 311β partially replacing
the catalytic benefit provided by the magnesium ion in FTase.66, 72 A catalytic Zn2+ ion enhances
peptide substrate binding and activates the cysteine thiol group for nucleophilic attack (Figure
1.4).73 The pKa of the thiol is lowered due to coordination with the Zn2+ resulting in the
formation of a Zn2+-coordinated thiolate anion at physiological pH. This thiolate anion performs
a nucleophilic attack on the alpha carbon of FPP or GGPP to form a thioether bond between the
cysteine residue of the peptide/protein substrate and the lipid.71, 73-75 The modification step of this
reaction is fast and the overall rate of the reaction depends on the slow product release step under
saturating conditions.76, 77 The prenylated product is released upon binding of a new molecule of
the respective prenyl donor followed by a conformation change in the peptide substrate.69, 78-80
FTase and GGTase-I are proposed to recognize their substrates by the presence of a
“CaaX” motif near the C-terminus of proteins. ‘C’ is the cysteine to be prenylated, ‘a’ is any
aliphatic amino acid, and ‘X’ is an amino acid which determines enzyme specificity.63, 77, 81
FTase substrates typically have an X residue of serine, methionine, alanine, or glutamine, while
GGTase-I usually recognizes leucine or phenylalanine at the X residue position. Some substrates
may also be recognized by both enzymes as targets for prenylation.82-85 Recent evidence,
however, from both yeast and mammalian systems supports the expansion of the FTase substrate
pool with the discovery of farnesylated C(x)3X sequences.86 This again highlights the potential
extent of prenylation in proteomes. Following prenylation of the CaaX sequence, a majority of
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prenylated proteins undergo further post-processing steps which are essential for their final
incorporation into the plasma membrane. The first step involves proteolysis of the last three
amino acids by the CaaX protease Rce1p or Ste24p in the endoplasmic reticulum (ER), resulting
in a negatively charged carboxyl group on the C-terminal cysteine which is then methylated by
the S-adenosylmethionine (AdoMet) dependent isoprenylcysteine methyltransferase (ICMT)
(Figure 1.3).87-93 Acting together, these two modifications increase protein hydrophobicity and
lead to localization of prenylated proteins to the cell membrane. Structural and functional studies
suggest that both enzymes process their substrates on the cytoplasmic surface of the ER.91, 94-97 A
crystal structure of human metalloprotease Ste24p showed that the catalytic site lies at the apex
of the enzyme’s membrane-spanning chamber. On the cytoplasmic side of the membrane, a Zn2+
ion is coordinated by His residues from the HEXXH zinc metalloprotease motif (HELGH in
Ste24p), where the Glu residue is predicted to be the catalytic residue that activates the attacking
water molecule based on similarities with other metalloproteases and mutagenesis analysis.98, 99
Moreover, the substrate-binding site was predicted to be between the Zn2+ ion and a  sheet
strand of the metalloprotease, containing hydrophobic pockets proposed to influence enzyme
specificity.99 More recently, a crystal structure of beetle ICMT revealed a breadth of information
regarding the enzyme’s ability to catalyze the reaction between two energectically unfavourable
reactants, AdoMet and prenylcysteine substrates.100 Specifically, ICMT exhibits two distinct
entry routes for the cytosolic AdoMet and ER bound prenylated substrate. The active site was
determined to be on the cytosolic leaflet of the membrane and exhibits a slender tunnel that
brings the methyl group of AdoMet in proximity to prenylcysteine substrate, where the Cterminal carboxylate is stabilized and oriented for attack through hydrogen bonding with
positively charged residues.100 Overall, all three modification steps are deemed necessary for
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function of most prenylated proteins. However, recent reports suggest that certain proteins in
yeast undergo prenylation without subsequent proteolysis or methylation in what has been
deemed the “shunt pathway”, with evidence of these processing steps being deleterious to the
protein’s function.88, 101
While these post-translational modifications increase the hydrophobicity of prenylated
proteins, evidence also suggests that in order for these proteins to associate with the plasma
membrane an additional secondary signal is often required.102, 103 For example, some proteins
contain a poylbasic region upstream of the CaaX site which promotes plasma membrane
localzation via electrostatic interactions with the negatively charged bilayer membrane. Other
proteins require an additional lipid modification such as palmitoylation of residues upstream of
the prenylated cysteine, which further enhances substrate hydrophobicity.
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Figure 1.3: The protein prenylation pathway. The canonical protein prenylation pathway
consists of three modification steps: isoprenoid addition, proteolysis, and carboxymethylation. A
shunt pathway for proteins undergoing only prenylation absent subsequent processing has
recently been reported.104 This figure has been reused with permission from reference 104
(Appendix I).
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Figure 1.4: Transition state for FTase-catalyzed prenylation. The cysteine side chain thiol
coordinates to the catalytic zinc ion, leading to an increase in nucleophilicity due to the lower
pKa of the zinc-coordinated thiolate. The pyrophophate leaving group coordinates to a
magnesium ion, with this interaction enhancing the prenylation rate ~700-fold.104 This figure has
been reused with permission from reference 104 (Appendix I).
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1.3 Structural, biochemical, and computational studies defining substrate selectivity of
FTase and GGTase-I
To understand the biological impact of prenylation, it is important to define the extent
and nature of the prenylated proteome. Numerous studies have aimed to gain insight into the
substrate specificty for prenyl donor and CaaX substrates of prenyltranferases through various
techniques such as structural studies, structure-function studies, peptide library studies and
computational approches.63, 105-110 Studies have also utilized radiolabeling, affinity tagging and
similar techniques to identify prenylated proteins in cells as described below.105, 111-114
Prenylation and the corresponding requirement of a CaaX motif were first described more
than 30 years ago, when yeast mating pheromone a-factor, Ras GTPases, and nuclear lamins
were found to be lipid-modified.115-119 Since their identification, studies of FTase and GGTase-I
have focused on substrate selectivity and their preference for amino acids within the CaaX
motif.120 Several structural studies revealed that FTase and GGTase-I are both heterodimeric
metalloenzymes consisting of an identical  subunit and distinct but homologous  subunits
(Figure 1.5).63, 64, 66, 121 The active site for both enzymes lies at the interface of the  and 
subunits and is predominantly composed of residues in the  subunit. The most obvious
functional difference between FTase and GGTase-I, their respective preferences for FPP and
GGPP as prenyl donor cosubstrates, was readily explained by comparison of their structures in
complex with FPP and GGPP mimics.66, 85, 121 The binding sites for GGPP in GGTase-I and FPP
in FTase are very comparable, constituting a cavity lined with conserved aromatic residues.
However, selectivity of FTase for the shorter FPP substrate is determined by the presence of
bulky tryptophan and tyrosine residues (W102 and Y365) which block binding by the larger
20-carbon GGPP prenyl donor.66 In comparison, GGTase-I has smaller threonine and
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phenylalanine residues at the corresponding positions which allows this enzyme to accommodate
the fourth isoprene unit of GGPP.66 The amino acid contacts responsible for determining
isoprenoid substrate selectivity were further confirmed via targeted mutagenesis of FTase to
enable its use of GGPP as the prenyl donor.122 The FTase isoprenoid preference was converted
by performing single and double mutations of the two bulky residues which contact FPP to their
smaller counterparts in GGTase-I. Interestingly, mutating a single W102 residue in FTase to
threonine was sufficient for efficient catalysis with the longer GGPP prenyl donor. Of note, these
mutations only changed FTase preference for its prenyl donor but did not change the peptide
substrate preference to favor sequences recognized by GGTase-I.122
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Figure 1.5: Structures of mammalian FTase and GGTase-I. Alpha subunits are shown in
blue, with the FTase beta subunit in orange and the GGTase-I beta subunit in red. The catalytic
zinc ions in both structures are depicted as grey spheres. Figure generated from PDB 1D8D
(FTase) and 1TNO (GGTase-I) using Pymol.104 This figure has been reused with permission
from reference 104 (Appendix I).
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In structural studies to identify the enzyme-substrate contacts responsible for FTase and
GGTase-I CaaX peptide substrate selectivity, a series of peptide substrates were co-crystallized
with FTase and GGTase-I. These substrates incorporated a series of different amino acids at the
a1, a2, and X positions to explore the structural determinants governing peptide specificity for
FTase and GGTase-I.85 This study revealed that the various CaaX sequences adopt essentially
the same conformation along one side of the funnel-shaped active site in both prenyltransferases
except for the C-terminal X residue as discussed below. These structures showed the a1 residue
in a solvent-exposed conformation at the interface of the α and β subunits, consistent with the
relaxed selectivity observed at the a1 position in biochemical studies.123-125 Although FTase and
GGTase-I generally exhibit broad amino acid tolerance at the a1 position, the amino acids most
commonly found at this position include V, A, K, and N, with the presence of a polar amino acid
at this position proposed to enhance substrate binding via direct or water-mediated hydrogen
bonding with the enzymes.85
The a2 and X residues, on the contrary, form interactions with enzyme residues within a
solvent-excluded binding pocket. With this restricted location, steric and electrostatic
interactions greatly influence amino acid specificity as compared to the a1 position.82, 84, 85, 126
The a2 binding pocket in FTase, for example, is composed of both the residues of the  subunit
(W102β, W106β, and Y361β) and the third isoprene unit of FPP. Specificity at this position was
therefore proposed to be restricted to nonpolar residues such as I, L, and V. A similar binding
site and specificity prediction is seen in GGTase-I with its analogous T49β, F53β, and L321β
residues.85
Structural studies of FTase enzyme-substrate complexes with peptide substrates bearing
varying amino acids at the C-terminal X position suggest that FTase utilizes two complementary
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binding pockets for the X residue, which defines specificity at this position within the substrate
sequence.85 An X residue of S, Q and M interact with a binding pocket comprised of Y131α,
A98β, S99β, W102β, H149β, A151β and P152β. This differs from substrates terminating in F, L,
H and N that interact with a separate binding pocket comprised of L96β, S99β, W102β, W106β,
A151β, the third isoprene unit of FPP and the a2 residue. GGTase-I differs greatly in its X
residue specificity in that it is composed of one binding pocket which contains the residues T49β,
H121β, A123β, F174β, as well as the fourth isoprene unit of GGPP and the a2 residue of the
peptide substrate. GGTase-I prefers hydrophobic residues such as L, F, I, M and V given this
hydrophobic binding pocket. In comparing the interactions of the a1, a2, and X residues with
FTase and GGTase-I, it is the differences in X residue binding in these two enzymes that largely
give them their varied preference for substrate targets and can allow for predictions of whether a
substrate is more likely to be farnesylated or geranylgeranylated.85
Functional studies utilizing peptide libraries have also proved useful for determining
substrates recognized by FTase and GGTase-I, as well as defining what components of these
substrates engender their recognition. Changes in peptide reactivity are correlated to changes in
amino acid properties such as size or charge thereby, providing insights into the substrate
recognition strategies employed by prenyltransferases. This method is based on monitoring
reactivity of fluorescently tagged short peptides with prenyltransferases.73, 84, 123-130 For example,
several peptide studies use a dansyl fluorophore attached to the N-terminus of the peptide
allowing monitoring of prenylation via fluorescence assays.131 Utilizing the environmentally
sensitive dansyl fluorophore facilitates real-time monitoring of prenylation through fluorescence
enhancement upon cysteine alkylation with the hydrophobic farnesyl or geranylgeranyl groups.
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The availability of high-throughput fluorescence assays has made peptide reactivity
studies amenable for analyzing large peptide libraries.82, 123, 125-127, 132 CaaX peptide libraries have
been employed in multiple studies to examine these effects by varying a1, a2, and X positions on
fluorescent peptides.123, 126, 127 A study by Hartman and co-workers tested the specificity of
prenyltransferases at the ‘X’ position of the substrate by investigating the TKCVIX peptide
library derived from the K-Ras4B sequence TKCVIM.77 This study showed that the specificity
for FTase versus GGTase-I arises from peptide reactivity rather than relative binding affinity and
that the reactivity strongly correlates with the hydrophobicity, volume and structure of the ‘X’
residue. FTase and GGTase-I were found to exhibit contrasting hydrophobicity preferences at the
‘X’ position, with GGTase-I preferring the more hydrophobic ‘X’ residues.77 Krzysiak and coworkers also highlighted the ability for some substrates to undergo both farnesylation and
geranylgeranylation depending on the amino acid at the X position, a phenomenon known as
“leaky prenylation”.84
Study of the a2 position has provided further insight into the structure-function
relationship of prenyltransferases with their substrates.126 In this study, the relative reactivity of a
series of peptides which varied at the a2 position (-GCVa2S and -GCVa2A) revealed that a2
selectivity of FTase substrates depends on both size and hydrophobicity of the residue, with the
enzyme discriminating against polar amino acids and both the largest and the smallest amino
acids at this position. Moreover, this study found evidence for context dependent a2 recognition,
wherein the a2 selectivity was influenced by the ‘X’ residue of the CaaX motif.126 In a
subsequent study, structure-targeted mutagenesis of GGTase-I was applied in combination with a
series of dansyl-peptide substrates to better understand selectivity at the a2 position.127 Mutations
of residues within GGTase-I, predicted to interact with the a2 residue of the substrate, drastically
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change substrate selectivity at the a2 position. In addition, these variant GGTase-I enzymes not
only accept non-natural peptide substrates in which the a2 residue bears a charge, they are able to
retain reactivity with a natural substrate (dns-GCVLL). In comparison to FTase variants with
similarly reengineered substrate selectivities, it is evident that these two enzymes employ
analogous mechanisms for substrate recognition with distinct sets of active site residues. These
biochemical studies support the substrate recognition interactions predicted by structural studies
of FTase and GGTase-I.63, 85
In another study, Hougland and co-workers investigated the FTase substrate selectivity
patterns by analyzing the reactivity of large scale peptide libraries whose sequences were derived
from C-termini of human proteins.123 The peptides from these libraries were screened under both
multiple turnover conditions (MTO, [E] << [S]) and single turnover conditions (STO, [E] >>
[S]). MTO conditions most closely represent the scenario inside the cell where multiple
substrates compete for prenylation by FTase or GGTase-I. From this study, it was found that of
the roughly 300 C-terminal -Cxxx sequences tested, 67% were farnesylated under singleturnover conditions ([E] >> [S]), suggesting that there are peptide sequence-dependent effects
within the FTase catalytic cycle on steps such as the binding of FPP to the enzyme-farnesylated
peptide complex and/or release of the farnesylated product. Moreover, the amino acid
distribution at both the a2 and X positions influences the preference for MTO vs STO reactivity,
with non-canonical amino acids at both positions favoring STO reactivity. This provided insight
into the role played by these positions on substrate binding, chemistry, and product release
during farnesylation. For MTO peptides, specificity occurs before or at the step of farnesylation,
while STO peptides exhibit a rate-limiting step at product release. The discovery that different
substrate classes exist for FTase provides valuable insights into the regulation and reactivity of
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FTase within the cell as well as the development of therapeutics for prenylation-dependent
diseases.
Building upon the structural and biochemical data, several computational approaches
have been developed to enable large scale prediction of prenylated proteins. Maurer-Stroh and
Eisenhaber developed the algorithm PrePS to predict prenyltransferase substrates.109 PrePS is
based on data from experimentally derived recognition motifs to predict the likelihood of new
motifs acting as a substrate for farnesylation or geranylgeranylation. This data resulted in
learning sets which consist of 692 FTase and 486 GGTase-I substrates which were developed
through a series of methods including a search of literature and BLASTP analysis with known
prenylated substrates against an NCBI database. In addition, an 11 amino acid sequence
upstream of the prenylcysteine was added to refine the algorithm. With this refinement of PrePS,
the algorithm expands the rules which predict the prenylation of a substrate to a 15-amino acid
sequence. However, due to the experimentally based nature of the algorithm development, PrePS
has the potential for many false negatives for a given set of motifs with a reported false negative
prediction near 40% when compared to substrates identified in peptide library screenings.108, 123
FlexPepBind is another computational approach for predicting FTase substrates,
developed by London and coworkers in 2011.108 This algorithm predicts peptide binding through
a structure-based modeling approach by aligning different peptide sequences onto a template
peptide-receptor complex. Using the structure of the binding site of FTase, FlexPepBind is a
more powerful tool than PrePS as it is not limited to information based on experimental data and
was able to identify a range of novel potential targets in the human genome. In validation
experiments, authors were able to verify 26 of the 29 tested peptides as being able to bind to
FTase in in vitro assays. In comparison to PrePS, FlexPepBind is predicted to have a 44% true
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positive rate and a 2% false positive rate but eliminates the large number of false negative
predictions seen with PrePS.
A recent statistical analysis of the number of substrates capable of undergoing
prenylation in yeast suggests that many prediction tools are biased against non-canonical motifs
which may undergo prenylation but not the subsequent processing steps of proteolysis and
methylation.133 To remedy this bias, authors used yeast Hsp40 Ydj1p chaperone as a genetic
reporter. Ydj1p is prenylated but is subject to the shunt pathway in which the prenylated protein
does not undergo further processing steps and stays cytosolic. Prenylated Ydj1p produces a
thermotolerant phenotype in yeast which serves as a proxy for the authors to monitor the
prenylation state of Ydj1p given different mutations within the Cxxx motif. Using this genetic
screen, the authors evaluated over 67,000 recombination events, correlating to 93.5% of the
possible amino acid combinations in the Cxxx motif. The sequences found capable of
undergoing prenylation using Ydj1p did not greatly overlap with those found in other screenings
that utilized common targets such as Ras, suggesting a much larger set of motifs capable of
prenylation than was previously thought. This includes a largely unbiased preference at each
position in the motif to accept amino acids that vary in their hydrophobicity, size, and charge. In
contrast to other predictive algorithms, very few sequences identified using the Ydj1p-based
screening were identified as having a high probability of prenylation by FlexPepBind and PrePS
with results of 27% and 7%, respectively. However, it is important to note that this discrepancy
may reflect different substrate selectivities for the mammalian and yeast enzymes.
Many of the techniques used to study prenylation, while useful, examine the prenylation
state of proteins in vitro. Use of fluorescent proteins within cells has been an indispensable
technique in the study of prenylation at endogenous levels, providing better insight into both the

21

biological significance of prenylation and the effects of prenyltransferase inhibitors. The earliest
examples of fluorescent localization studies include immunofluorescence microscopy. One study
investigated the ability of prenyltransferase inhibitors to selectively target oncogenic Ras
isoforms in cancer cells.134 Upon treatment with two FTIs which block Ras protein farnesylation,
cells studied with immunofluorescence of nuclear lamins did not show an impact on lamin ability
to be farnesylated as reflected by proper localization to the nuclear membrane and metabolic
labeling. This work provided some of the first insight into the effect of prenyltransferase
inhibitors at a cellular level to better understand their potential as therapeutics.
Localization studies have evolved over the years to include conjugation of fluorescent
proteins directly to the protein of interest.86, 127, 128, 135-142 In this method, an N-terminal
fluorescent protein is appended to a protein of interest allowing direct visualization of protein
localization. Fluorescence and protein localization at cellular membranes serves as a proxy for
protein prenylation, whereas diffuse fluorescence throughout the cell indicates cytoplasmic
localization. The latter implies a protein either not undergoing prenylation or becoming
prenylated without further processing as noted in the shunt pathway. These fluorescent reporter
proteins have been used to determine the sequence requirements and roles of CaaX
modifications. Early studies into the role of post-prenylation processing include use of these
fusion proteins to observe the effect of proteolysis and methylation on localization of prenylated
proteins. In defining the mammalian Rce1 gene and its role in localization, Young and coworkers
used Rce1+/+ and Rce1-/- fibroblast cells transfected with a fusion protein containing green
fluorescent protein and mouse Ki-Ras. Fluorescence was localized to the plasma membrane in
Rce1+/+ cells but diffuse in Rce1-/- cells, identifying proteolysis as necessary for Ras localization
and introducing a new target for potential inhibitors.138
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A study in 2008 by Der et al. supported the requirement of proteolysis and methylation of
Rho proteins following prenylation in determining cellular localization and protein function.139
With green fluorescent protein cloned to several Rho proteins and grown in both wild-type cells
and cells lacking either Rce1 (Rce1–/–) or ICMT (Icmt–/–), it was found that sensitivity to Rce1p
and ICMT differed between Rho proteins. RhoB appeared to be more sensitive to loss of Rce1p,
while RhoA was more dependent on ICMT as evidenced by the loss of fluorescent protein at the
cell membrane.
Prenylated reporter protein cellular localization has also been employed to define the
intrinsic reactivity required for a given FTase substrate sequence to be prenylated within a
mammalian cell.128 Development of a fluorescent reporter fusion protein terminating in Cterminal CaaX sequences with known levels of reactivity with FTase allowed for a calibrated
sensor for protein farnesylation, with membrane localization indicating modification of the
reporter protein. This study showed that in addition to the intrinsic reactivity of the reporter
protein with FTase, the expression level of the reporter played a role in the extent of
farnesylation of the reporter protein pool within the cell. This finding strongly suggested that
results from overexpression studies of FTase substrates must be interpreted critically. Further,
analysis of these panels of reactivity-defined reporter proteins provided the first cell-based
quantitative measurements of FTase activity and provided potential reactivity thresholds for
biologically relevant FTase substrates.
Another method for facilitating the detection of prenylated proteins is direct in vivo
determination. The first approaches towards defining protein prenyltransferase selectivity
included studies using radiolabeled 3H FPP and GGPP for protein labeling, as well as
radiolabeled precursors of these prenyl donors.112, 143, 144 In these studies, cells were grown in the
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presence of these radiolabeled donors with subsequent 3H incorporation into proteins
endogenously prenylated in cells. This method was limited in its ability to provide a high yield of
labeled protein against competing endogenous FPP or GGPP and in the limitation of pulling
down the target protein from cells. While antibodies have been developed to aid in the selection
of prenylated proteins from cells, they are unable to discriminate prenylation from other lipid
posttranslational modifications.145
Improvements upon this approach have centered around development of FPP and GGPP
analogs that are functionalized with immunogenic tags, affinity tags or tags for chemoselective
biorthogonal labeling (Figure 1.6). For example, Spielmann and co-workers showed the
application of an immunogenic tag by using anilinogeraniol (AGOH) to detect FTase
substrates.146 Anilinogeraniol is an analog of an upstream precursor of FPP. It is converted to 8anilinogeranyl diphosphate (AGPP) in vivo and replaces the third isoprene unit of FPP with an
aniline moeity that then serves as an epitope for detection by Western blot.146, 147 Further,
Alexandrov and co-workers developed biotin-geranyl diphosphate (BGPP) for use as an affinity
tag.148 BGPP only allowed for the efficient identification of GGTase-II substrates as the bulky
nature of the biotin group was found to interfere with the protein substrate binding for FTase and
GGTase-I. Reengineered FTase and GGTase-I variants that were capable of utilizing BGPP as a
donor for protein modification were developed. Cell lysates were incubated with BGPP and
wild-type or mutant prenyltransferases, with biotin-tagged proteins being subsequently pulled
down using streptavidin beads and identified via mass spectrometry. This resulted in the
identification of many Rab proteins as GGTase-II substrates, as well as various substrates which
were identified from the lysates containing engineered FTase and GGTase-I.148
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Recently, new alkyne-tagged isoprenoid analogues which closely mimic FPP and GGPP
have been used for direct detection of prenylated proteins via mass spectrometry.149 These
analogues not only allow for identification and quantification of prenyltransferase targets, they
are able to maintain their transferase specificity and allow for a proteome-scale investigation of
prenylated proteins at endogenous levels. Upon addition of the alkyne tagged analogue, proteins
are captured via click CuAAC ligation to azide-containing reagents which have been
functionalized with fluorophores or affinity tags such as biotin. These functionalizations allow
for enrichment of the prenylated proteins and subsequent analysis via LC-MS/MS. In this study,
proteins were identified at various stages of post-prenylation processing including ones in which
cleavage of -aaX residues occurred but the protein (or the C-terminus) did not undergo
subsequent methylation. The analogues also proved useful in determining the effects of
prenyltransferase inhibitors (PTIs) across the prenylated proteome thus, providing a new avenue
into the design of therapeutics that target prenylation specific diseases.
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Figure 1.6: Selected FPP and GGPP analogues utilized for prenylated protein labeling and
identification.104 This figure has been reused with permission from reference 104 (Appendix I).
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Overall, these analogues have enabled high-throughput identification of several FTase
and GGTase-I substrates including members of the Ras, Rho, Rac, Rheb, Rab protein family
members that were known to be prenylated.150-153 However, this approach also has certain
limitations. Specifically, the use of FPP and GGPP analogues may alter the protein substrate
specificity since the isoprenoid forms a part of the protein substrate binding pocket.154-156
Further, the use of mutant enzymes with certain analogues may not reflect the behavior of the
wild type enzyme.122 Lastly, analogues used in several studies failed to identify known
prenylated proteins, reflecting inefficient incorporation of the analog into substrates because of
competition with endogenous prenyl donors.148 In light of the limitations associated with
chemical analogues and recent observations in yeast suggesting the prenylation of non-canonical
C(x)3X and Cxx motifs in the context of a heat-shock protein, Ydj1p (see chapter 2), it is
important that we expand our approaches for the identification of potential prenyltransferase
substrates.
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1.4 Biological significance of prenylation
Prenylation plays an important role in signal transduction, control of cell differentiation
and proliferation, cell survival and death, and cell migration.157-161 This post-translational
modification has been implicated in numerous diseases, with cancer receiving the most attention.
The well-known GTPases H-Ras, N-Ras, K-Ras4 and N-Ras are involved in signal transduction
and cell growth and have known oncogenic forms that are in an “always active” form, causing
over-proliferation of cells.162-168 Prenylation is also not only crucial for plasma membrane
localization and normal biological function of Ras proteins, but also for the transformation of
cells by oncogenic Ras.60, 169, 170 Therefore, targeting Ras prenylation for mitigating oncogenesis
has been of great interest.
Proteins beyond Ras family members have also been of interest in studying the role of
prenylation in cancer. Certain members of the Rap family of proteins are implicated in
tumorigenesis. For example, mutational activation of Rap1A signaling is associated with
myeloproliferative disorder, a type of cancer involving aberrant development of blood cells.
Abnormal Rap1 activity has also been linked to prostate cancer and osteosarcoma,171-174 while
Rap2B protein has been reported to promote invasion, proliferation and migration in breast
cancer.171 The Rho proteins which are predominantly geranylgeranylated are involved in
regulation of actin cytoskeleton. Both RhoA and RhoB play a role in actin stress fibers and focal
adhesions formation.175-178 CDC42 is associated with control of cell cycle, cell polarity, and
filopodia formation. And Rac is involved in the regulation of lamellipodia and membrane ruffles,
which are motile cell surface formations that are crucial for cell motility.179, 180 Several of these
Rho proteins have been linked to angiogenesis and metastasis.181-183
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With prenylation heavily implicated in cancer and tumor growth as described, several
farnesyltransferase inhibitors (FTI) and geranylgeranyltransferase inhibitors (GGTI) have been
explored as potential therapeutics.184-187 Despite the wide range of developed FTIs and GGTIs,
all have shown limited success at the clinical level for treating cancer.184, 188-190 The low level of
effectiveness for these inhibitors in cells and human patients stems from the observation that
there is no correlation between inhibition of tumor growth and the mutations of Ras. While Ras
is mutated and involved in cancer, the efficacy of these prenyltransferase inhibitors potentially
lies in their ability to inhibit both prenyltransferases.191, 192 For example, K-Ras and N-Ras have
been found to undergo geranylgeranylation when subjected to FTI treatment.193 This realization
highlights the importance of identifying other proteins that undergo prenylation in order to
design new, better therapeutic inhibitors or improve upon previously developed ones.
Protein prenylation of prelamin A has also been implicated in Hutchinson-Gilford
progeria syndrome (HGPS). HGPS is a rare genetic disorder that manifests with reduced weight
gain, loss of body fat, alopecia, and a variety of bone and dental abnormalities resulting in
premature aging and death caused by myocardial infarction or stroke during teenage years.194
Following prenylation and subsequent CaaX proteolysis, the final step in lamin maturation
involves cleavage of the C-terminal 15 amino acid peptide by the endoprotease ZMPSTE24.195197

However, in HGPS, the ZMPSTE24 cleavage site is lost due to alternative splicing of the

prelamin A transcript due to a point mutation in LMNA, resulting in an in-frame deletion of 50
amino acids.198, 199 Consequently, the farnesylated and carboxymethylated prelamin A
accumulate on the nuclear envelope leading to misshapen cell nuclei and ultimately to the
phenotypic manifestations of HGPS. Several clinical trials for the use of FTIs as therapeutic
agents were initiated after promising results in cells and mice.200-203 The use of FTIs such as
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lonafarnib, pravastatin, and zoledronic acid increased life expectancy for children with progeria
and improved their quality of life through measurement of weight gain and arterial density.204-207
Moreover, FTI treatment was also shown to decrease neurological symptoms such as seizures
and headaches in one study, which are common comorbidities in HGPS patients.208 It is
important to note however, that while FTIs proved useful in managing progeria symptoms and
helped prolong life, they do not represent a cure for the disease. Investigations are focusing on
gene therapy through stem cells and CRISPR-Cas9 gene editing as a potential avenue for curing
patients who suffer from HGPS.209
Prenylation is also involved in infectious diseases. More specifically, Legionella
pneumophila, a gram-negative pathogenic bacterium that causes Legionnaires’ disease, was
found to encode proteins that undergo prenylation.210-212 This bacterium employs a Dot/Icm
secretion system where it introduces numerous effectors that modulate and allow for bacterial
proliferation as well as induce host cell apoptosis.213-215 The F-box effector Ankyrin B (AnkB)
protein is one such vital effector that enables bacterial proliferation. It was shown that
prenylation of this effector protein by the host’s prenylation machinery is essential for anchoring
the protein to the LCV membrane. This supports prenyltransferase inhibitors as attractive
therapeutic agents to pursue for the treatment of Legionnaires’ disease.212
Candida albicans is a yeast organism where the role of prenylation has been studied to
gain a better understanding of the etiology of various types of yeast infections.216, 217 A genetic
study by Song and coworkers reported that RAM2, a gene that encodes the common alphasubunit of both FTase and GGTase-I, is essential for C. albicans survival, suggesting that protein
prenylation is an essential modification in the development of this organism.218 Indeed, genetic
and pharmacological interventions that target the C. albicans GGTase-I resulted in a
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morphologically abnormal phenotype. However, this treatment failed to inhibit yeast growth,
most likely due to the cross-reactivity with FTase.217
There has also been much interest in the prenylated proteome of the protozoan parasite,
Plasmodium falciparum, which causes malaria. Studies show that P.falciparum exhibits protein
prenyltransferase activity and can incorporate both farnesyl and geranylgeranyl moieties onto
protein substrates.219-221 Howe and coworkers noted that inhibition of isoprenoid biosynthesis by
chemical treatment blocks protein prenylation and is lethal to cultured P.falciparum, suggesting a
critical role for prenylation in this parasite’s growth.222 Other studies report that parasite
prenyltransferase activity inhibition blocks parasite replication.223-225 Taken together, these
studies demonstrate the essential nature of prenylation for parasitic growth and provide an
alternative potential avenue for the treatment of malaria as drug resistance to current
antimalarials develops.226, 227
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1.5 Importance and objectives
As discussed, prenylation serves as an important post-translational modification step for
the proper functioning of several proteins that are implicated in many diseases. With over 1166
proteins estimated to contain a CaaX motif in the human proteome, gaining a more
comprehensive picture of the prenylome represents a key step in understanding the roles played
by prenylation in protein maturation and disease. While current investigations into the prenylome
have limited their scope of investigation into the four amino acid C-terminal CaaX motif, recent
evidence for prenylation of non-canonical C(x)3X sequences in yeast and mammalian systems
calls for the expansion of the classically recognized prenylation motif.86
This work aims to further expand the substrate selectivity of FTase by presenting
evidence for the prenylation of a new motif, Cxx, by both yeast and mammalian enzymes
through yeast genetic screening and biochemical characterization at the peptide and protein level.
In addition to sequences identified from yeast genetic screening, a library of potential Cxx
prenylation motifs was generated and tested for activity with mammalian FTase. In addition,
studies were performed to assess the viability of FPP analogues with azo-benzene moieties that
can be modulated with light as potential FTase donor substrates. In the last data chapter, efforts
to develop a FRET-based system using phosphodiesterase delta subunit (PDE) as the acceptor
protein for potentially prenylated Cxx sequences are presented. The main objective of this work
is to characterize, identify, and expand upon the list of proteins that can be potentially prenylated
in both in vitro and cellular contexts using a Cxx C-terminal motif.
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Chapter 2: Investigation of shortened “Cxx” target sequence
recognition by FTase and GGTase-I

Portions of this chapter including figures and experimental results have been published and
reprinted with permission from the publisher, reference 44, Ashok, S.; Hildebrandt, E. R.; Ruiz,
C. S.; Hardgrove, D. S.; Coreno, D. W.; Schmidt, W. K.; Hougland, J. L., Protein
farnesyltransferase catalyzes unanticipated farnesylation and geranylgeranylation of shortened
target sequences. Biochemistry 2020, 59 (11), 1149-1162. Copyright (2020) American Chemical
Society.
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2.1 Introduction
Protein lipidation is a posttranslational modification (PTM) that plays an essential role in
the proper biological function of many proteins including protein trafficking and protein-protein
interactions.1-9 Prenylation is one such modification wherein proteins are modified by the
covalent attachment of an isoprenoid group to a cysteine residue near the C-terminus of the
substrate protein. FTase catalyzes cysteine alkylation with a 15-carbon (C15) farnesyl group
from farnesyl diphosphate (FPP) (Scheme 2.1), whereas GGTase-I performs this reaction with a
20-carbon (C20) geranylgeranyl group.2-6, 9 Prenylation augments the hydrophobicity of modified
proteins, which can influence membrane association and/or protein-protein interactions that are
essential to the biological function of many prenylated proteins.7, 8, 10-12
Following prenylation of the cysteine residue, many prenylated proteins undergo two
additional processing steps.13, 14 Proteolytic removal of the amino acids C-terminal to the
prenylcysteine is performed by the Rce1p or Ste24p proteases, and the C-terminal prenylcysteine
is subsequently methylated by isoprenylcysteine carboxyl methyltransferase (ICMT). These
additional post-prenylation modifications are vital for the proper function of many prenylated
proteins.14-17 These additional modifications are not, however, necessarily coupled to prenylation
as has been commonly accepted. For example, farnesylation of yeast Ydj1p HSP40 occurs
without proteolysis or methylation.18, 19 While farnesylation is required for optimal Ydj1p
function, proteolysis and carboxymethylation are detrimental to Ydj1p’s role. Continuing studies
indicate that the protein prenylation pathway is more complex than originally proposed.
The ‘CaaX’ motif has served as the defining paradigm for substrate selectivity for FTase
and GGTase-I for three decades, beginning with the discoveries of prenylation in the context of
yeast mating factors, Ras GTPases, and nuclear lamins.20-30 This sequence consists of an
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invariant cysteine residue that is alkylated on its side-chain thiol, two amino acids commonly
described to be aliphatic, and an X residue that can vary and influences peptide reactivity with
FTase versus GGTase-I.25, 26, 31 The expanding number of known prenylated proteins stimulated
biochemical, cell-based, and structural examinations of substrate determinants for selectivity by
FTase and/or GGTase-I, which defined rules governing selectivity at each amino acid position
within the CaaX motif.4, 26, 29, 32-37 Structural studies provided a needed framework for
understanding FTase and GGTase-I substrate selectivity by revealing specific molecular
interactions involved in recognizing both the CaaX substrate sequence and the FPP and GGPP
prenyl donor cosubstrates.25, 26, 38, 39 Studies guided by FTase and GGTase-I structural models
have allowed for efficient reengineering of both peptide and prenyl donor selectivity, reinforcing
the importance of the interactions observed in these models for enzyme-substrate recognition.36,
40, 41

More recently, bioinformatics and computational/docking approaches have facilitated

prediction of CaaX motifs as likely FTase and/or GGTase-I substrates.27, 28, 30, 42
Expanding upon the well-established ability of protein prenyltransferases to recognize
and modify CaaX sequences, recent work supports the ability of FTase to modify cysteine
residues in other sequence contexts. Both yeast and mammalian FTase can accept longer five
amino acid ‘C(x)3X’sequences as substrates.6 We now show that both yeast and mammalian
FTase can prenylate shorter three-amino acid Cxx sequences. We demonstrate that yeast FTase
can modify Cxx sequences in vivo in the context of Ydj1p Hsp40 while mammalian FTase can
modify Cxx reporter peptides in vitro. Surprisingly, we found that mammalian FTase can accept
both FPP and GGPP as the prenyl donor cosubstrate for modification of certain Cxx substrate
sequences in the first reported example of wild type FTase catalyzing peptide
geranylgeranylation with comparable efficiency to farnesylation.43 This new class of FTase
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substrates and the potential for their promiscuous modification with farnesyl and geranylgeranyl
groups increases the complexity of protein prenylation, expanding the potential range of
prenylation within proteomes and the roles played by these prenylated proteins in biological
systems.
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Scheme 2.1. The protein farnesylation and processing pathway. FTase catalyzes the covalent
attachment of a 15-carbon farnesyl group to proteins terminating in CaaX (n=2) or C(x)3X (n=3)
sequences, with subsequent proteolytic and carboxymethylation steps required for many but not
all farnesylated proteins. Modification of CaaX (n=2) sequences is well-documented in various
organisms; modification of C(x)3X sequences (n=3) has not yet been verified for a naturally
occurring protein but has been demonstrated using an in vivo reporter. This figure has been
reused with permission from reference 44 (Appendix II).

67

2.2 Genetic screening in yeast reveals prenylation of Cxx sequences can occur in vivo
Note: This data was collected and analyzed by our collaborator Walter K. Schmidt (University
of Georgia).
Our research group recently reported that pentapeptide C(x)3X sequences can support
prenylation of yeast genetic reporters based on the a-factor mating pheromone and Ydj1p Hsp40
chaperone.6 Using these same reporters and complementary selection screens, our studies show
that certain tripeptide Cxx sequences are also recognized and modified by yeast FTase in vivo.
The biological activity of the yeast a-factor mating pheromone normally depends on
farnesylation, proteolysis, and carboxylmethylation of the CVIA CaaX motif associated with its
precursor. To explore whether shorter sequences could be similarly modified, a genetic selection
scheme using a plasmid library of a-factor-Cxx variants was examined. Using MATa mfa1 mfa2
yeast that cannot make a-factor on their own, the plasmid-encoding a-factor mutants were
introduced, and the a-factor halo assay was performed. In this assay, MATa cells are either
spotted or replica printed onto a thin lawn of MAT sst2-1 yeast that are super sensitive to afactor mating pheromone. The release of a-factor by MATa cells results in a zone of MAT cell
growth inhibition (i.e. halo) surrounding the MATa cells. We pursued a yeast mating approach
(i.e. positive selection) over the halo assay approach (i.e. screening) for easier identification of afactor producing colonies.
Out of ~8,100 colonies screened; 45 diploid colonies were identified. The corresponding
haploid parents were recovered from the replica master and scored for their a-factor production
phenotype using the halo assay. A subset of 19 colonies having the strongest halo production was
identified and associated plasmids were recovered and sequenced.44 A reduced set of 10 plasmids
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represented the unique Cxx sequences after eliminating duplicate sequences (i.e. CII, CTI, and
CVI). We estimate that ~99% of Cxx sequence space was evaluated during the selection strategy
(see the Materials and Methods for description of coverage estimate). The plasmids were
retransformed into MATa mfa1 mfa2 yeast and retested for the ability to confer a-factor
production using the halo assay (Figure 2.1a). The halos formed with Cxx sequences were
similar in size to each other and all smaller than that associated with wild type a-factor (CVIA),
implying overall less a-factor production was associated with this wide variety of Cxx
sequences. Of note, the a-factor halo assay is an extremely sensitive and qualitative method for
measuring a-factor production that quickly saturates at low levels of pheromone.18
A quantitative mating assay of a-factor production revealed that Cxx sequences were far
less effective at promoting mating than wild type a-factor (Figure 2.1b); similar results were
previously observed with longer C(x)3X sequences.6 Nonetheless, mating for Cxx sequences was
reproducible and higher than that observed for unprenylated a-factor variants (i.e. a-factor-C, CV, -AVI, and -SVI) for which no mating was ever observed. Following mating analysis, we
assessed whether increased expression of genes associated with a-factor production could
improve mating of a-factor-CVI (Figure 2.1c). While over-expressed RAM1 (FTase  subunit)
and STE24 (protease) had comparable levels of mating to the vector control, over-expressed
RCE1 (CaaX protease) improved mating, suggesting that proteolysis of CVI by Rce1p may be
limiting for production of a-factor in this instance.
By comparison to the a-factor reporter, the Hsp40 Ydj1p only requires farnesylation of its
CASQ CaaX motif to support its role in yeast thermotolerance. It does not undergo CaaX
proteolysis and carboxymethylation, which are detrimental to its function.6, 18, 19, 45 Ydj1p thus
served as a more direct reporter for farnesylation of Cxx sequences. A plasmid library of Ydj1p
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Cxx mutants was transformed into ydj1∆ yeast in order to identify thermotolerant colonies .6 Out
of ~1,200 colonies screened, 13 thermotolerant colonies were identified. The associated plasmids
were recovered and sequenced. A reduced set of 10 plasmids represented the unique sequences
after eliminating duplicate sequences (CAL, CEV, and CLL). We estimate that ~82% of Cxx
sequences were evaluated during the screen (see the Materials and Methods for description of
coverage estimate). The ability of these Cxx sequences to support prenylation was confirmed
using a thermotolerance assay (Figure 2.2a). Moreover, several Cxx sequences identified in the
a-factor halo assays were transferred onto Ydj1p and evaluated (i.e. CTI, CII, CFV and CVI).
The growth observed for all mutants was qualitatively better than that observed for a nonprenylated Ydj1p mutants that fail to grow at 40 °C (i.e. AVI and SVI). Most test sequences
exhibited a thermotolerance phenotype like that observed for wildtype Ydj1p (CASQ) that is
prenylated but uncleaved, while a few displayed an intermediate phenotype similar to that
observed for a prenylated and cleaved Ydj1p mutant (CTLM).
In addition to the thermotolerance phenotypic manifestations, prenylation of Ydj1p
affects its mobility in SDS-PAGE counterintuitively such that the farnesylated protein has
increased mobility (i.e. smaller apparent kDa) relative to unprenylated. The latter can be
produced by expression in a FTase-deficient yeast strain (i.e. ram1). All the Ydj1p Cxx hits
exhibited prenylation, albeit partially in most cases (Figure 2.2b). Importantly, Ydj1p-AVI and SVI variants were neither thermotolerant nor displayed a gel-shift, implying lack of prenylation
and consistent with results derived using a-factor-AVI and -SVI. To confirm that observed gelshift phenotypes were not due to plasmid-based overexpression of the Ydj1p reporter, each Cxx
hit was subsequently integrated into the genome as the sole copy of Ydj1p and gel-shift
reassessed; thermotolerance was also assessed. More complete prenylation of Ydj1p-Cxx
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variants was quantifiably observed, with several displaying complete modification (Figures
2.2b). The Cxx sequences recovered with the a-factor reporter (i.e. CTI, CII, CFV and CVI)
were generally prenylated to a higher extent than those directly recovered with the Ydj1p
reporter as assessed by gel-shift, while two displayed weaker thermotolerance (i.e. CFV and
CVI). These results are consistent with the hypothesis that a-factor-derived sequences are likely
more extensively modified after initial prenylation (i.e. cleaved and carboxylmethylated), which
is known to diminish Ydj1p-based thermotolerance.18, 19 Overall, complete or near complete
prenylation of Cxx sequences in the context of Ydj1p supports the possibility that such
sequences may be modified when in a natural protein context.
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Figure 2.1. Phenotypes of a-factor Cxx variants. a) The spot halo assay is a highly sensitive
and qualitative measure of a-factor production. SM2331 (MATa mfa1 mfa2) was transformed
with plasmids encoding a-factor mutants or vector (CEN LEU2), resultant strains cultured as
spots on YPD for 48 hours at 30 °C, and spots replica transferred onto a thin lawn of RC757
(MATa sst2-1). A zone of growth inhibition (i.e. halo) indicates pheromone production. b) The
mating assay is used for relative measures of a-factor production. The MATa strains described in
panel a) were tested in combination with IH1793 (MAT lys1). All values are relative to diploid
production (i.e. mating events) observed with MATa yeast expressing wildtype a-factor (CVIA;
set to 100% mating efficiency). Mating values were determined from two experiments in which
each sample was minimally evaluated in duplicate. c) The mating efficiencies for a-factor-CVI
were determined as described in panel b) under conditions where the indicated CaaX modifying
enzyme was overexpressed via a 2µ plasmid. All values are relative to diploid production (i.e.
mating events) observed with an empty vector 2µ plasmid. Values represent the average of three
biological replicates. RCE1 encodes the Ras Converting Enzyme 1 (Rce1p) CaaX protease.
STE24 encodes Sterile Protein 24 (Ste24p). Both Rce1p and Ste24p can cleave the a-factor CaaX
motif. RAM1 encodes the FTase  subunit, whose overexpression improves FTase activity in
some yeast strains.46 This figure has been reused with permission from reference 44 (Appendix
II). This data was collected and analyzed by our collaborator Walter K. Schmidt (University of
Georgia).
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Figure 2.2. Phenotypes and isoprenylation status of Ydj1p Cxx variants. a) The indicated
Ydj1p Cxx variants were transformed into the yWS2544 (ydj1::NATR) strain background and
assessed for farnesyl-dependent biological activity using a thermotolerance assay. At 37 °C,
yeast cannot grow in the absence of Ydj1p (i.e. vector). At 40 °C, yeast cannot grow in the
absence of farnesylated Ydj1p (i.e. AVI and SVI), and shunted Ydj1p (i.e. CASQ) supports
better growth than cleaved and carboxylmethylated Ydj1p (i.e. CTLM); shunted refers to
sequences that are farnesylated but not additionally modified (see Scheme 1). Each set of spots
represents a 10-fold dilution series derived from a saturated culture initially grown in selective
media. b) The mobility shift assay assesses the prenylation level of each Ydj1p Cxx variant. It
relies on the observation that unmodified and farnesylated Ydj1p can be separated by SDSPAGE, with the farnesylated species exhibiting a counterintuitive smaller apparent molecular
mass relative to unmodified. Whole cell extracts were prepared as two sets then analyzed by
SDS-PAGE and anti-Ydj1p immunoblot. One set was prepared from yWS2544 and yWS2542
(ram1::KANR ydj1::NATR) strain backgrounds that were transformed with the same plasmids
used for thermotolerance testing; see panel a); RAM1 encodes the FTase  subunit, and its
absence eliminates endogenous FTase activity. Bands associated with the yWS2544 extracts
shown in panel b) were quantified using ImageJ, and these values were used to plot the percent
modification for each Cxx sequence (black bars, single biological replicate). ND – not
determined; A – Cxx sequences initially identified using a-factor reporter and subsequently
transferred onto Ydj1p; B – Cxx sequences directly identified using Ydj1p reporter. This figure
has been reused with permission from reference 44 (Appendix II). This data was collected and
analyzed b your collaborator Walter K. Schmidt (University of Georgia).
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2.3 Farnesylation of Cxx peptide substrates by mammalian prenyltransferases
Yeast and mammalian FTase orthologs have been shown to exhibit non-identical but
largely overlapping peptide selectivities.47 Accordingly, the ability of purified mammalian FTase
and GGTase-I to prenylate Cxx sequences was determined in the context of fluorescently labeled
synthetic peptides (i.e. dns-GCxx). To supplement the 10 Cxx sequences selected from those
identified as prenylation substrates by genetic screening (see Figures 2.1 and 2.2), a peptide
panel of Cxx sequences derived from the human proteome was constructed. A Prosite database
scan revealed 1074 human proteins with C-terminal Cxx sequences, with 847 of these not
contained within longer CaaX or C(x)3X sequences or associated with CC or CxC sequences that
can serve as Rab GGTase-II substrates (Table 2.1).48 From this pool, 75 candidate Cxx
sequences were selected for detailed analysis based on the requirements of annotated membrane
localization of the parent protein; conservation of the cysteine in at least two other species;
evidence of protein expression; and lack of any predicted transmembrane helices (Table 2.2).
This list of human-derived sequences included 12 sequences that were identified by genetic
screening in yeast.
The panel of 85 dns-GCxx peptides were screened for prenylation activity with rat FTase
and GGTase-I using RP-HPLC to directly detect the prenylated product.6 Farnesylation of 64 of
the 85 peptide sequences was confirmed, with the extent of peptide farnesylation following
overnight incubation (~16 hours) varying across these 64 sequences and 26 peptides reacting to
completion (Table 2.3 and Figure 2.3). The varying reactivity of these Cxx peptides suggests that
FTase exhibits sequence selectivity with these truncated prenylation motifs rather than
recognizing the cysteine thiol sidechain alone. In contrast to FTase, peptide geranylgeranylation
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with GGTase-I and GGPP under analogous conditions was not observed, indicating that these
shorter peptide sequences do not serve as GGTase-I substrates.
To confirm dns-GCxx farnesylation, two representative dns-GCxx peptides were found to
be modified by FTase via mass spectrometry (Figure 2.4). Two major ions were observed for
dns-GCYL, corresponding to the farnesylated peptide (M+H = 892 Da) and a higher molecular
weight peak consistent with oxidation of the farnesyl cysteine thioether to a sulfone, (S=O,
M+16+H = 908 Da) as noted in mass spectrometry of related molecules.49 For dns-GCWI, only
one major species was identified, corresponding to an oxidized farnesylated product (S=O,
M+16+H = 931 Da).
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Table 2.1. Potential FTase substrate sequences within the human proteome
Potential FTase substrate sequences

Prosite search stringb

Number of sequences

unconstrained searches
Cxx

Cxx>

1074

CaaX

Cxxx>

1208

C(x)3X

Cxxxx>

1015

Cxx not within CaaX or C(x)3X

{c}C-{c}C{c}{c}>

847

CaaX without downstream Cys

C{c}{c}{c}>

1062

C(x)3X without downstream Cys

C{c}{c}{c}{c}>

824

constrained searchesa

a

noted constraints were applied to ignore Cxx sequences that were part of a longer sequence (e.g.
CCxx and CxCxx) and potential GGTase-II consensus sequences (e.g. CxC, xCC).
b

lower case c denotes positions where Cys was a negative constraint; > denotes the C-terminal
constraint.
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Table 2.2. Peptide information table for C-terminal Cxx sequences tested in the human
genome.
Humanderived
Uniprot
sequences ID
CAF*
CAG

CAL*

CAP

CAV
CDI

Protein
Oxygen-dependent coproporphyrinogen-III oxidase,
P36551
mitochondrial
Q8NI17
Interleukin-31 receptor subunit alpha
Q9NP78
ATP-binding cassette sub-family B member 9
Glutaredoxin domain-containing cysteine-rich
A8MXD5 protein 1
Q9NUI1
Peroxisomal 2,4-dienoyl-CoA reductase
Q1HG43

Dual oxidase maturation factor 1

Q6IA86
O15504

Elongator complex protein 2
Nucleoporin-like protein 2

Q9UKA8
P19419

Calcipressin-3
ETS domain-containing protein Elk-1

Q6NT32
P10914
P15941

Carboxylesterase 5A
Interferon regulatory factor 1
Mucin-1
Mitochondrial import receptor subunit TOM5
homolog
UPF0462 protein C4orf33
Homeobox protein SIX6
Protein phosphatase inhibitor 2 family member C
Homeobox protein SIX3
Pulmonary surfactant-associated protein A2

CDP
CDV
CEF

Q8N4H5
Q8N1A6
O95475
O14990
O95343
Q8IWL1

CEG

Q8IWL2
P35247
P04155
P78346

CEV*

P0CG00
P56559
Q7L8W6
Q86UE6
O43300

Pulmonary surfactant-associated protein A1
Pulmonary surfactant-associated protein D
Trefoil factor 1
Ribonuclease P protein subunit p30
Putative zinc finger and SCAN domain-containing
protein 5D
ADP-ribosylation factor-like protein 4C
Diphthine--ammonia ligase
Leucine-rich repeat transmembrane neuronal protein
1
Leucine-rich repeat transmembrane neuronal protein
2

Notes
Isoform 2 only
Isoform 11 only
Isoform 5 only
Isoform 1 only
Isoform 2 only
Isoforms 1 & 3
only
Isoforms 1, 2, 3, 5,
6, & 7 only
Isoform 2 only
Isoforms 1, 2, 5, &
6 only
Isoform 2 only
Isoforms 1, 2, 3, &
4 only
Isoform 1 only
Isoform 13 only
Isoform 2 only
Isoform 1 only
Isoform 1 only
Isoform 1 only
Isoform 1 only
Isoform 1 only
Isoforms 1 & 2
only
Isoform 1 only
Isoform 1 only
Isoform 1 only
Isoform 1 only
Isoform 2 only
Isoform 2 only
Isoform 1 only
Isoform 1 only
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Q8N957
Q13111
O15440
P05997
Q96L33
P0DML2

Leucine-rich repeat transmembrane neuronal protein
3
Immunity-related GTPase family M protein
CAMPATH-1 antigen
Mediator of RNA polymerase II transcription
subunit 12-like protein
Ankyrin repeat and fibronectin type-III domaincontaining protein 1
Chromatin assembly factor 1 subunit A
Multidrug resistance-associated protein 5
Collagen alpha-2(V) chain
Rho-related GTP-binding protein RhoV
Chorionic somatomammotropin hormone 1

P0DML3

Chorionic somatomammotropin hormone 2

Q14406
Q13772

Chorionic somatomammotropin hormone-like 1
Nuclear receptor coactivator 4

P01242

Growth hormone variant

CHF
CHP
CIE

P01241
Q8WVE0
O15533
Q15059
P61626
Q9BRL7
O60548
Q9H3Y6
Q96DP5

Somatotropin
EEF1A lysine methyltransferase 1
Tapasin
Bromodomain-containing protein 3
Lysozyme C
Vesicle-trafficking protein SEC22c
Forkhead box protein D2
Tyrosine-protein kinase Srms
Methionyl-tRNA formyltransferase, mitochondrial

CII*

Q9Y6K9
Q5T1H1

NF-kappa-B essential modulator
Protein eyes shut homolog

Q96CV9

Optineurin

CIQ

Q6WBX8
P82675
P08174
Q13278
Q96NS5

Cell cycle checkpoint control protein RAD9B
28S ribosomal protein S5, mitochondrial
Complement decay-accelerating factor
Putative protein RIG
Ankyrin repeat and SOCS box protein 16

CKH

Q6ZVN8
O14905

Hemojuvelin
Protein Wnt-9b

CEY
CFS

Q86VH5
A1A4Y4
P31358
Q86YW9

CFT*

CFV*
CGF

CGI
CGV

CIL

Isoform 2 only
Isoform 1 only
Isoform 1 only
Isoforms 2 & 3
only
Isoform 1 only
Isoform 2 only
Isoform 2 only
Isoform 1 only
Isoform 1 only
Isoform 1 only
Isoforms 1 & 3
only
Isoforms 1, 2, 3, &
4 only
Isoform 4 only
Isoforms 1 & 3
only
Isoforms 1, 2, 3, 4,
& 5 only
Isoform 1 only
Isoform 2 only
Isoform 2 only
Isoform 1 only
Isoform 1 only
Isoform 1 only
Isoform 1 only
Isoform 1 only
Isoforms 1, 2, & 3
only
Isoform 2 only
Isoforms 1, 2, & 3
only
Isoforms 1 & 4
only
Isoform 2 only
Isoform 3 only
Isoform 1 only
Isoform 1 only
Isoform 1, 2, & 3
only
Isoform 1 only
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CKI

CKK

CKP

CKS

CKV

P26371
P61244
Q7RTM1
O76000
P25398
O43147

Keratin-associated protein 5-9
Protein max
Proton channel OTOP1
Putative olfactory receptor 2B3
40S ribosomal protein S12
Small G protein signaling modulator 2

P04179
P28335

Superoxide dismutase [Mn], mitochondrial
5-hydroxytryptamine receptor 2C

Q15131
P16671
Q9NYP9
P08949
Q9Y3N9

Cyclin-dependent kinase 10
Platelet glycoprotein 4
Protein Mis18-alpha
Neuromedin-B
Olfactory receptor 2W1
HLA class I histocompatibility antigen, A-1
chain
HLA class I histocompatibility antigen, A-2
chain
HLA class I histocompatibility antigen, A-3
chain
HLA class I histocompatibility antigen, A-11
chain
HLA class I histocompatibility antigen, A-23
chain
HLA class I histocompatibility antigen, A-24
chain
HLA class I histocompatibility antigen, A-25
chain
HLA class I histocompatibility antigen, A-26
chain
HLA class I histocompatibility antigen, A-29
chain
HLA class I histocompatibility antigen, A-30
chain
HLA class I histocompatibility antigen, A-31
chain
HLA class I histocompatibility antigen, A-32
chain
HLA class I histocompatibility antigen, A-33
chain
HLA class I histocompatibility antigen, A-34
chain
HLA class I histocompatibility antigen, A-36
chain

P30443
P01892
P04439
P13746
P30447
P05534
P18462
P30450
P30512
P16188
P16189
P10314
P16190
P30453
P30455

Isoform 1 only
Isoform 5 only
Isoform 1 only
Isoform 1 only
Isoform 1 only
Isoform 5 only
Isoforms 1, 2, 3, &
4 only
Isoform 2 only
Isoforms 1, 2, 3, &
7 only
Isoform 2 only
Isoform 1 only
Isoform 2 only
Isoform 1 only
alpha
Isoform 1 only
alpha
Isoform 1 only
alpha
Isoform 1 only
alpha Isoforms 1 & 2
only
alpha
Isoform 1 only
alpha
Isoform 1 only
alpha
Isoform 1 only
alpha
Isoform 1 only
alpha
Isoform 1 only
alpha
Isoform 1 only
alpha
Isoform 1 only
alpha
Isoform 1 only
alpha
Isoform 1 only
alpha
Isoform 1 only
alpha
Isoform 1 only
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Q09160
Q9Y271

HLA class I histocompatibility antigen, A-43
chain
HLA class I histocompatibility antigen, A-66
chain
HLA class I histocompatibility antigen, A-68
chain
HLA class I histocompatibility antigen, A-69
chain
HLA class I histocompatibility antigen, A-74
chain
HLA class I histocompatibility antigen, A-80
chain
Cysteinyl leukotriene receptor 1

Q14680
Q8NBU5

Maternal embryonic leucine zipper kinase
ATPase family AAA domain-containing protein 1

P30456
P30457
P01891
P10316
P30459

CLD

Q9BSJ5

CLG
CLK

CLL*

CLP

CLV*

alpha
Isoform 1 only
alpha
Isoform 1 only
alpha
Isoform 1 only
alpha
Isoform 1 only
alpha
Isoform 1 only
alpha
Isoform 1 only
Isoform 1 only
Isoforms 1, 2, 3, 4,
5, 6, 7, & 8 only
Isoform 1 only
Isoforms 1 & 2
only

Uncharacterized protein C17orf80
Mediator of RNA polymerase II transcription
O95402
subunit 26
Isoform 1 only
Q9UJV8 Purine-rich element-binding protein gamma
Isoform 1 only
Q8WVN8 Ubiquitin-conjugating enzyme E2 Q2
Isoform 2 only
Isoforms 1 & 2
Q9UNE2 Rab effector Noc2
only
Q9BU02 Thiamine-triphosphatase
Isoform 1 only
Q8IX21
SMC5-SMC6 complex localization factor protein 2 Isoform 2 only
Q8TDI7
Transmembrane channel-like protein 2
Isoform 4 only
P61081
NEDD8-conjugating enzyme Ubc12
Isoform 1 only
Q86YA3 Protein ZGRF1
Isoform 3 only
Q6ZUX7 LHFPL tetraspan subfamily member 2 protein
Isoform 1 only
Mediator of RNA polymerase II transcription
Q9NVC6 subunit 17
Isoform 1 only
Q75NE6 Putative microRNA 17 host gene protein
Isoform 1 only
Q00765
Receptor expression-enhancing protein 5
Isoform 2 only
Isoforms 1 & 2
Q7Z2W9 39S ribosomal protein L21, mitochondrial
only
Isoforms 1 & 2
Q96I59
Probable asparagine--tRNA ligase, mitochondrial
only
P02545
Prelamin-A/C
Isoform 4 only
Q9Y5Y2 Cytosolic Fe-S cluster assembly factor NUBP2
Isoform 1 only
Q9Y6I8
Peroxisomal membrane protein 4
Isoform 2 only
Q96HL8 SH3 domain-containing YSC84-like protein 1
Isoform 5 only
Q9P2F9
Zinc finger protein 319
Isoform 1 only
Q9H694
Protein bicaudal C homolog 1
Isoform 2 only
O60308
Centrosomal protein of 104 kDa
Isoform 2 only
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Q14166
Q6NVY1
Q9GZX9
Q9C091
P29728

Tubulin--tyrosine ligase-like protein 12
3-hydroxyisobutyryl-CoA hydrolase, mitochondrial
Twisted gastrulation protein homolog 1
GREB1-like protein
2'-5'-oligoadenylate synthase 2

P22234

Multifunctional protein ADE2

Q9UJT1

Tubulin delta chain

CNR

O15194

CTD small phosphatase-like protein

CPG

Q6ZMM2 ADAMTS-like protein 5

CMF
CNL

Q8TDQ1

CPH

CPI
CPK

CPL

Q8N9R0
Q6TCH4
Q9Y6S9
Q8NFI3
Q9Y5X2
Q9BSY4
Q9GZS3
Q9H9Q2
Q3SYA9
Q96LQ0
P30926
Q9UP79
P38398
Q8TDM6

CPP

Q7Z695
Q00975
P56202
Q00535
Q8NEG7
O15527

CPR

O75818
O95863

CMRF35-like molecule 1
Putative uncharacterized protein encoded by
LINC00304
Membrane progestin receptor delta
Ribosomal protein S6 kinase-like 1
Cytosolic endo-beta-N-acetylglucosaminidase
Sorting nexin-8
Coiled-coil-helix-coiled-coil-helix
domaincontaining protein 5
WD repeat-containing protein 61
COP9 signalosome complex subunit 7b
Putative POM121-like protein 1
Protein phosphatase 1 regulatory subunit 36
Neuronal acetylcholine receptor subunit beta-4
A disintegrin and metalloproteinase with
thrombospondin motifs 8
Breast cancer type 1 susceptibility protein

Isoform 1 only
Isoform 2 only
Isoform 1 only
Isoform 4 only
Isoform 3 only
Isoforms 1 & 2
only
Isoforms 1, 2, 3, 4,
5, & 6 only
Isoform 1 & 2
only
Isoform 1 & 2
only
Isoform 2, 4, & 5
only
Isoform 1 only
Isoform 2 only
Isoform 2 only
Isoform 3 only
Isoform 1 only
Isoform 2 only
Isoform 1 only
Isoform 3 only
Isoform 1 only
Isoform 1 only
Isoform 2 only
Isoform 1 only
Isoform 2 only
Isoforms 1, 2, 4, &
5 only

Disks large homolog 5
Uncharacterized aarF domain-containing protein
kinase 2
Isoform 1 only
Voltage-dependent N-type calcium channel subunit
alpha-1B
Isoforms 2 only
Cathepsin W
Isoform 1 only
Isoform 1 & 2
Cyclin-dependent-like kinase 5
only
Protein DENND6B
Isoform 1 only
N-glycosylase/DNA lyase
Isoform 2 only
Isoforms 1 & 2
Ribonuclease P protein subunit p40
only
Zinc finger protein SNAI1
Isoform 1 only
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CPT

CPV

CPY
CQA

CQL*

CQS
CQV

CRD
CRE

CRF
CRL
CRQ

CRV
CSA

CSF

O43435
P25067
Q99689

T-box transcription factor TBX1
Collagen alpha-2(VIII) chain
Fasciculation and elongation protein zeta-1

Isoform 3 only
Isoform 1 only
Isoform 1 only
Isoforms 1 & 2
Q9UHY8 Fasciculation and elongation protein zeta-2
only
Tumor necrosis factor receptor superfamily member Isoforms 5 & 6
Q93038
25
only
Isoforms 1 & 2
P60981
Destrin
only
Double-stranded
RNA-specific
adenosine Isoforms 1, 2, 3, 4,
P55265
deaminase
& 5 only
Q7Z7L9
Zinc finger and SCAN domain-containing protein 2 Isoform 4 only
P51460
Insulin-like 3
Isoform 1 only
Q92784
Zinc finger protein DPF3
Isoform 1 only
Q5VZR4 Hippocampus abundant transcript-like protein 2
Isoform 1 only
P09086
POU domain, class 2, transcription factor 2
Isoform 4 only
Q8WXX0 Dynein heavy chain 7, axonemal
Isoform 4 only
Isoforms 1 & 2
P55082
Microfibril-associated glycoprotein 3
only
P04054
Phospholipase A2
Isoform 1 only
A6NFN3 RNA binding protein fox-1 homolog 3
Isoform 2 only
Q96M34 Testis-specific expressed protein 55
Isoform 1 only
Isoforms 1 & 2
P0C0L4
Complement C4-A
only
P0C0L5
Complement C4-B
Isoform 1 only
Q8IWL8 Saitohin
Isoform 1 only
Isoforms 1 & 2
Q86UQ0 Zinc finger protein 589
only
Q96CX2 BTB/POZ domain-containing protein KCTD12
Isoform 1 only
Q15615
Olfactory receptor 4D1
Isoform 1 only
Isoforms 1, 2, & 3
P09466
Glycodelin
only
Isoforms 1 & 2
Q8TDW5 Synaptotagmin-like protein 5
only
P08908
5-hydroxytryptamine receptor 1A
Isoform 1 only
Mediator of RNA polymerase II transcription Isoforms 1 & 2
Q6P2C8
subunit 27
only
Q4G0F5
Vacuolar protein sorting-associated protein 26B
Isoform 1 only
Q9Y2C4 Nuclease EXOG, mitochondrial
Isoform 2 only
Q1MX18 Protein inscuteable homolog
Isoform 6 only
Q8N983
39S ribosomal protein L43, mitochondrial
Isoform 1 only
P51811
Membrane transport protein XK
Isoform 1 only
Q9BTY2 Plasma alpha-L-fucosidase
Isoform 2 only
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CSG

CSI
CSK
CSL

Q6QHF9
Q9Y2Y8
P12757
P41223
O43866
Q96KN8
Q12794
Q9BXT6
Q9Y2T5
Q9Y5Q9
Q53EZ4
P04275
Q9P2M7
O95278
O75593
Q6KB66
P14598
Q9NQB0

CSQ

CSS

Q96N03
Q9ULD5
Q5HY92
Q8IVF1
A6NNL0
Q5VT03
B1AL46
A1L443
Q5VZR2
P33764
Q5T1V6
Q9H0R5
P05112
Q86X10

CST

Q9NY57
Q9BPY3
Q8TC05
P16471
Q7Z4G4

Peroxisomal
N(1)-acetyl-spermine/spermidine
oxidase
Proteoglycan 3
Ski-like protein
Protein BUD31 homolog
CD5 antigen-like
Phospholipase A and acyltransferase 5
Hyaluronidase-1
RNA helicase Mov10l1
G-protein coupled receptor 52
General transcription factor 3C polypeptide 3
Centrosomal protein of 55 kDa
von Willebrand factor
Cingulin
Laforin
Forkhead box protein H1
Keratin, type II cytoskeletal 80
Neutrophil cytosol factor 1
Transcription factor 7-like 2
V-set and transmembrane domain-containing
protein 2-like protein
Zinc finger protein 777
Fidgetin
NUT family member 2A
NUT family member 2B
NUT family member 2D
NUT family member 2E
NUT family member 2F
NUT family member 2G
Protein S100-A3
Probable ATP-dependent RNA helicase DDX59
Guanylate-binding protein 3

Isoform 8 only
Isoform 1 only
Isoform 2 only
Isoform 1 only
Isoform 1 only
Isoform 2 only
Isoform 4 only
Isoform 5 only
Isoform 1 only
Isoform 1 only
Isoform 1 only
Isoform 1 only
Isoform 2 only
Isoforms 1, 3, 6, 7,
& 8 only
Isoform 1 only
Isoform 2 only
Isoform 2 only
Isoform 12 only

Isoform 1 only
Isoform 1 only
Isoform 1 only
Isoform 1 only
Isoform 1 only
Isoform 1 only
Isoform 1 only
Isoform 1 only
Isoform 1 only
Isoform 1 only
Isoform 2 only
Isoform 4 only
Isoforms 1 & 2
Interleukin-4
only
Isoforms 1, 2, 3, &
Ral GTPase-activating protein subunit beta
4 only
Isoforms 1 & 2
Serine/threonine-protein kinase 32B
only
Protein FAM118B
Isoform 1 only
Nuclear protein MDM1
Isoform 3 only
Prolactin receptor
Isoform 9 only
tRNA (guanine(10)-N2)-methyltransferase homolog Isoform 3 only
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CSV*

CSY
CTE

CTH
CTP

CTS

CTV*
CVF
CVG

CVK
CVL*

CVM

CVY

Isoforms 1 & 2
Q9UEW3 Macrophage receptor MARCO
only
Isoforms 1, 2, 3, 4,
Q9H3H1 tRNA dimethylallyltransferase
5, & 6 only
A8MW92 PHD finger protein 20-like protein 1
Isoform 1 only
Isoforms 5 & 6
Q9UKA9 Polypyrimidine tract-binding protein 2
only
O95969
Secretoglobin family 1D member 2
Isoform 1 only
Isoforms 1 & 2
P13727
Bone marrow proteoglycan
only
A4D1P6
WD repeat-containing protein 91
Isoform 3 only
Q9H3K6 BolA-like protein 2
Isoform 2 only
Q14204
Cytoplasmic dynein 1 heavy chain 1
Isoform 1 only
Q14141
Septin-6
Isoform 1 only
Isoforms 1 & 2
Q6PF04
Zinc finger protein 613
only
P02790
Hemopexin
Isoform 1 only
Isoforms 1 & 2
Q9UBL6 Copine-7
only
Q5T1A1 DC-STAMP domain-containing protein 2
Isoform 2 only
O43776
Asparagine--tRNA ligase, cytoplasmic
Isoform 1 only
P28222
5-hydroxytryptamine receptor 1B
Isoform 1 only
Q6UX04 Spliceosome-associated protein CWC27 homolog
Isoform 2 only
O15534
Period circadian protein homolog 1
Isoform 1 only
A6H8Y1 Transcription factor TFIIIB component B'' homolog Isoform 2 only
O75044
SLIT-ROBO Rho GTPase-activating protein 2
Isoform 1 only
P59541
Taste receptor type 2 member 30
Isoform 1 only
P29144
Tripeptidyl-peptidase 2
Isoform 1 only
Q96PK6
RNA-binding protein 14
Isoform 3 only
Q9BWF3 RNA-binding protein 4
Isoform 3 only
Q9Y336
Sialic acid-binding Ig-like lectin 9
Isoform 2 only
P01008
Antithrombin-III
Isoform 1 only
Q9C0E2
Exportin-4
Isoform 1 only
Q32MH5 Protein FAM214A
Isoform 2 only
Isoforms 1 & 2
P23510
Tumor necrosis factor ligand superfamily member 4 only
Q12946
Forkhead box protein F1
Isoform 1 only
Q12947
Forkhead box protein F2
Isoform 1 only
Q9NS66
Probable G-protein coupled receptor 173
Isoform 1 only
Isoforms 1, 2, & 3
Q14156
Protein EFR3 homolog A
only
Isoforms 1 & 2
Q9Y2G0 Protein EFR3 homolog B
only
Q6ZUU3 FOXL2 neighbor protein
Isoform 1 only
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Q92750

Transcription initiation factor TFIID subunit 4B
Isoform 2 only
Pleckstrin homology domain-containing family B Isoforms 1, 2, 3, &
CWF
Q9UF11
member 1
4 only
CWI
Q68EM7 Rho GTPase-activating protein 17
Isoform 5 only
CYL
Q9BQ51 Programmed cell death 1 ligand 2
Isoform 3 only
*sequences that were also recovered from yeast genetic screening
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Table 2.3. Reactivity of Cxx peptides with mammalian FTase and prenyl donorsa,b
Complete prenylation by both prenyl donors (3 total)b
CFTc
CFVd
CMF
Complete prenylation with FPP; partial prenylation with GGPP (22 total)b
CAFc
CIL
CQA
CALc
CLLc
CQLc
d
CAV
CLV
CQV
CEVc
CNVc
CSI
CFS
CPI
CSVc
CIId
CPV
CTVc

CVLc
CWF
CWI
CYL

Complete prenylation with FPP; no prenylation with GGPP (1 total)b
CGI
Complete prenylation with GGPP; partial prenylation with FPP (2 total) b
CGF
CVF
Partial prenylation with FPP and GGPP (11 total)b
CEF
CLP
CSY
CHF
CPL
CTS
CLG
CSF
CVG
Partial prenylation with FPP; no prenylation with GGPP (25 total)b
CAG
CIE
CPH
CAP
CIQ
CPT
CDI
CKI
CRL
CDV
CKV
CRV
CEG
CLD
CSA
CEY
CLK
CSL
CHP
CNL
CSQ
Non-reactive with either prenyl donor (21 total)b
CDP
CNR
CGV
CPG
CKH
CPK
CKK
CPP
CKP
CPR
CKS
CPY

CQS
CRD
CRE
CRF
CRQ
CSG

Peptide sequences from a-factor screen that were not tested (7 total)
CVId
CTId
CLId
d
d
CRI
CCI
CFYd

CVM
CVY

CST
CTH
CTP
CVK

CSK
CSS
CTE

CLAd

86

a

Sequences were analyzed in the context of the indicated dns-GCxx peptide; each dns-GCxx
peptide (3 μM) was reacted with FTase (200 nM) and FPP or GGPP (10 µM) and products
analyzed by RP-HPLC as described in Materials and Methods.
b
Peptide reactivity was assigned into one of three levels: “Complete”, 85% or greater substrate
to product conversion by peak integration; “Partial”, detectable substrate to product conversion
(up to 84%); or no detectable product.
c
Peptide sequence identified from Ydj1p screen.
d
Peptide sequence identified from a-factor screen.
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Figure 2.3. FTase-catalyzed farnesylation of Cxx peptides confirmed by RP-HPLC
analysis. a) dns-GCFV; b) dns-GCFS; c) dns-GCSL; d) dns-GCDV. Purple and black lines
denote reactions with or without 10 μM FPP, respectively. Reactions and RP-HPLC analysis
were carried out as described in Materials and Methods. This figure has been reused with
permission from reference 44 (Appendix II).
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Figure 2.4. LC-MS confirmation of FTase-catalyzed dns-GCxx peptide farnesylation. a)
LC-MS analysis of farnesylated dns-GCYL, with peaks at 892 m/z and 908 m/z corresponding to
non-oxidized and oxidized farnesylated peptide, respectively; b) LC-MS analysis of farnesylated
dns-GCWI, with peak at 931 m/z representing the oxidized farnesylated peptide. (Fr) denotes the
farnesylation of cysteine sidechain. This figure has been reused with permission from reference
44 (Appendix II). LC-MS analysis of prenylated peptides was assisted by Tongyin Zheng from
the Castañeda Lab (Syracuse University).
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2.4 Geranylgeranylation of Cxx peptide sequences by FTase
The selectivity of FTase for FPP over GGPP as prenyl donor has been attributed to steric
clashes between FTase active site residues and the larger GGPP isoprenoid chain when it
occupies the active site. Certain engineered FTase active site mutations have been shown to
relive this clash.39, 41, 50 With the Cxx sequences being one amino acid shorter than the
established CaaX prenylation motif, we hypothesized that FTase might be able to accommodate
the larger isoprenoid donor GGPP for prenylation. Indeed, geranylgeranylation was observed for
38 of the 85 dns-Cxx peptides by RP-HPLC when reactions contained FTase and GGPP (Figure
2.5 and Table 2.3). FTase-catalyzed geranylgeranylation of Cxx peptides displayed sequencedependent variation of peptide reactivity as well with only 5 peptides exhibiting complete or
near-complete modification. Geranylgeranylation of two representative dns-GCxx peptides, dnsGCFT (S=O, M+16+H = 948 Da) and dns-GCYL (S=O, M+16+H = 976 Da), was verified by
mass spectrometry (Figure 2.6).
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Figure 2.5. FTase-catalyzed geranylgeranylation of dns-GCxx peptides. a) dns-GCVF; b)
dns-GCMF; c) dns-GCAL; d) dns-GCLV. Orange and black lines denote reactions with or
without 10 μM GGPP, respectively. Reactions and RP-HPLC analysis were carried out as
described in Materials and Methods. This figure has been reused with permission from reference
44 (Appendix II).
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Figure 2.6. LC-MS confirmation of FTase-catalyzed dns-GCxx peptide
geranylgeranylation. a) LC-MS analysis of geranylgeranylated dns-GCYL, with peak at 976
m/z corresponding to the oxidized geranylgeranylated peptide; b) LC-MS analysis of
geranylgeranylated dns-GCFT, with peak at 948 m/z representing the oxidized
geranylgeranylated peptide. (Gr) denotes the geranylgeranylation of cysteine sidechain. This
figure has been reused with permission from reference 44 (Appendix II). LC-MS analysis of
prenylated peptides was assissted by Tongyin Zheng from the Castañeda lab (Syracuse
University).
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2.5 Competition assay to assess FTase preference for FPP versus GGPP
We used a direct competition assay to delineate the relative lipid preference for FTase between
FPP and GGPP given that it can use either to modify Cxx sequences. The five peptides (dnsGCFT, dns-GCFV, dns-GCGF, dns-GCMF and dns-GCVF) that displayed the highest activity
with GGPP in the RP-HPLC assay were selected to assess lipid preference by FTase (Tables
2.3). Each peptide was incubated with FTase and 10 μM total prenyl donor, where the molar
ratio of lipid varied from 100% GGPP to 100% FPP. Following the overnight reaction (~16
hours), the modification associated with the product (farnesylation or geranylgeranylation) was
determined by its RP-HPLC retention time (Figure 2.7a). For each peptide, the relative amount
of geranylgeranylated product decreased in favor of farnesylation even when GGPP comprised
the majority (i.e. 75%) of the prenyl pool available (Figure 2.7b-f). Unsurprisingly, this indicates
a strong preference for FPP as an FTase co-substrate under most conditions but allows for
unexpected use of GGPP in the absence of a farnesyl donor.
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Figure 2.7. Prenyl donor competition reveals FTase preference for FPP over GGPP for
modifying dns-GCxx peptides. a) Representative chromatogram for prenyl donor competition
experiment with the dns-GCFV peptide and a 25:75 FPP:GGPP ratio; b) Product distribution for
dns-GCFT; c) Product distribution for dns-GCFV; d) Product distribution for dns-GCVF; e)
Product distribution for dns-GCMF; f) Product distribution for dns-GCGF. Purple and orange
lines and symbols denote farnesylated and geranylgeranylated products, respectively. Each plot
represents two independent trials per peptide reaction. Reactions were performed and analyzed
as described in Materials and Methods. This figure has been reused with permission from
reference 44 (Appendix II).
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2.6 Steady state analysis of dns-GCxx peptide prenylation by FTase
For steady-state analysis of Cxx prenylation by FTase and GGTase-I, we used an
established fluorescence-based assay that employs the environmentally sensitive dansyl
fluorophore which allows continuous monitoring of peptide prenylation.51, 52 As described in
section 1.3, upon prenylation, dansylated peptides exhibit fluorescence enhancement which
permits for more facile measurement of initial reaction rates compared to HPLC-based assays
(Figures 2.8 and 2.9). Surprisingly, only 12 of the 85 peptides in our study set displayed
fluorescence enhancement when reacted with FTase and FPP, consistent with peptide
farnesylation. By comparison, 64 peptides were found to be farnesylated by RP-HPLC analysis
under identical reaction conditions (Table 2.3). The high false negative rate for detecting peptide
farnesylation through the fluorescence-based assay mirrors that observed for longer C(x)3X
peptides sequences,6 suggesting limitations on the utility of the fluorescence-based assay for
determining peptide reactivity with FTase. Importantly, no false positives were observed with the
fluorescence-based assay for peptides that were deemed unreactive by RP-HPLC analysis. In
reactions with FTase and GGPP, 4 of the 85 peptides exhibited fluorescence enhancement (dnsGCFT, dns-GCII, dns-GCLL, and dns-GCYL). None of the 85 dns-GCxx peptides yielded
fluorescence enhancement when reacted with mammalian GGTase-I and GGPP, consistent with
the lack of Cxx peptide reactivity with GGTase-I as noted by RP-HPLC analysis.
Steady-state characterization of peptide reactivity was performed for dns-GCxx peptides
exhibiting fluorescence enhancement upon prenylation with either FPP or GGPP in the presence
of saturating (10 μM) prenyl donor cosubstrate (Table 2.4 and Figures 2.8 and 2.9). Saturation of
prenylation velocity was not observed within the experimentally accessible peptide concentration
range for any of the peptides tested, allowing only measurement of kcat/Km for these FTase
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substrates. In reaction with FPP, dns-GCxx peptides exhibited much less reactivity as compared
to highly reactive CaaX sequences, such as the H-Ras derived CVLS sequence.53 For example,
one of the more active dns-GCLL peptide sequence was farnesylated ~40-fold less efficiently by
FTase than dns-GCVLS under subsaturating (kcat/Km) conditions. For the Cxx peptides for which
steady state reactivity with both FTase and GGPP could be determined, all peptides exhibited
comparable reactivity (within 2-fold) in the presence of saturating FPP or GGPP.
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Figure 2.8. Steady state characterization of FTase-catalyzed dns-GCxx peptide
farnesylation with FPP. a-l) Representative plots for dependence of farnesylation activity on
peptide substrate concentration catalyzed by FTase in the presence of 10 μM FPP: a) dns-GCFT;
b) dns-GCEV; c) dns-GCII; d) dns-GCLL; e) dns-GCNV; f) dns-GCQL; g) dns-GCRL; h) dnsGCSV; i) dns-GCTV; j) dns-GCVL; k) dns-GCWI; l) dns-GCYL. The curve represents the best
fit to the Michaelis-Menten equation. Reactions were performed and analyzed as described in
Materials and Methods. This figure has been reused with permission from reference 44
(Appendix II).
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Figure 2.9. Steady state characterization of FTase-catalyzed dns-GCxx peptide
geranylgeranylation with GGPP. a-d) Representative plots for dependence of farnesylation
activity on peptide substrate concentration catalyzed by FTase in the presence of 10 μM GGPP:
a) dns-GCLL; b) dns-GCYL; c) dns-GCFT; d) dns-GCII. The curve represents the best fit to the
Michaelis-Menten equation. Reactions were performed and analyzed as described in Materials
and Methods. This figure has been reused with permission from reference 44 (Appendix II).
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Table 2.4. Steady state reactivity of dns-GCxx peptides catalyzed by FTasea
dns-GCxx
sequence
dns-GCEV
dns-GCFT
dns-GCII
dns-GCLL
dns-GCNV
dns-GCQL
dns-GCRL
dns-GCSV
dns-GCTV
dns-GCVL
dns-GCWI
dns-GCYL
dns-GCVLS

Prenyl donor
10 μM FPP
kcat/Km (M-1 s-1)
950 ± 200
1900 ± 70
1400 ± 200
4000 ± 100
1900 ± 100
2500 ± 90
340 ± 100
1000 ± 90
1900 ± 40
2200 ± 200
2600 ± 200
1300 ± 100
170000 ± 40000c

10 μM GGPP
kcat/Km (M-1 s-1)
ndb
1700 ± 300
700 ± 100
6100 ± 1000
nd
nd
nd
nd
nd
nd
nd
920 ± 30
nd

Steady state analyses were carried out at saturating FPP or GGPP (10 μM) and varying peptide
concentrations (0.5 – 10 μM) as described in Materials and Methods. Reported values are the
average of at least three independent determinations, with the error indicating the standard
deviation.
b
No detectable activity. This assay has a lower limit for measuring kcat/Km of 0.4 M-1 s-1 per
reference 29.
c
Previously reported per reference 29.
a
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2.7 Prenylation of Cxx motifs by FTase is inhibited by tipifarnib
There are several FTase inhibitors that have been developed as targets for cancer
treatment.54, 55 One such inhibitor is tipifarnib, also known as Zarnestra, which is currently under
investigation as a treatment for squamous cell carcinomas with HRas mutations.56 This
compound prevents the prenylation of C-terminal motifs by binding at the peptide substrate
binding site of FTase. When treated with varying amounts of tipifarnib, farnesylation of dnsGCWI and dns-GCYL by FTase was efficiently blocked with an IC50 value of 9.5 +/- 5.6 nM and
6.8 +/- 7.9 nM, respectively (Figure 2.10A and B). In addition, tipifarnib blocked
geranylgeranylation by FTase of dns-GCYL with an IC50 value of 7.4 +/- 12.2 nM (Figure 2.11).
These results suggest prenylation of these shortened Cxx sequences occurs through the same
binding interaction as of classical CaaX motifs.
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A)

B)

Figure 2.10. Inhibition of FTase-catalyzed farnesylation of dns-GCxx peptides by
tipifarnib. A) dns-GCWI; B) dns-GCYL. Initial slopes were normalized to reactions without
tipifarnib and IC50 values were calculated as described in Materials and Methods.
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Figure 2.11. Inhibition of FTase-catalyzed geranylgeranylation of dns-GCYL by tipifarnib.
Initial slopes were normalized to reactions without tipifarnib and IC50 values were calculated as
described in Materials and Methods.
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2.8 Investigating prenylation of Cxx c-terminal sequences via in cell fluorescence
localization studies
To be considered biologically relevant in mammalian systems, proteins terminating in
Cxx sequences must exhibit sufficient reactivity to be modified by endogenous FTase within an
intact human cell. The minimum reactivity is estimated to be in the range of kcat/Km = 0.5-2 x 104
M-1s-1 when peptide reactivity was determined in an in vitro assay using purified FTase.57 The
reactivity of several dns-GCxx peptides with purified FTase (see Table 2.4) falls closer to the
lower limit of the range determined in the aforementioned study, suggesting that these shorter
prenylation motifs might be reactive enough to support protein prenylation within mammalian
cells. In addition, the apparent reactivity observed for several Cxx sequences within yeast cells
suggests the ability of these motifs to be modified in a biological context.
We tested for the ability of 9 Cxx C-terminus sequences to undergo prenylation in
HEK293 cells using a pEGFP-KRas vector (gift from Casey Lab, Duke University), which has
the canonical motif -CVIM at its C-terminus. The vector was modified to contain the Cxx
sequence of interest through PCR and subsequent ligation (see Materials and Methods). The use
of an eGFP-KRas fusion protein serves as a proxy for directly detecting prenylation through
visualization of eGFP fluorescence at the membrane (prenylated) or diffused throughout the cell
(not prenylated, or prenylated but not processed).58 The 9 sequences tested in this study included,
-CLL, -CQI, -CQL, -CSI, -CQV, -CMF, -CQA, -CFV, and -CVF. These sequences represented
the most active sequences from the 85 sequences investigated in vitro using purified FTase based
on either steady-state analysis or RP-HPLC analysis (see Tables 2.3 and 2.4).
Transfection of 6x104 cells with 1 µg DNA and 2 µL Turbofect (Promega) in a 24-well
plate was found to be the ideal transfection condition with 24-hour incubation post-transfection.
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Of the 9 sequences tested, all were found to be diffuse throughout the cell, which does not
provide evidence these proteins are modified inside cells (Figure 2.12). The positive control
containing the canonical -CVIM sequence was confirmed to be membrane localized. While not
promising, these results do not conclusively indicate that Cxx sequences are not modified inside
mammalian cells. It is highly plausible that these sequences do not undergo the subsequent postprocessing steps required for them to be shuttled to the cell membrane after prenylation. Analysis
of these non-canonical sequences in a mammalian system requires a different approach that is
not reliant on membrane localization to serve as the signal for detecting prenylation.
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Figure 2.12. Fluorescence imaging of HEK293 cells expressing eGFP-KRas-C(x)(x) at 24
hours post transfection. a) -CVIM (positive control). b) -CLL. c) -CWI. d) -CQL. e) -CSI.
f) -CQV. g) -CMF. h) -CQA. i) -CFV. j) -CVF. All images were collected at 20x magnification
with 470/40 nm excitation filter, a 495 nm beam splitter and a 525/50 nm emission filter.
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2.9 Investigating prenylation of Cxx c-terminal sequences in a biological context via protein
lipidation quantification (PLQ)
Note: The PLQ data was collected and analyzed by Stanislav Beloborodov in the Krylov Lab
(York University).
Despite not observing evidence for membrane localization of the modified eGFP-KRas
protein that had Cxx sequences appended at its C-terminus, we could not conclusively interpret
that these sequences were not modified inside HEK293 cells because these motifs may not
undergo the subsequent post-processing steps required for them to be shuttled to the cell
membrane following prenylation. To further evaluate the biological relevance of non-canonical
Cxx sequences, we utilized another strategy for directly detecting protein lipidation inside a
mammalian system that is not reliant on membrane localization as a proxy for prenylation.
One such approach is Protein Lipidation Quantification (PLQ), which is derived from an
established method of Micellar Electro-Kinetic Chromatography (MEKC) that utilizes detergent
micelles to provide molecular separation during capillary electrophoresis.59-61 In this method, a
detergent such as SDS is used to form micelles in the running buffer with which the analyte can
interact. These micelles serve as pseudo-stationary phase and travel relatively slowly through the
capillary tube compared to free analyte or buffer because of an electrophoretic drag associated
with the viscosity and charge of the micelle as it moves through the electric field within the
capillary. The electrophoretic mobility of the micelle is opposite to the direction of the
electroosmotic flow (EOF) in the capillary resulting in micelle-associated analytes that exhibit a
slower overall velocity towards the cathode. PLQ has been successfully used to separate
prenylated full length fluorescent protein with a C-terminus CaaX motif in in-cell studies.61
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Before we could probe prenylation of non-canonical Cxx motifs in a mammalian system
via PLQ, we established standards using bacterially expressed and purified eGFP proteins
appended with a canonical motif, -CVLS and two non-canonical motif of the form, -CLL and CVL. The plasmids for these proteins were obtained by performing site-directed mutagenesis on
a pJExpress414-eGFP-CVDS plasmid (see Materials and Methods). This plasmid has a His-tag
at the N-terminus allowing for Ni2+-resin based purification. Following expression and
purification of eGFP-CVLS, eGFP-CVL, and eGFP-CLL, reactions were carried out to
farnesylate the purified proteins with purified FTase enzyme and FPP donor (see Materials and
Methods). Negative controls were performed in parallel without FPP. Reactions were incubated
overnight under foil and then stored in -80°C the following day. PLQ analysis was performed by
our collaborators in the Krylov Lab, York University. The results in Figure 2.13 show that we
were able to detect the non-prenylated eGFP-CVLS/-CVL/-CLL and their prenylated
counterparts at a longer retention time. However, it is important to note that the prenylated
eGFP-Cxx protein products are modified to a smaller extent compared to the eGFP-CVLS
positive control suggesting that these shorter sequences are not as reactive as CVLS, which is in
agreement with our steady-state analysis (Section 2.6). Nonetheless, this study laid the
groundwork for using PLQ to analyze prenylation of eGFP-CVLS/-CVL/-CLL proteins in a
mammalian cellular context.
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Figure 2.13. Prenylation assessment of purified eGFP samples appended with various cterminal motifs via PLQ at 520 nm: a) eGFP-CLL in presence of FTase and FPP. b) eGFPCLL in presence of FTase only. c) eGFP-CVL in presence of FTase and FPP. d) eGFP-CVL in
presence of FTase only. e) eGFP-CVLS (positive control) in presence of FTase and FPP. f)
eGFP-CVLS in presence of FTase only. PLQ analysis was performed by Stanislav Beloborodov
from the Krylov Lab (York University).
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After establishing bacterial standards as described, we transfected HEK293 cells with
eGFP reporter proteins fused to canonical and non-canonical peptide sequences at the C-terminus
to determine if prenylation of non-canonical Cxx sequences inside cells could be detected by
PLQ. Six total plasmids were transfected, including pCAF1-eGFP-CVLS/-CVL/-CLL and their
respective serine negative controls of the form, pCAF1-eGFP-SVLS/-SVL/-SLL. The serine
mutants should block prenylation. Transfection of 2x105 with 4 µg DNA and 6 µL Turbofect
(Promega) in a 6-well plate was found to be the ideal transfection condition with 24-hour
incubation post-transfection (see Materials and Methods). Robust eGFP expression was
confirmed via fluorescence imaging, following which cells were collected by scraping, resuspended in 1X PBS, harvested by centrifugation, and stored immediately in -80°C.
The results obtained did not provide evidence for prenylation of non-canonical Cxx
sequences in a mammalian context as both -Cxx sequences and their serine negative controls
displayed the same pattern of detection (Figure 2.14). We were able to detect the prenylated
eGFP-CVLS protein, confirming that the system is viable for this study, with the serine mutant
not shown to be prenylated. Of note, we observed additional peaks that may represent different
phosphorylation states of the serine residues in the proteins tested; this phenomenon will be the
focus of further studies.
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Figure 2.14. Prenylation assessment via PLQ of HEK293 cell lysate expressing eGFPC(S)xx: a) -SLL. b) -CLL. c) -SVL. d) -CVL. e) -SVLS. f) -CVLS. Blue arrows indicate peaks
representing both the unmodified eGFP sample and modified products. Black dotted lines serve
as reference points for retention times of the unmodified substrates, while red dotted lined serve
as reference points for potentially phosphorylated products. The mono- and di-phosphorylated
labeled products are assigned purely hypothetically and require further investigation. PLQ
analysis was performed by Stanislav Beloborodov in the Krylov Lab (York University).
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2.10 Conclusions
Prenylation by FTase and GGTase-I is an important post-translational modification
within eukaryotic proteomes. The canonical CaaX C-terminal motif is generally accepted as the
most prevalent class of substrates for these enzymes. The recent finding that FTase can target
longer C(x)3X sequences has expanded the potential substrate scope for this enzyme,6 which we
have further expanded by our current findings that FTase can accept shorter Cxx sequences. The
Cxx sequences that we identified in vivo using yeast-based a-factor and Ydj1 reporter assays
were also among the most reactive in in vitro studies using human FTase, suggesting these
identified Cxx sequences have potential biological relevance. In this study, we additionally
demonstrate that mammalian FTase can utilize GGPP as the prenyl donor for modification of a
subset of Cxx sequences. While FTase can be mutated to allow GGPP to serve as the prenyl
donor,41 this is the first reported example of wild type FTase catalyzing peptide
geranylgeranylation with comparable efficiency to farnesylation of the same sequences. Our
findings support the further investigation of proteins terminating in Cxx sequences in cellular
systems to determine their prenylation status and impact of such modification on the biological
activities of Cxx proteins.
This work expands both the peptide and prenyl donor substrate pools for FTase, which
further highlights the truly remarkable degree of substrate flexibility exhibited by this enzyme.
By contrast, the inability of GGTase-I to accept dns-GCxx sequences as substrates demonstrates
that it displays stricter peptide length and sequence determinants than FTase. While the outcome
of our FPP/GGPP competition assay clearly shows FTase prefers FPP over GGPP as a prenyl
donor, the promiscuous utilization of GGPP as a prenyl donor could lead to alternative
prenylation when FPP levels are depleted. It is also possible that certain Cxx sequences can be
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preferentially geranylgeranylated by FTase, as it is well established for CaaX sequences that
there is interplay between peptide sequence and prenyl donor selectivity.53, 62-64 Indeed, in this
study using a-factor and Ydj1p reporters, while we assume the Cxx sequences are modified with
farnesyl, we cannot formally discount that geranylgeranylation has also occurred. We expect to
gain a better understanding of how FTase utilizes FPP and GGPP for prenylation of Cxx
sequences through future structural and computational modeling studies of peptides from this
new substrate class in complex with FTase and prenyl donors.
In interpreting the biochemical significance of FTase-catalyzed Cxx sequence
prenylation, it is important to consider whether these sequences are being recognized as
peptide/protein sequences or merely as thiols with appended functional groups. Previous work
has shown FTase can farnesylate nonpeptidic thiols such as dithiothreitol and methyl
thioglycolate (MTG).65 That study demonstrated that thiol coordination to the catalytic zinc ion
of FTase can lead to substrate binding, but peptide interactions enhance binding and catalysis.
Our data suggests that the latter occurs with Cxx sequences. First, the steady state parameters
(kcat/Km) determined for Cxx sequences range from 200- to 2300-fold higher than the highest
kcat/Km reported for a nonpeptidic thiol (MTG, 1.7 M-1s-1).65 Second, the substrate selectivity
between Cxx peptides exhibited in FTase reactions with both FPP and GGPP prenyl donors
indicates the peptide sequence strongly influences the ability of FTase to accept these peptides as
substrates. Together, our findings support that the Cxx substrates are recognized by FTase as
peptide sequences, although with lower reactivity than CaaX sequences.
Looking to the future, assessing the impact of Cxx sequence prenylation in biological
systems represents the most important research avenue motivated by our current findings. Within
yeast, we have demonstrated the ability of these sequences to support effective prenylation of
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Ydj1p and a Ydj1p-based thermotolerance phenotype, indicating that Cxx sequences can exhibit
biologically relevant reactivity. While no prenylated Cxx proteins have been identified by mass
spectrometry-based proteomics studies utilizing chemically modified prenyl donors,66-71 this may
reflect multiple factors including reduced reactivity with prenyl donor analogues used for
proteomics analysis, low Cxx sequence reactivity or protein abundance, or mass spectrometry
complications such as neutral loss or peptide oxidation. The lack of evidence for the prenylation
of Cxx sequences inside cells suggests that the sequences tested in this study are not reactive
enough to be modified by FTase in our cell-based assay. The subset of Cxx sequences derived
from the human proteome that were examined in this work are less reactive than canonical CaaX
sequences (e.g. dns-GCLL peptide is ~40 fold less reactive than dns-GCVLS),53 but the
reactivity of dns-GCLL lies near the range established as viable for prenylation within a
mammalian cell.57 Thus, prenylated yeast and human Cxx proteins remain an intriguing
possibility with a significant number of proteins bearing Cxx-terminal sequences predicted in the
human proteome (Table 2.1). In addition to the selectivity rules defining Cxx sequence reactivity
with FTase with both FPP and GGPP prenyl donors, cell-based studies of novel prenylated Cxx
sequences will be essential for defining the biological roles potentially played by these proteins
and the expanding importance of prenylation within proteomes.
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2.11 Materials and Methods
2.11.1 Miscellaneous Methods: All in vitro FTase and GGTase-I assays were performed at 33
°C. All curve fitting was performed with KaleidaGraph (Synergy Software, Reading, PA).
Geranylgeranyl diphosphate (GGPP) and farnesyl diphosphate (FPP) were purchased from
Isoprenoids.com (Tampa, FL). Peptides were commercially synthesized (Sigma-Genosys, The
Woodlands, TX) and exhibited >90% purity, as determined by RP-HPLC or after semi-prep
purification via RP-HPLC. Peptides were solubilized in ethanol containing 10% (v/v) DMSO
and stored at -80 °C. Peptide concentrations were determined spectrophotometrically using
Ellman’s reagent. The isoprenoid analog C15Alk-OPP was prepared as previously described.72

2.11.2 Yeast strains (These experiments were performed in the Schmidt laboratory,
University of Georgia): Several of the yeast strains used in this study have been previously
described: IH1793 (MAT lys1), RC757 (MAT sst2-1 rme his6 met1 can1 cyh2), SM2331
(MATa trp1 leu2 ura3 his4 can1 mfa1 mfa2), BY4741 (MATa his3∆1 leu2∆0 met15∆0 ura3∆0),
yWS304 (MATa his3∆1 leu2∆0 met15∆0 ura3∆0 ydj1::KANR).73-76 Multiple other strains were
created for this study.44 yWS2542 (MATa his3∆1 leu2∆0 met15∆0 ura3∆0 ram1::KANR
ydj1::NATR) was created by replacing the YDJ1 open reading frame with the nourseothricin
resistance cassette (NATR) in yWS1632 (MATa his3∆1 leu2∆0 met15∆0 ura3∆0 ram1::KANR).
This was accomplished by transformation of the strain with a restriction enzyme digestion of
pWS1623 (BamHI, HindIII, PvuII) and selection on yeast rich media agar plates (YPD)
containing 100 µg/ml nourseothricin. yWS2544 (MATa his3∆1 leu2∆0 met15∆0 ura3∆0
ydj1::NATR) was made in similar fashion using BY4741 as the parent strain. yWS2938-2951 and
yWS2958-2959 were created by integrating Ydj1p-Cxx mutants into the ydj1::NATR locus of
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yWS2544. Integrating DNA fragments were derived by restriction digestion from appropriate
CEN URA3 YDJ1-Cxx plasmids (BamHI, XhoI, PvuI, BglI). Candidate colonies were scored for
improved thermotolerance and concomitant loss of nourseothricin resistance. The gene
replacements and integrations were confirmed by PCR using primers external and internal to the
integrated fragment and sequencing of PCR products derived from the Cxx encoding genomic
DNA. Yeast strains were propagated at 30 °C (IH1793, RC757, SM2331, yWS2938-2952,
yWS2958-2959) or room temperature (yWS2542, yWS2544) on either YPD or appropriate
selective media when plasmid transformed.

2.11.3 Yeast plasmids and oligo designs (These experiments were performed in the Schmidt
laboratory, University of Georgia): The plasmids used in this study were either pre-existing or
newly constructed for this study as noted.44 Unless noted otherwise, new constructs were created
in vivo by recombination of a linearized parent plasmid and appropriate PCR amplified DNA
fragments. Plasmids encoding a-factor mutants (i.e. CVI, CV, C, AVI, SVI) were created using
parent plasmids pWS610 (MluI) or pWS817 (PstI, MluI). Plasmids encoding Ydj1p mutants (i.e.
CTI, CII, CFV, CVI, AVI, SVI) were created using parent plasmid pWS1132 (NheI, or NheI and
AflII).6, 77 pWS1623 (CEN URA3 ydj1::NATR) was created using a NATR PCR product and
pWS1132 (NheI and BsaBI). The NATR PCR product was derived from p4339 and was designed
to have flanking sequence identical to the 5´ and 3´ UTRs of the YDJ1 ORF. pWS114 (2µ URA3
RCE1) was constructed by subcloning the BglI fragment from pSM1275 (CEN URA3 RCE1)
into the BglI site of pSM217.75, 78 pWS1808 (2µ URA3 RAM1) was constructed in two steps.
First, pWS1767 (CEN URA3 RAM1) was created through in vivo recombination of HindIIIlinearized pRS316 (CEN URA3) and a PCR-derived DNA fragment containing the RAM1 gene
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that was amplified from BY4741 genomic DNA. Second, the XhoI-SacI fragment from
pWS1767 was subcloned into the same sites of pRS426 (2µ URA3).79 Introduction of plasmids,
plasmid digests, and PCR-derived DNA fragments into yeast strains was via a lithium acetatebased transformation procedure.80
The synthetic oligonucleotides used for generating random Cxx sequences that underwent
genetic screening were based on the CaaX encoding region of either MFA1 or YDJ1 as encoded
in pWS1024 and pWS1132, respectively. The forward PCR oligo encoded the Cxx sequence and
was flanked by sequences on the 5´ and 3´ ends that were homologous to the target gene; the 5´
sequence facilitates recombination and the 3´sequence facilitates PCR priming. All nucleotides
were allowed at the x positions, allowing for the formation of all 400 Cxx permutations and two
nonsense mutations (i.e. C-stop and Cx-stop). The reverse oligo matched a region in the
polylinker sequence adjacent to the 3´ UTR of each gene. The synthetic oligonucleotides used
for generating specific Cxx sequences were as described above for random Cxx sequence but
were individually designed to create the desired Cxx sequence. The synthetic oligonucleotides
used to amplify the RAM1 gene contained 5´ sequences homologous to the recipient vector
pRS316 to facilitate recombination and 3´ sequences homologous to intergenic regions
surrounding the RAM1 gene to facilitate PCR priming such that 491 and 271 nucleotides of the
5´ and 3´ intergenic regions were amplified, respectively.

2.11.4 a-factor mating pheromone screen, halo assay, and mating test (These experiments
were performed in the Schmidt laboratory, University of Georgia): MATa yeast lacking the
MFA1 and MFA2 a-factor genes (SM2331) were co-transformed with digested pWS1024 (MluI,
SphI) and a PCR product encoding randomized Cxx sequences. The transformation mix was
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plated on synthetic complete agar plates lacking leucine (SC-leucine) and incubated at 30 °C for
72-96 hours to allow for colony formation. Colony counts were determined before replica plating
the colonies onto an SC-leucine plate (replica plate) and a minimal media plate (diploidselective) containing a thin lawn of IH1793 yeast. Plates were incubated at 30 °C for 72-96
hours, diploid colonies were identified, and the corresponding MATa parent colony recovered
from the SC-leucine replicate plate. The MATa strains were individually cultured to saturation,
spotted onto a lawn of MAT sst2-1 yeast (RC757), and strains visually scored for strength of
halo production. Plasmids were isolated and sequenced from the strongest halo producing strains.
For figure production, plasmid transformants of SM2331 were cultured to saturation in selective
SC-leucine liquid media, cultures pinned onto SC-leucine plates, plates incubated for 24-36
hours at 30 °C, and the dense spots of growth were replica transferred onto a thin lawn RC757
yeast. Plates were scanned as described below after incubation at 30 °C for 16-20 hours.
Quantitative mating was performed as previously described.6, 18 MATa strains derived from
SM2331 to express indicated a-factor Cxx mutants were cultured to saturation in selective liquid
media, diluted to A600 ~1.0 using fresh culture media, then mixed with an excess of IH1793
MAT lys1 strain cultured and diluted in the same manner but with non-selective YPD. The
number of colony forming units (CFUs) were determined on both SC-lysine and synthetic
minimal media agar plates (SD) using empirically determined dilutions; SC-lysine selects for the
total of MATa haploid and MATa/ diploid cells, while SD selects for diploids only. Mating
frequencies (CFUdiploid/CFUtotal) were determined for each mutant and were reported as a
percentage relative to a strain producing wild type a-factor.
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2.11.5 Thermotolerance screen and assays (These experiments were performed in the
Schmidt laboratory, University of Georgia): The Ydj1p screen was performed essentially as
previously described.6 In brief, yeast lacking the YDJ1 gene (yWS304) were co-transformed with
the PCR product encoding randomized Cxx sequences and digested pWS1132 (NheI). A portion
of the transformation mix was plated on SC-uracil solid media and incubated at 25 °C for 96
hours to assess the total number of CFUs in the mix. The remaining transformation mix was
plated on YPD solid media and incubated at 40 °C for 96 hours. Plasmids were recovered from
thermotolerant colonies, sequenced, and re-introduced into yWS304 to confirm plasmid-linked
thermotolerance prior to detailed thermotolerance analysis involving incubation at various
temperatures (25 °C, 37 °C, or 40 °C). In brief, saturated cultures grown at room temperature in
SC-uracil liquid media were serially diluted into YPD, dilutions pinned onto YPD solid media,
and plates incubated for several days at desired temperature. Each experiment was performed at
least twice on separate days, and each strain was evaluated in duplicate within each experiment.

2.11.6 Estimate of Cxx complexity in a-factor and thermotolerance screens (These
experiments were performed in the Schmidt laboratory, University of Georgia): The
GLUE-IT algorithm was used to estimate coverage of the screen.81 The algorithm takes into
account the CFUs evaluated for each screen and the number and redundancy of the codons used
for amino acid randomization. The number of colonies associated with transformation of
linearized plasmids or PCR products alone (i.e. false positives) were not counted toward the CFU
total. The false positive rate was typically low (<2%) relative to co-transformed sample. In the
case of the thermotolerance screen, the CFU value derived from growth observed on SC-uracil
solid media at 25 °C (i.e. ~8,400) was adjusted to 14% of its value to account for the observation
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that incubation at 40 °C reduces transformation efficiency.19

2.11.7 Immunoblot analysis for protein prenylation in yeast (These experiments were
performed in the Schmidt laboratory, University of Georgia): Whole cell lysates of mid-log
yeast were prepared as previously described, separated by SDS-PAGE (14%), transferred onto
nitrocellulose, and blots incubated with rabbit anti-Ydj1p primary antibody (courtesy of Dr.
Avrom Caplan) and HRP-conjugated goat anti-rabbit secondary antibody (Kindle Biosciences,
Greenwich, CT).18, 82 Immune complexes were detected using a KwikQuant Imager at multiple
exposure times after development of blots with the KwikQuant Western Blot Detection Kit
(Kindle Biosciences).

2.11.8 Image analysis for yeast plates and immunoblot films (These experiments were
performed in the Schmidt laboratory, University of Georgia): A flat-bed scanner was used to
image plates at 300 dpi (grayscale). Plates were scanned face down without lids using a black
background. Digitized TIFF images of plates and immunoblots were imported into Photoshop for
minor adjustments (i.e. image rotation, contrast, cropping, etc.) then copied to PowerPoint for
final figure assembly. Contrast settings within Photoshop were adjusted for all plate images to be
identical and to maximize dynamic range of signal; settings for immunoblot images were
unchanged.

2.11.9 Expression and purification of FTase and GGTase-I: Rat FTase and GGTase-I were
expressed in BL21(DE3) E. coli and purified as previously described.6, 40
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2.11.10 RP-HPLC-based assay for screening the reactivity of dns-GCxx peptides and
assessing prenylation preference by FTase: Dns-peptides (3 μM) were diluted into 1x FTase
reaction buffer (50 mM HEPPSO-NaOH, pH 7.8, 5 mM TCEP, 5 mM MgCl2; 50 μL total) and
incubated for 20 minutes in 0.65 mL low-adhesion microcentrifuge tubes. Prenylation reactions
were initiated by adding an enzyme mix (200 nM rat FTase, 10 μM FPP or GGPP, in 1x FTase
reaction buffer). Reactions were incubated at 33 °C for 16 hours and then quenched with an
equal volume of 20% acetic acid in isopropanol. RP-HPLC analysis was performed at ambient
temperature on an Agilent 1260 HPLC system with auto-sampler, UV-Vis, and fluorescence
detection using a C18 reversed-phase analytical column (Zorbax XDB-C18) with a linear
gradient from 30% acetonitrile in 25 mM ammonium acetate to 100% acetonitrile flowing at 1
mL/min over 30 minutes; peptides and products were detected by fluorescence (ex 340 nm, em
496 nm). Chromatogram analysis and peak integration was performed using Chemstation for LC
(Agilent Technologies).
For prenyl donor preference assays, the reactivity of dns-GCxx peptides (CFT, CFV,
CGF, CMF, and CVF) was evaluated as described above with varying concentration of FPP and
GGPP (10 µM FPP only, 7.5 µM FPP + 2.5 µM GGPP, 5 µM FPP + 5 µM GGPP, 2.5 µM FPP +
7.5 µM GGPP, and 10 µM GGPP only).

2.11.11 Fluorescence-based assay for screening reactivity of dns-GCxx peptides,
determining prenyl donor saturating concentration, and determining steady-state kinetic
parameters: Steady-state kinetic parameters were determined for FTase from a time-dependent
increase in fluorescence (ex 340 nm, em 520 nm) upon prenylation of the dansylated peptide,
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with assays performed with 0.5–10 μM dansylated peptide, 100 nM purified rat FTase, and 10
μM FPP or GGPP in 1x FTase reaction buffer at 33 °C in a 96-well plate (Corning); reactivity
screening was performed using 3 µM peptide. Peptides were incubated in reaction buffer for 20
minutes prior to reaction initiation by addition of FTase and prenyl donor. The fluorescence was
monitored over a period of 7-8 hours at 33 °C in the BioTek H1 Synergy plate reader (ex 340
nm, em 520 nm) with fluorescence measured at intervals of 30-40 seconds. Initial velocity for
prenylation of dns-GCxx peptides was determined from a time-dependent increase in
fluorescence upon prenylation of the dansylated peptide. To confirm that 10 μM FPP and GGPP
represented a saturating concentration of these cosubstrates (Figure 2.15), assays were performed
as described above with 3 μM dns-GCFT peptide, 100 nM purified rat FTase, and 2–10 μM FPP
or GGPP in 1x FTase reaction buffer at 33 °C in a 96-well plate (Corning). The initial velocities
for dns-GCFT prenylation using both FPP and GGPP prenyl donors decrease less than 2-fold
when the prenyl donor concentration is reduced from 10 μM to 2 μM, consistent with 10 μM
representing saturating prenyl donor (Figure 2.15).
To obtain steady state (kcat/Km) parameters for peptide reactivity, the total fluorescence
change observed upon reaction completion was divided by the initial concentration of the peptide
substrate in a given reaction to yield a conversion factor from fluorescence units to product
concentration (μM). These values were averaged over several peptide concentrations to give an
amplitude conversion (AmpConv), whose units are fluorescence units per micromolar of product
formed (Fl/μM). The linear initial rate, whose units are fluorescence intensity per second
(Fl/Sec), was converted to a velocity (μM/sec) using equation 1, where V is velocity (μM/s), R is
the velocity (Fl/s), and AmpConv is the ratio described above (Fl/μM).
V = R/AmpConv (equation 1)
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The reaction velocities (V) were divided by the enzyme concentration (μM) to get V/[E]
ratios having units of sec-1. A steady-state kinetic parameter (kcat/Km) was determined from a fit
of the Michaelis-Menten equation to the dependence of the initial velocity divided by the enzyme
concentration (V/[E]) on the peptide concentration in presence of saturating prenyl donor (10
μM). Errors represent the standard deviation from three replicate measurements.
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Figure 2.15. Determination of saturating FPP and GGPP concentrations for FTasecatalyzed prenylation of dns-GCFT. a) Time course for FTase-catalyzed farnesylation of dnsGCFT in the presence of various FPP concentrations (2 μM, red; 5 μM, blue; 10 μM, green); b)
Determination of initial velocities for FTase-catalyzed farnesylation of dns-GCFT in the
presence of various FPP concentrations (2 μM, red; 5 μM, blue; 10 μM, green). c) Time course
for FTase-catalyzed geranylgeranylation of dns-GCFT in the presence of various GGPP
concentrations (2 μM, red; 5 μM, blue; 10 μM, green); b) Determination of initial velocities for
FTase-catalyzed geranylgeranylation of dns-GCFT in the presence of various GGPP
concentrations (2 μM, red; 5 μM, blue; 10 μM, green). This figure has been reused with
permission from reference 44 (Appendix II).
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2.11.12 RP-HPLC-based and fluorescence-based assays for screening the reactivity of dnsGCxx peptides by GGTase-I: Dns-peptides (3 μM) were diluted into 1x GGTase-I reaction
buffer (50 mM HEPPSO-NaOH, pH 7.8, 5 mM TCEP; 50 μL total) and incubated for 20 minutes
in 0.65 mL low-adhesion microcentrifuge tubes. Prenylation reactions were initiated by adding
an enzyme mix (200 nM rat GGTase-I, 10 μM GGPP, in 1x reaction buffer). Reactions were
incubated at 33 °C for 16 hours then quenched with an equal volume of 20% acetic acid in
isopropanol. RP-HPLC analysis was performed similarly to reactions with FTase. The
fluorescence-based assay was monitored over a period of 10 hours at 33 °C in the BioTek H1
Synergy plate reader (ex 340 nm, em 520 nm) with fluorescence measured at intervals of 37
seconds.

2.11.13 LC-MS analysis of dns-GCxx peptides modified by FTase (LC-MS experiments
were performed in the Castaneda laboratory with assistance from Tongyin Zheng,
Syracuse University): In vitro reactions with dns-GCxx peptides (3 μM) were prepared in 1x
FTase reaction buffer in the presence of rat FTase (200 nM) and prenyl donor (10 µM) and
incubated at 33 °C for 16 hours before isolation of the farnesylated or geranylgeranylated peptide
by RP-HPLC. Reactions (2 mL) were purified via semipreparative RP-HPLC (Zorbax Eclipse
XDB-C18 column 9 x 250 mM) using a linear gradient of 30:70 TFA in water
(0.05%):acetonitrile (HPLC grade) with a flow rate of 3.2 mL/min over 42 min. The peak
corresponding to the prenylated peptide was detected by UV absorbance at 360 nM, with this
peak collected and dried under reduced pressure overnight before re-dissolving in 50%
acetonitrile. Product peptide mass was determined by LC-MS (ESI) using a Shimadzu LCMS8040 mass spectrometer with a mobile phase of 5% ACN, 95% water used at a flow rate of 0.2
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mL/min using 5 μL of purified prenylated peptide dissolved in 50% ACN and DI water; peak
intensity was monitored from m/z = +200 to +2000.
2.11.14 Determination of tipifarnib inhibition of dns-GCxx peptide prenylation: Assays
were performed as described in our plate-reader based activity screening, with varying
concentrations of tipifarnib (0-500 nM) included in the reaction. Initial slopes (fluorescence
change per second) were determined for each reaction and normalized to the reaction without
tipifarnib. Normalized slope values were plotted against tipifarnib concentration and analyzed
using the equation shown below to calculate IC50 values.
Normalized Slope = 1 – [tipifarnib]/[tipifarnib] + IC50

2.11.15 Construction of eGFP-KRas-CLL/-CWI/-CQL reporter protein plasmids: The
vector plasmids encoding for eGFP-KRas-Cxx were prepared by PCR using the pEGFP-KRas
vector obtained from the Casey Lab (Duke University) serving as a template and -CLL, -CWI,
and -CQL C-terminal sequence and KpnI restriction site present in the 3’ primers (Integrated
DNA Technology, Coralville, IA):
eGFP-KRas-CLL:
5’-GAAAAAGAAGTCAAAGACAAAGAGTACTGGATGTCTGCTGTAAGGTACCCTAAG-3’

eGFP-KRas-CWI:
5’-GAAAAAGAAGTCAAAGACAAAGAGTACTGGATGTTGGATCTAAGGTACCCTAAG-3’

eGFP-KRas-CQL:
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5’-GAAAAAGAAGTCAAAGACAAAGAGTACTGGATGTGAACTGTAAGGTACCCTAAG-3’

The PCR reaction (50 μL) consisted of 1x Standard OneTaq buffer, 10 mM dNTPs, 125 ng
reverse and forward primers each, 10 ng template plasmid, and OneTaq DNA polymerase (0.25
µL, 5U/µL). The PCR reactions were performed in a BioRad Mycycler thermal cycler using the
following program: Initial denaturation (94°C, 1 min); thirty cycles of denaturation (94°C, 30
sec), annealing (56°C, 1 min), and extension (68°C, 2 min); final extension (68°C, 5 min); and a
final hold (10°C, ∞). PCR products were purified using BIO Basic Inc. EZ-10 Spin Column PCR
purification Kit following the manufacturer’s protocol. Following digestion by Nhe1 and Kpn1,
the eGFP-KRas-Cxx insert was ligated into the pEGFP-KRas plasmid using the Quick Ligase kit
(NEB), following the manufacturer’s instructions. Insert ligation was verified by analytical
restriction digest and gene sequencing (Genewiz).

2.11.16 Site-directed mutagenesis of eGFP-KRas-CLL reporter protein to generate 6
remaining -Cxx sequences: PCR mutagenesis primers were designed to obtain the desired Cxx
sequence per manufacturer’s protocols (Stratagene) and were synthesized by Integrated DNA
Technologies. Primers were dissolved in ultra-pure water and concentrations were measured by
UV absorbance at 260 nm (1 OD= 33 µg/mL). Each PCR mutagenesis reaction (50 µL)
contained the following components: 10x Pfu reaction buffer (5 µL), template plasmid (10 ng),
forward primer (125 ng), reverse primer (125 ng), dNTP mixture (1 µL of 10 mM). The reaction
was gently mixed, centrifuged, and 1 µL of Pfu Turbo DNA polymerase (Agilent) was added.
PCR mutagenesis reactions were performed in a BioRad Mycycler thermal cycler using the
following temperature program: Initial denaturation (95°C, 1 min); 18 cycles of denaturation
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(95°C, 50 sec); annealing (60°C, 50 sec) and extension (68°C, 12 min) followed by final
extension (68°C, 12 min). Following PCR, reactions were treated with DpnI (1 µL, 10 units/ µL)
and incubated at 37°C for 1 hour. Z-competent DH5α E. coli cells (Zymo Research) were thawed
on ice for 10 minutes and then transformed with 5 µL of the PCR reaction following which the
cells were plated on pre-warmed LB-Amp plates and incubated overnight at 37°C. Two colonies
were picked from each plate and inoculated into LB media (5 mL) containing 100 µg/ mL
ampicillin and incubated with shaking (225 rpm) overnight at 37°C. Following overnight growth,
a 10% glycerol stock was prepared stored at -80°C. Plasmid DNA was purified from the
remaining saturated culture using EZ-10 spin column DNA purification kit (BioBasic) per the
manufacturer’s protocol. The mutations were confirmed by DNA sequencing (Genewiz).

2.11.17 Transfection and visualization of eGFP-KRas-Cxx fusion proteins in HEK293 cells:
HEK293 cells were maintained in 75 mL vented tissue culture flasks (Celltreat), and were split
once reaching 80% confluency. Cells were grown in complete DMEM (DMEM supplemented
with 10% fetal bovine serum (FBS) and 1 % (v/v) penicillin-streptomycin (MediaTech) in 5%
CO2 at 37°C. After allowing cells to adhere for 24 hours in complete DMEM media, a reaction
mixture consisting of 1 µg DNA, 2 µL Turbofect reagent (Promega), and supplement free
DMEM for a total volume of 500 µL was prepared and incubated at RT for 20 min. During this
time, fresh complete DMEM was added to the HEK293 cells to a total volume of 1 mL per well.
The reaction mixture was then added dropwise to 6x104 HEK293 cells in a 24-well plate and
incubated at 37°C, 5% CO2 with humidity, for 24 hours. Following incubation, live cells were
imaged using a Zeiss Axio Vert.A1 inverted fluorescence microscope with a 470/40 nm
excitation filter, a 495 nm beam splitter and a 525/50 nm emission filter to verify successful
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fluorescent protein expression and analyze fluorescence localization.

2.11.18 Site-directed mutagenesis of pJExpress414-eGFP-CVLL reporter protein to CVLS/-CLL/-CVL sequences: PCR mutagenesis primers were designed to obtain the desired
C-terminal sequence per manufacturer’s protocols (Stratagene) and were synthesized by
Integrated DNA Technologies. Primers were dissolved in ultra-pure water and concentrations
were measured by UV absorbance at 260 nm (1 OD= 33 µg/mL). Each PCR mutagenesis
reaction (50 µL) contained the following components: 10x Pfu reaction buffer (5 µL), template
plasmid (10 ng), forward primer (125 ng), reverse primer (125 ng), dNTP mixture (1 µL of 10
mM). The reaction was gently mixed, centrifuged, and 1 µL of Pfu Turbo DNA polymerase
(Agilent) was added. PCR mutagenesis reactions were performed in a BioRad Mycycler thermal
cycler using the following temperature program: Initial denaturation (95°C, 1 min); 18 cycles of
denaturation (95°C, 50 sec); annealing (60°C, 50 sec) and extension (68°C, 12 min) followed by
final extension (68°C, 12 min). Following PCR, reactions were treated with DpnI (1 µL, 10
units/ µL) and incubated at 37°C for 1 hour. Z-competent DH5α E. coli cells (Zymo Research)
were thawed on ice for 10 minutes and then transformed with 5 µL of the PCR reaction
following which the cells were plated on pre-warmed LB-Amp plates and incubated overnight at
37°C. Two colonies were picked from each plate and inoculated into LB media (5 mL)
containing 100 µg/ mL ampicillin and incubated with shaking (225 rpm) overnight at 37°C.
Following overnight growth, a 10% glycerol stock was prepared stored at -80°C. Plasmid DNA
was purified from the remaining saturated culture using EZ-10 spin column DNA purification kit
(BioBasic) per the manufacturer’s protocol. The mutations were confirmed by DNA sequencing
(Genewiz).
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2.11.19 Expression and purification of pJExpress414-eGFP-CVLS/-CVL/-CLL: Chemically
competent BL21 (DE3) E. coli were transformed with pJExpress414-eGFP-CVLS/-CVL/-CLL
vectors. Following transformation and antibiotic selection, a colony from the transformation
plate was inoculated into LB media (5 mL) containing 100 µg/mL ampicillin. Cultures were
incubated and shaken at 225 rpm for 4 h at 37°C and then transferred to 0.5 liter of prewarmed
auto-induction media (5 g tryptone, 2.5 g yeast extract, 10 mL 50X 5052 media [25% glycerol,
10% lactose, 2.5% glucose], 25 mM Na2HPO4, 25 mM KH2PO4, 50 mM NH4Cl, 5 mM Na2SO4,
2 mM MgSO4, 100 µL trace metals [50 µM FeCl2, 20 µM CaCl2, 10 µM MnCl2, 10 µM ZnCl2],
100 µg/mL ampicillin. Expression cultures were incubated for 19 h at 37˚C with shaking. Cells
were harvested by centrifugation and resuspended in 50 mL resuspension buffer (20 mM
NaH2PO4, 300 mM NaCl, and 10 mM imidazole). Bacterial cell suspensions were lysed by
sonication, clarified by centrifugation, and purified by affinity chromatography using a Ni-NTA
HisTrap column (GE S4 Healthcare). Fractions containing the protein were combined and
concentrated using a centrifugal concentrator. Concentrated samples were buffer exchanged to
50 mM Tris buffer (pH 7.8), divided into 20 µL aliquots, and stored at −20°C. Protein
concentration was determined using the molar absorption of eGFP at 488 nm.

2.11.20 Farnesylation of purified His6-eGFP-CVLS/-CVL/-CLL: 2 µM eGFP-CVLS/-CVL/CLL were incubated with both 1X reaction buffer (50 mM HEPPSO-NaOH, pH7.8, 5 mM
TCEP) and 5 mM MgCl2 (0.5 mL total) for 20 minutes in 1.5 mL low-adhesion eppendorf tube.
Farnesylation reactions were initiated by adding an enzyme mix (0.5 mL) containing 200 nM
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FTase, 5 mM MgCl2, 1X reaction buffer, and 10 µM FPP. Reactions were incubated at RT for 16
hours under foil before storage at −80°C. Negative controls were also set up without FPP.

2.11.21 Site-directed mutagenesis of pCAF1-eGFP-CVLS vector to obtain -CVL/-CLL/SVLS/-SVL/-SLL vectors: PCR mutagenesis primers were designed to obtain the desired Cterminus sequence per manufacturer’s protocols (Stratagene) and were synthesized by Integrated
DNA Technologies. Primers were dissolved in ultra-pure water and concentrations were
measured by UV absorbance at 260 nm (1 OD= 33 µg/mL). Each PCR mutagenesis reaction (50
µL) contained the following components: 10x Pfu reaction buffer (5 µL), template plasmid (10
ng), forward primer (125 ng), reverse primer (125 ng), dNTP mixture (1 µL of 10 mM). The
reaction was gently mixed, centrifuged, and 1 µL of Pfu Turbo DNA polymerase (Agilent) was
added. PCR mutagenesis reactions were performed in a BioRad Mycycler thermal cycler using
the following temperature program: Initial denaturation (95°C, 1 min); 18 cycles of denaturation
(95°C, 50 sec); annealing (60°C, 50 sec) and extension (68°C, 12 min) followed by final
extension (68°C, 12 min). Following PCR, reactions were treated with DpnI (1 µL, 10 units/ µL)
and incubated at 37°C for 1 hour. Z-competent DH5α E. coli cells (Zymo Research) were thawed
on ice for 10 minutes and then transformed with 5 µL of the PCR reaction following which the
cells were plated on pre-warmed LB-Amp plates and incubated overnight at 37 °C. Two colonies
were picked from each plate and inoculated into LB media (5 mL) containing 100 µg/mL
ampicillin and incubated with shaking (225 rpm) overnight at 37 °C. Following overnight
growth, a 10% glycerol stock was prepared stored at -80°C. Plasmid DNA was purified from the
remaining saturated culture using EZ-10 spin column DNA purification kit (BioBasic) per the
manufacturer’s protocol. The mutations were confirmed by DNA sequencing (Genewiz).
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2.11.22 Preparation of HEK293 cells expressing eGFP-CVLS/-CVL/-CLL/-SVLS/-SVL/SLL: The mammalian cell line HEK293 (ATCC) was maintained in 75 mL vented tissue culture
flasks (Celltreat), and were split upon reaching 80% confluency. The cells were grown in
complete DMEM (Dulbecco's Modified Eagle's Medium supplemented with 10% fetal bovine
serum (FBS) and 1% (v/v) penicillin streptomycin (MediaTech)) in a humidified atmosphere
with 5% CO2 at 37 °C. For expression of the eGFP reporter proteins, 2 x 105 cells were placed
in 2 mL of complete DMEM per well of a tissue culture treated 6-well plate (Corning) (total of 5
wells). The cells were incubated 24-28 hours prior to transfection. The DNA-transfection
reagent complex was prepared by incubating 4 µg of each reporter protein expression plasmid
pCAF-eGFP-CVLS/-SVLS/-CVL/-SVL/-CLL/-SLL and 6 µL of the Turbofect transfection
reagent (Thermo Scientific) in a total volume of 500 µL supplement free DMEM for 15 minutes
at room temperature. The cells were then transfected with the prepared DNA-transfection
reagent complex by drop wise addition into the wells of a 6-well tissue culture plate. Following
transfection for 24 h, live cells were imaged using a Zeiss Axio Vert.A1 inverted fluorescence
microscope with a 470/40 nm excitation filter, a 495 nm beam splitter and a 525/50 nm emission
filter to verify fluorescent protein expression. The cells were then scraped and resuspended in
PBS followed by centrifugation to harvest the cell pellet. The cell pellets were stored at −80 °C.

2.11.23 Preparation and analysis of proteins by PLQ (PLQ experiments were performed in
the Krylov laboratory, York University): Prior to the CE experiments, HEK293 cells were
centrifuged for 2 min at ∼13000 × g (Eppendorf 5417R centrifuge with F45−30−11 rotor (Fisher
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scientific, PA, USA)) at 4 °C and the supernatant was collected. The obtained supernatant as well
as purified proteins were diluted with the sample buffer consisting of 50 mM HEPES sodium salt
(NaHEPPSO), 10 mM MgCl2, 5 mM tris(2-carboxyethyl)- phosphine hydrochloride (TCEP), and
10 mg/mL bovine serum albumin (BSA) at pH 7.8. The BSA was added to reduce adsorption of
the proteins onto capillary surface.
PLQ analysis was carried out with MDQ-PACE instrument (Sciex, formerly
BeckmanCoulter, Caledon, ON, Canada) using laser-induced fluorescence (LIF) detection with
excitation at 488 nm and emission at 520 nm for the detection of eGFP derivatives. Fused silica
capillaries with total length of 50 cm were preconditioned by sequential washing with 100 mM
HCl, 100 mM NaOH, Milli-Q water and running buffer (25 mM Borax, 20 mM SDS, pH 10.0)
each for 2 min at 30 psi. The samples were injected into the capillary by 0.5 psi pressure pulse of
10 s. Electrophoretic separation was carried out with a positive electrode at the injection end of
the capillary, with electric field strength of 15 kV at 25 oC.
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Chapter 3: Investigating photo-switchable FPP analogs as donors
for FTase
The work presented herein is unpublished.
Syntheses and characterization of both azo-benzene FPP analogs were completed by our
collaborator Johannes Morstein from the Trauner Group (Department of Chemistry, New York
University).
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3.1 Introduction
Given prenylation’s impact on many signaling pathways, gaining a comprehensive
understanding of its function in terms of time and space represents an intriguing challenge and is
limited by the current utilization of genetic or pharmacological interventions. Spatiotemporal
details of prenylated proteins are lost when studied under in vitro conditions with purified
protein. Genetic approaches such as gene knockouts lack temporal precision as they eliminate
the function of prenylated proteins at all times and positions. While small molecules offer better
temporal control, they suffer from off-target issues.1 And although several functionalized
isoprenoid analogs have been developed (see Chapter 1), their utility is limited to identification
of prenylated proteins and does not offer the dynamic control that may influence membrane
localization in a reversible manner. An ideal approach for probing the role of a specific
prenylated protein in its native environment is one that allows for spatial and temporal control on
a time frame and spatial scale comparable to that which occurs naturally.2-5
Light is a promising external chemical and biological modulator of protein function
because it exhibits a high level of spatiotemporal resolution, is generally non-invasive (for a
range of wavelengths) and well-tolerated by most chemical and biochemical elements leading to
minimal interference with living systems, and does not cause contamination. Moreover, its
wavelength and intensity can be precisely controlled allowing for unparalleled manipulations of
biological phenomena.1, 5 Light can influence the biological activity of synthetic molecules that
are modified with a light-sensitive group by changing their pharmacokinetic or
pharmacodynamic properties. This approach is termed photopharmacology.1
The most widely used method for rendering biomolecules light sensitive is the “caging”
approach, in which, a key functional group is protected with a light-sensitive “caging” group.
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This causes the biomolecule to be in its inactive form until the caging group is removed with
light. There are several examples of light-sensitive protecting groups used in biological studies.69

However, this approach is limited by the irreversible nature of this photochemistry because

once “uncaged”, the bioactive molecule remains active until it is removed or degraded. In
contrast, “photoswitches” represent a class of chemical compounds that may undergo a
reversible change in their structure and properties multiple times. While several classes of such
light-responsive compounds have been developed, azobenzene has received considerable
attention in biological applications.1-4, 10 Azobenzene groups are relatively small, allowing them
to be easily incorporated into a drug-like molecule of low molecular weight. Furthermore, they
can be synthesized through a wide variety of methods, including classical azo-coupling to Mills
reactions or the cross-couplings of hydrazine derivatives followed by oxidation.10, 11 The
repertoire of azobenzene incorporated compounds has grown substantially recently.
Photoirradiation of azobenzene results in a trans to cis isomerization that is accompanied
by a large change in geometry and a considerable change in polarity.12 The trans conformation of
azobenzene is 10-12 kcal mol-1 more stable than the cis isomer, which means that trans is the
dominant isomer (>99.99%) in the dark at equilibrium.2, 12, 13 The trans conformation is near
planar and has a dipole moment near zero.14, 15 A substantial amount of the cis isomer can be
induced by irradiation with 340 nm light, which causes azobenzene to adopt a bent confirmation
with its phenyl rings twisted out of the plane from the azo group and has a dipole moment of ~3
Debye (Figure 3.1).14 Relaxation to the thermodynamically more stable trans-isomer can be
achieved by either irradiation with ~450 nm light or may proceed spontaneously by thermal
isomerization in the absence of light. The photoisomerization events occur with high quantum
yields and minimal photo-bleaching.2, 14 Moreover, photo-induced isomerization of azobenzene
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results in a substantial difference between the end-to-end distance of each isomer and
isomerization occurs on a picosecond timescale, much faster than most biological events.14, 16, 17
Photoswitchable lipids have emerged as tools useful in the control of cell signaling in a
reversible manner.3, 10 They rely on the incorporation of an azobenzene photoswitch in the
hydrophobic tail and mediate optical control of lipid function by reversible, light-induced
isomerization between a cis and trans isomer, as described. In comparison to caged lipids,
photoswitchable lipids require less intense radiation and do not lead to the formation of side
products. To date, photoswitchable lipids have been applied in the optical modulation of ion
channels,18-20 the fatty acid receptor GPR40,21 lipid rafts,22 lipid vesicle budding and fission,23
lipid-protein interactions in canonical lipid signaling and sphingolipid metabolism.24, 25
Inspired by the success of recent studies on photoswitchable lipids in modulating cell
signaling events in various contexts,3 we examined the reactivity of two FPP azobenzenecontaining “azologs” (AzoFPP1 and AzoFPP2) developed by the Trauner Group (Department of
Chemistry, New York University) (Figure 3.2) in reactions with mammalian prenyltransferases.
As with other compounds incorporating azobenzene, azo-FPP analogs favor their thermally
stable trans isoform but can be isomerized to their less stable cis isoform by irradiation at 365
nm. Moreover, both azologs thermally relax to the trans isomer with a half-life of ~24 hours or
can be induced by irradiation with 460 nm light allowing reversible control (Figure 3.3). We
tested these Azo-FPP analogs in a proof of principle in vitro assay to validate incorporation by
protein prenyltransferase using peptide substrates. This work moves towards the goal of utilizing
the photo-isomerization ability of these azologs in cells to modulate membrane localization
behavior and thus potentially influence protein function and consequential downstream events in
cells.
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Figure 3.1. Structure and absorption spectra of trans- and cis-azobenzene: (a) Structures of
trans and cis isomers of azobenzene. (b) Space-ﬁlling models colored by electrostatic potential
(red—negative to blue—positive). (c) Electronic absorption spectra of the trans and cis isomers
of azobenzene dissolved in ethanol. This figure has been reproduced from Reference 2 with
permission from The Royal Society of Chemistry (Appendix III).
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Figure 3.2. Structures of Azo-FPP1 and Azo-FPP2. Both azologs were inspired by
farnesylpyrophosphate (FPP) and an aryl-derivative FPP analog26, respectively.
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Figure 3.3. Photophysical properties of Azo-FPP1. Ultraviolet-visible spectra of Azo-FPP1 in
the dark-adapted (black, trans), 365 nm-adapted (gray, cis) and 460 nm-adapted (blue, trans)
photostationary states. Reversible cycling between photoisomers with alternating illumination at
365/460 nm. A.U., arbitrary units. Azo-FPP2 exhibited similar photophysical properties (data not
shown). This data was collected and analyzed by our collaborator Johannes Morstein from the
Trauner Group (Department of Chemistry, New York University).
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3.2 WT FTase-catalyzed prenylation of dns-GCVLS peptide using Azo-FPP1
We performed an initial assay to validate incorporation of the two azologs without any
irradiation by monitoring the reaction between the canonical FTase/GGTase-I peptide substrates
dns-GCVLS and dns-GCVLL, respectively with Azo-FPP donors by reverse phase HPLC.27-30
HPLC analysis indicated that of the two Azo-FPP analogs, Azo-FPP1 was incorporated in a
reaction with FTase and dns-GCVLS whereas Azo-FPP2 was unable to be utilized by FTase as a
donor (Figure 3.4). In contrast, GGTase-I did not accept either of the two analogs as the prenyl
donor in a reaction with dns-GCVLL (Figure 3.5).
Following confirmation that Azo-FPP1 could serve as a substrate for FTase, we probed
the photo-isomerization of Azo-FPP1 and whether we could detect the two different isomers by
monitoring reactions via HPLC. After incubating peptide reactions with FTase and Azo-FPP1
overnight in the dark, reactions were stopped by adding stop solution and irradiated for three
minutes with either 365 nm light to induce the cis-isomer favoring photo-stationary state or with
460 nm light to enrich the trans-isomer favoring photo-stationary state prior to HPLC analysis of
the modified peptides (see Materials and Methods). By this approach, we were able to
unambiguously assign distinct peaks in the HPLC chromatogram to the peptide substrates
appended with the two different photo-isomers of the Azo-FPP1 group (Figure 3.6). This study
supported further testing of Azo-FPP1 to determine its steady-state reaction parameters with
FTase and canonical FTase substrates.
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a)

b)

c)

d)

Figure 3.4. Modification of dns-GCVLS by FTase using Azo-FPP analogs as monitored by
RP-HPLC. a) Negative control consisting of peptide and FTase only. b) Peptide reaction with
FTase and FPP (positive control). c) Peptide reaction with FTase and Azo-FPP1. d) Peptide
reaction with FTase and Azo-FPP2. Asterisks represent background peaks. Reactions and HPLC
analysis carried out as described in Materials and Methods.
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a)

b)

c)

d)

Figure 3.5. Modification of dns-GCVLL by GGTase-I using Azo-FPP analogs as monitored
by RP-HPLC. a) Negative control consisting of peptide and GGTase-I only. b) Peptide reaction
with GGTase-I and GGPP (positive control). c) Peptide reaction with GGTase-I and Azo-FPP1.
d) Peptide reaction with GGTase-I and Azo-FPP2. Asterisks represent background peaks.
Reactions and HPLC analysis carried out as described in Materials and Methods.
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a)

b)

c)

d)

Figure 3.6. RP-HPLC detection of modified dns-GCVLS with photoisomers of Azo-FPP1
generated by post-enzymatic reaction illumination. A) Negative control consisting of peptide
only. b) Peptide reaction with Azo-FPP1 (non-illuminated post-reaction). c) Peptide reaction
with Azo-FPP1 (illuminated with 460 nm light post-reaction). d) Peptide reaction with AzoFPP1 (illuminated with 365 nm light post-reaction). Asterisks represent background peaks.
Reactions, illumination, and HPLC analysis were carried out as described in Materials and
Methods.
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3.3 Azo-FPP1 exhibits sufficient reactivity with FTase to be considered for cellular studies
To completely define the functional role of prenylated proteins in their native
environment by use of azologs, it is imperative to establish if Azo-FPP1 can be utilized inside
cells by endogenous FTase. Following confirmation of FTase’s ability to incorporate Azo-FPP1
onto purified peptides, we determined steady-state parameters for Azo-FPP1 with FTase and
canonical FTase substrates by carrying out a time course study. This allows us to gauge the
reactivity of the azolog and compare its reactivity to known FPP analogs that have been
successfully used in cell studies. To determine the time-course of FTase-catalyzed prenylation
using Azo-FPP1, reactions with dns-GCVLS were stopped at various time points and product
conversion was determined via RP-HPLC. In our initial studies, we assessed the time required to
reach completion for both the trans and cis isomers (Figures 3.7 and 3.8). We determined the
peptide prenylation reaction with trans Azo-FPP1 reached complete conversion to product more
quickly than the cis Azo-FPP1 isomer reaction, suggesting that the trans isomer is a more
reactive substrate for FTase under these conditions. More specifically, the time required to reach
reaction completion was 120 minutes for trans Azo-FPP1 compared to 240 minutes required for
the cis isomer for reaction completion (Figure 3.9).
We also tested parallel reactions with FTase and farnesyl pyrophosphate containing a
terminal alkyne group (AlkC15OPP). This allowed us to compare the reactivity of trans AzoFPP1 with another FPP analog prenyl donor which has been successfully used in cells to
prenylate canonical and non-canonical substrates.31-33 Since peptide modification with the
AlkC15OPP probe results in a greater fluorescence enhancement than the AzoFPP1 analog,
HPLC chromatograms were analyzed at by UV absorbance of 340 nm for the dansyl group to
allow direct comparison between these two analogs. The extent of reaction progress at any one
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point was calculated based on the integration of the UV absorbance peak, which was converted
to concentration by normalization to the final peak integration with the assumption of 100%
conversion to product. Through this analysis, we found the non-irradiated Azo-FPP1 donor
showed comparable reactivity to AlkC15OPP with reactions involving both analogs going to
completion in approximately 120 minutes (Figure 3.10). This supports that trans Azo-FPP1 is
sufficiently reactive to support cell-based studies for protein modification with this lightswitchable farnesyl group, provided that this analog can enter the cell.
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a)

b)

c)

d)

e)

Figure 3.7. RP-HPLC detection of dns-GCVLS modified with trans-Azo-FPP1 at various
time points under no illumination. a) Negative control consisting of peptide only. b) Peptide
reaction with Azo-FPP1 at 30 mins. c) Peptide reaction with Azo-FPP1 at 60 mins. d) Peptide
reaction with Azo-FPP1 at 120 mins. e) Peptide reaction with Azo-FPP1 at 240 mins. Asterisks
represent background peaks. Reactions and HPLC analysis carried out as described in Materials
and Methods.
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a)

b)

c)

d)

e)

f)

Figure 3.8. RP-HPLC detection of dns-GCVLS modified with cis-Azo-FPP 1 at various
time points after illumination with 365 nm light. a) Negative control consisting of peptide
only. b) Peptide reaction with Azo-FPP1 at 30 mins. c) Peptide reaction with Azo-FPP1 at 60
mins. d) Peptide reaction with Azo-FPP1 at 120 mins. e) Peptide reaction with Azo-FPP1 at 240
mins. f) Peptide reaction with Azo-FPP1 at 360 mins. Asterisks represent background peaks.
Reactions, illumination, and HPLC analysis were carried out as described in Materials and
Methods.
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Figure 3.9. Time course for FTase-catalyzed modification of dns-GCVLS by both photoisomers of Azo-FPP1. Data reflect integration of substrate and product peaks shown in Figures
3.7 and 3.8, as described in the Materials and Methods. Reactions with the trans-isomer are
represented in red, while the cis-isomer reactions are shown in blue.
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Figure 3.10. Time course for FTase-catalyzed modification of dns-GCVLS by both trans
Azo-FPP1 and AlkC15OPP. Data reflect integration of substrate and product peaks, as
described in the Materials and Methods. Reactions with the trans-Azo-FPP1 are represented in
red, while the C15AlkOPP reactions are shown in blue.
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3.4 Conclusions
We employed an in vitro RP-HPLC based assay to determine whether FTase and/or
GGTase-I can incorporate two different prenyl donor analogs with azobenzene in their
hydrophobic chain to target peptide substrates. These azologs represent intriguing molecules as
they are photo-sensitive, with dramatic structural changes controllable by light irradiation. This
photoswitching ability could be harnessed to potentially mediate membrane localization behavior
of prenylated proteins. Our initial analysis showed that FTase, but not GGTase-I, can utilize
Azo-FPP1 as a viable donor to modify the canonical dns-GCVLS peptide substrate. This
observation again speaks towards the flexibility exhibited by FTase in substrate selection in
comparison to GGTase-I.33, 34 As for the preference of FTase for Azo-FPP1 over Azo-FPP2, we
speculate that the aryl-ether moiety of Azo-FPP2 could be out of plane when bound to FTase and
is not recognized by FTase. Alternatively, the location of the azobenzene in the middle of AzoFPP2, rather than the distal end as in Azo-FPP1, is not as well accommodated by FTase.
Moreover, Azo-FPP1 is more structurally similar to FPP than Azo-FPP2 is to FPP, which could
also explain FTase selectivity of Azo-FPP1. These hypotheses require further investigation,
perhaps through mutagenesis studies. In addition, we were able to observe the two different trans
and cis photostationary states of Azo-FPP1 when bound to peptide substrate (dns-GCVLS) in our
HPLC analysis, consistent with the distinct polarity / hydrophobicity predicted for these two
isomers. These results suggest that due to the differing polarities observed, irradiation of AzoFPP1 in cells could potentially modulate membrane localization behavior of proteins modified
with Azo-FPP1.
In terms of reactivity, comparison with a known prenyl analog successfully used in cell
studies provided useful insight that non-irradiated Azo-FPP1 exhibits sufficient reactivity to be
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applied in cellular studies with endogenously expressed FTase.33 As noted above, for these
studies this azolog would need to cross the plasma membrane from the cell growth media in
order to be utilized for protein modification within the cell. Current efforts by our collaborators
are underway to test the utility of Azo-FPP1 in cell-based studies of protein modification,
membrane localization, and biological function. Success in these studies will open interesting
new options for modulating the behavior of lipidated proteins modified by Azo-FPP1, which
could help further define the functional roles of prenylated proteins and investigate associated
signaling pathways within biological systems.
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3.5 Materials and Methods
3.5.1 Synthetic schemes of Azo-FPP analogs (Both synthetic procedures were completed by
Johannes Morstein of the Trauner Group (Department of Chemistry, New York
University):

Synthesis Scheme 3.1: Chemical synthesis of Azo-FPP1. This synthetic procedure was
performed by our collaborator Johannes Morstein from the Trauner Group (Department of
Chemistry, New York University).
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Synthesis Scheme 3.2: Chemical synthesis of Azo-FPP2. This synthetic procedure was
performed by our collaborator Johannes Morstein from the Trauner Group (Department of
Chemistry, New York University).

3.5.2 Assessing activity of Azo-FPP analogs with FTase and dns-GCVLS via RP-HPLC:
dns-GCVLS (3 μM) were incubated with both 1x reaction buffer (50 mM HEPPSO-NaOH, pH
7.8, 5 mM TCEP) and 5 mM MgCl2 (50 μL total) for 20 minutes in 0.65 mL low-adhesion
eppendorf tubes. Peptide reactions were initiated by adding an enzyme mix (50 μL) containing
100 nM FTase, 5 mM MgCl2, 1x reaction buffer, and 10 μM prenyl donor [FPP (positive
control), Azo-FPP1 or Azo-FPP2]. Reactions were incubated at RT for 16 hours before adding
an equal volume of 20% acetic acid in isopropanol to stop the reaction. HPLC analysis was
performed at ambient temperature on an Agilent 1260 HPLC system with auto-sampler, UV-Vis,
and fluorescence detection using a C18 reversed-phase analytical column (Zorbax XDB-C18)
with a linear gradient from 30% acetonitrile in 25 mM ammonium acetate to 100% acetonitrile
flowing at 1 mL/min over 30 minutes; peptides and products were detected by fluorescence (ex
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340 nm, em 496 nm).

3.5.3 Assessing activity of Azo-FPP analogs with GGTase-I and dns-GCVLL via RPHPLC: dns-GCVLL (3 μM) was incubated with both 1x reaction buffer (50 mM HEPPSONaOH, pH 7.8, 5 mM TCEP) (50 μL total) for 20 minutes in 0.65 mL low-adhesion eppendorf
tubes. Peptide reactions were initiated by adding an enzyme mix (50 μL) containing 100 nM
GGTase-I, 1x reaction buffer, and 10 μM prenyl donor [FPP (positive control), Azo-FPP1 or
Azo-FPP2]. Reactions were incubated at RT for 16 hours before adding an equal volume of 20%
acetic acid in isopropanol to stop the reaction. HPLC analysis was performed at ambient
temperature on an Agilent 1260 HPLC system with auto-sampler, UV-Vis, and fluorescence
detection using a C18 reversed-phase analytical column (Zorbax XDB-C18) with a linear
gradient from 30% acetonitrile in 25 mM ammonium acetate to 100% acetonitrile flowing at 1
mL/min over 30 minutes; peptides and products were detected by fluorescence (ex 340 nm, em
496 nm).

3.5.4 Detection of Azo-FPP1 photoisomers via RP-HPLC analysis: dns-GCVLS (3 μM) was
incubated with both 1x reaction buffer (50 mM HEPPSO-NaOH, pH 7.8, 5 mM TCEP) and 5
mM MgCl2 (50 μL total) for 20 minutes in 0.65 mL low-adhesion eppendorf tubes. Peptide
reactions were initiated by adding an enzyme mix (50 μL) containing 100 nM FTase, 5 mM
MgCl2, 1x reaction buffer, and 10 μM Azo-FPP1. Reactions were incubated at RT for 16 hours
before adding an equal volume of 20% acetic acid in isopropanol to stop the reaction. Following,
the reaction mixtures were illuminated with either 365 nm or 460 nm LED lights for three
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minutes before performing the HPLC analysis. HPLC analysis was performed at ambient
temperature on an Agilent 1260 HPLC system with auto-sampler, UV-Vis, and fluorescence
detection using a C18 reversed-phase analytical column (Zorbax XDB-C18) with a linear
gradient from 30% acetonitrile in 25 mM ammonium acetate to 100% acetonitrile flowing at 1
mL/min over 30 minutes; peptides and products were detected by fluorescence (ex 340 nm, em
496 nm).

3.5.5 Time course study to determine reactivity of trans- and cis-Azo-FPP1: Peptide mix
consisting of dns-GCVLS (3 μM) incubated with both 1x reaction buffer (50 mM HEPPSONaOH, pH 7.8, 5 mM TCEP) and 5 mM MgCl2 (50 μL total) for 20 minutes in 0.65 mL lowadhesion eppendorf tubes. Before peptide reactions were initiated by adding an enzyme mix (50
μL) containing 100 nM FTase, 5 mM MgCl2, 1x reaction buffer, and 10 μM Azo-FPP1, the
enzyme mix was either non-illuminated or illuminated with 365 nm LED light (cis isomer) for 3
minutes in dark. Reactions were incubated at RT for different time points; 30 minutes, 60
minutes, 120 minutes, 240 minutes, or 360 minutes. HPLC analysis was performed at ambient
temperature on an Agilent 1260 HPLC system with auto-sampler, UV-Vis, and fluorescence
detection using a C18 reversed-phase analytical column (Zorbax XDB-C18) with a linear
gradient from 30% acetonitrile in 25 mM ammonium acetate to 100% acetonitrile flowing at 1
mL/min over 30 minutes; peptides and products were detected by fluorescence (ex 340 nm, em
496 nm). Reaction progress was calculated by % peptide conversion to prenylated product, with
substrate and product peaks assigned per retention times:
% conversion = Product Integration / (Product + Substrate Integration)
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3.5.6 Time course study to gauge reactivity of non-illuminated Azo-FPP1 in comparison to
AlkC15OPP: To probe the reactivity of Azo-FPP1 and to determine if the reactivity of AzoFPP1 is sufficient to potentially support cell-based metabolic labeling, this analogue was
compared with C15AlkOPP (an isoprenoid alkyne analogue from DiStefano Lab, University of
Minnesota) using a time course experiment with peptide substrate. A peptide mix consisting of
dns-GCVLS (3 μM) was incubated with both 1x reaction buffer (50 mM HEPPSO-NaOH, pH
7.8, 5 mM TCEP) and 5 mM MgCl2 (50 μL total) for 20 minutes in 0.65 mL low-adhesion
eppendorf tubes. Peptide reactions were initiated by adding an enzyme mix (50 μL) containing
100 nM FTase, 5 mM MgCl2, 1x reaction buffer, and either 10 μM Azo-FPP1 or C15AlkOPP.
Following addition of equal volume of 20% acetic acid in isopropanol stop solution at different
time intervals, 30 minutes, 60 minutes, 120 minutes, and 240 minutes; reaction mixtures were
analyzed by reverse-phase HPLC to determine the extent of peptide prenylation by both donor
substrates. Since the C15AlkOPP probe results in a greater fluorescence enhancement/detection
on the HPLC, UV chromatograms were analyzed at absorbance of 340 nm for the dansyl group.
Reaction progress was obtained by calculating the concentration of product formation (μM) with
normalization to the UV absorbance observed upon reaction completion. HPLC analysis was
performed at ambient temperature on an Agilent 1260 HPLC system with auto-sampler, UV-Vis,
and fluorescence detection using a C18 reversed-phase analytical column (Zorbax XDB-C18)
with a linear gradient from 30% acetonitrile in 25 mM ammonium acetate to 100% acetonitrile
flowing at 1 mL/min over 30 minutes; peptides and products were detected by fluorescence (ex
340 nm, em 496 nm).
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Chapter 4: Development of a FRET assay to monitor protein
prenylation within cells

The work presented herein is unpublished.

FLIM-FRET microscopy and analysis was performed by Peter Calvert (Center for Vision
Research, Upstate Medical University). HEK293 cell maintenance and preparation for
microscopy was assisted by Himanshu Malhotra from the Calvert Lab (Center for Vision
Research, Upstate Medical University).

David W. Coreno (Syracuse University) assisted with expression and purification of His6-PDEδ.
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4.1 Introduction
As described in Chapter 2, membrane localization studies in mammalian cells using the
modified eGFP-KRas fusion protein did not provide evidence for the prenylation of noncanonical Cxx sequences. This could be because Cxx sequences are not prenylated inside cells as
in vitro steady-state analysis showed that the sequences tested are not as reactive as the most
reactive CaaX sequences (see section 2.6).1 Or these Cxx proteins are modified by FTase, but are
shunted (i.e. not proteolysed and methylated following prenylation) as several of the sequences
tested were recovered from a Ydj1p-based assay.2, 3 Therefore, membrane localization studies
would not help identify potential substrates in a mammalian context, as post-processing of
prenylated proteins is often required for localization at the plasma membrane.
To expand our ability to monitor protein prenylation, we aimed to develop a FRET based
assay that would allow us to detect prenylation of Cxx sequences in cells. Förster Resonance
Energy Transfer (FRET) is a photo-physical process by which energy (non-radiative) is
transferred from an excited state of one fluorophore (termed the donor (D*)) to another
fluorophore (the acceptor (A)) via a dipole-dipole interaction.4 For this energy transfer to occur, a
number of criteria must be satisfied. First, the absorption spectra of the acceptor must have
sufficient overlap with the emission spectra of the donor. Second, the transition dipole moments
of the donor and acceptor must be favorably aligned. Finally, the donor and acceptor must be
near each other for energy transfer to occur (generally within ~10 nm).5-7 The energy transfer
rate from the donor to the acceptor decreases with the sixth power of the distance. Due to the
dependence on the distance between the donating and the accepting fluorophores, FRET has
become a valuable tool for studying biological phenomena.8-11 By labeling different proteins
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with the donor and the acceptor, FRET can be used to ascertain if proteins interact with each
other.
One common approach for monitoring FRET utilizes the increase in acceptor
fluorescence due to the energy transfer from the donor.12 However, these measurements must
account for the concentration dependence of the fluorescence intensities of the donor and the
acceptor. In addition, there can be complications from ‘donor bleed through’ due to the overlap
of the donor fluorescence into the acceptor emission band and non-FRET fluorescence from
directly excited acceptor molecules. Therefore, such measurements require careful calibration of
these factors using data of samples containing only the donor and only the acceptor.13-16
In addition to the fluorescence intensity, detecting changes in the fluorescence/excited
state lifetime of a donor molecule provides another option for monitoring FRET. When a
molecule absorbs a photon, it enters an electronically excited singlet state. From this excited
state, the molecules can return to the ground state by emitting a photon, by internally converting
the absorbed energy into heat, by passing the energy to its molecular environment, or by crossing
into the triplet state and returning to the ground state by phosphorescence or internal
conversion.17 For a homogenous population of molecules, the resulting fluorescence decay can
be fit to a single exponential function. The time constant of this function, the fluorescence
lifetime, is the reciprocal sum of the rate constants of all possible return paths. The fluorescence
lifetime is dependent on the fluorescent molecule’s conformation and the way the molecule
interacts with its environment.18 Of all fluorescence parameters, it is the fluorescence decay
function that provides the most direct insight into the molecular interactions with its biological
environment.18 For in cellulo studies, fluorescence lifetime imagining microscopy (FLIM) of the
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donor is the gold standard for FRET measurements as FRET results in a quenching of the donor
fluorescence and thus, decreases the donor lifetime (Figure 4.1).6, 7, 18, 19
To establish a FRET assay for assessing the prenylated state of non-canonical Cxx
sequences in cells, a prenyl binding protein is required which will associate with the modified
“Cxx” protein. This bimolecular association can be used to place donor and acceptor groups in
proximity to allow FRET between them. The cytoplasmic prenyl binding factor PDEδ has been
reported as a binding partner for various prenylated small G proteins including K/HRas and nonprenylated small G proteins such as Arl1 and Arl3.20-23 PDEδ has also been proposed to assist in
H/N/KRas signaling in a similar way to Rho- and Rab-GDIs (Guanine-nucleotide Dissociation
Inhibitors) that bind to prenylated GDP-bound small G-proteins and thus constitute a
cytoplasmic pool of inactive G-proteins.20 The Bastiaens group showed that PDEδ plays a role in
modulating cell signaling through Ras family G proteins by sustaining their dynamic distribution
in cellular membranes.24 Moreover, they also showed that farnesylation of target proteins was
necessary for the observed modulation by PDEδ. This work utilized FLIM-FRET to study the
impact of PDEδ on the dynamic distribution of multiple prenylated Ras proteins and inspired the
efforts reported in this chapter.24
The work herein describes development of a FRET based assay which would allow for
the detection of prenylated non-canonical Cxx motifs in a biological context. First, we attempted
an in vitro characterization using purified His6-mCherry-PDEδ fusion protein with purified eGFP
protein appended with prenylation motifs to determine if PDEδ binds prenylated non-canonical
Cxx sequences. Followed by studies that utilized purified His6-PDEδ with purified prenylated
dansyl peptides. We also report initial studies towards in cellulo characterization utilizing FLIM-
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FRET to detect binding of non-canonical Cxx sequences in the context of two different fusion
proteins.
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Figure 4.1. Fluorescence resonance energy transfer. Left panel: FRET is an interaction of two
fluorophore molecules with the emission band of one overlapping the absorption band of the
other. Right panel: FRET results in a quenching of the donor fluorescence and consequently,
decrease in the donor lifetime. This figure has been reused with permission from reference 18
(Appendix IV).
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4.2 Establishing an in vitro FRET assay to assess binding of mCherry-PDEδ and prenylated
eGFP-fusion peptide
We aimed to design another system for detecting prenylation of non-canonical sequences
inside a mammalian cell. This assay is based on a mCherry-PDEδ fusion protein, the mammalian
plasmid for which was generously provided by the Bastiaens Group (Max Planck Institute of
Molecular Physiology). Phosphodiesterase 6 (PDE6) delta subunit (PDEδ) is a cytoplasmic
prenyl binding factor that has been proposed to assist in H/N/KRas intracellular trafficking by
binding to the prenylated domain.21, 22 In their study, Chandra et al. demonstrated the role of
PDEδ in modulating signaling through Ras family G proteins by using a FRET system consisted
of mCherry-PDEδ and various Ras proteins fused to the monomeric yellow fluorescent protein
Citrine.24 Interactions between the prenylated mCitrine-Ras proteins and mCherry-PDEδ
produced a FRET signal allowing them to visualize the direct interaction of these two proteins.
We aimed to develop a similar FRET signaling system to investigate prenylation of noncanonical Cxx sequences in cells.
Towards that goal, we first investigated whether this system would be viable for
monitoring Cxx prenylation within an intact cell by establishing an in vitro model assay. After
sequence confirmation of the mammalian mCherry-PDEδ vector, the mCherry-PDEδ insert was
cloned into a pET-28a bacterial expression vector. The pET-28a vector inserts a His-tag at the Nterminus of the expressed protein to allow for affinity purification. Successful cloning was
confirmed via sequencing. Expression of His6-mCherry-PDEδ in a bacterial cell culture was
visually detected by the bright pink color change in the bacterial culture and visualization of a
pink band when analyzing the cell lysate on SDS-PAGE gel. While the predicted molecular
weight for His6-mCherry-PDEδ is 46.8 kDa, the pink band representing the fluorescent protein
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was observed to run aberrantly low closer to the 40 kDa ladder band suggesting incomplete
denaturation of the expressed protein (Figure 4.2A). Following protein expression, the His6mCherry-PDEδ protein was purified using Nickel resin-based metal affinity chromatography
(Figure 4.2B). Again, His6-mCherry-PDEδ’s pink band was observed to run aberrantly low when
analyzed via a denaturing SDS-PAGE. Of note, we also observed two bands for the purified
protein when diluted. A non-denaturing SDS-PAGE analysis was carried out on purified His6mCherry-PDEδ where only a single band was observed running at ~40 kDa, consistent with the
non-denatured protein exhibiting lower apparent molecular weight (Figure 4.2C).
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Figure 4.2. Expression and purification of His6-mCherry-PDEδ shown in white. A)
Denaturing SDS-PAGE gel analysis of His6-mCherry-PDEδ purification. B) Serial dilution of
purified His6-mCherry-PDEδ under denaturing conditions. C) Purified His6-mCherry-PDEδ
under non-denaturing conditions; the doublet in gel B) lane 2 collapses to the lower band in C).
Bands on all three SDS-PAGE Gels were assigned for the expressed and purified protein based
on the visualization of a clear pink band. His6-mCherry-PDEδ was expressed and purified as
described in Materials and Methods.

A)
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B)

C)
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Following expression and purification, His6-mCherry-PDEδ was used in assays to
measure FRET activity that would reflect binding to a prenylated eGFP fluorescent protein. A
binding event is expected to produce a FRET signal, as the mCherry and eGFP fluorescent
proteins are compatible with FRET given their overlapping emission (eGFP) and absorption
(mCherry) spectra.25 To ensure the two protein constructs were FRET compatible, emission
spectral scans of both His6-mCherry-PDEδ and eGFP-CVIA were performed. However, as
shown in Figure 4.3A and 4.3B, we observed a strong emission from His6-mCherry-PDEδ at the
excitation wavelengths of 420 nm and 450 nm, where we expected to only observe emission
from eGFP. Moreover, we found that both fluorescent fusion proteins emit at 510 nm during an
excitation scan, where we again expected to only see eGFP emit (Figure 4.3C). These
unexpected excitation and emission spectral results for His6-mCherry-PDEδ suggest that it is not
an ideal FRET pair for eGFP, at least for this in vitro analysis.
Despite these results, purified prenylated eGFP-CVIA and mCherry-PDEδ were
incubated together under foil and analyzed on the plate reader at 15- and 60-minutes increments
by exciting eGFP at 488 nm and observing emission of mCherry at 610 nm. A negative control
with purified non-prenylated eGFP-CVIA was also analyzed (Figure 4.4). No appreciable change
in mCherry fluorescence was observed between the two tested conditions, suggesting that
binding between the two proteins was not achieved.
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Figure 4.3. Spectral characterization of His6-mCherry-PDEδ and eGFP-CVIA. A)
Emission spectral scan of His6-mCherry-PDEδ and eGFP-CVIA obtained via plate-reader
monitoring (ex = 420 nm) B) Emission spectral scan of His6-mCherry-PDEδ and eGFP-CVIA
obtained via plate-reader monitoring (ex = 450 nm) C) Excitation spectral scan of His6mCherry-PDEδ and eGFP-CVIA obtained via plate-reader monitoring (em = 510 nm).

A)

B)

C)

184

Figure 4.4. FRET analysis to assess binding interaction of His6-mCherry-PDEδ with
farnesylated and non-farnesylated eGFP-CVIA at 15- and 60-minutes post-incubation.
Fluorescence measurements obtained via plate-reader monitoring of FRET-based emission from
mCherry (ex = 488 nm, em = 610 nm), which do not provide evidence for FRET.
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4.3 Expression and purification of PDEδ and development of FRET assay using PDEδ and
a prenylated dansyl-peptide
With our initial efforts to measure FRET activity between His6-mCherry-PDEδ and
prenylated eGFP-CVIA unfruitful, we sub-cloned PDEδ into the pET-28a vector to directly
examine binding of a prenylated dansyl-peptide and PDEδ based on previous work.26 This
system utilizes direct excitation of tryptophan residues in PDEδ and FRET-based emission from
the dansyl fluorphore in the peptide. Successful sub-cloning was verified via Sanger sequencing.
Expression of His6-PDEδ was verified by the visualization of a prominent band on a nondenaturing SDS-PAGE gel at ~20 kDa corresponding to the His6-PDEδ molecular weight (~17.4
kDa). The His6-PDEδ protein was purified using Ni2+-affinity resin (Figure 4.5).
Following purification of His6-PDEδ protein, assays were performed to determine the
presence of FRET signal indicating binding of farnesylated dns-GCVLS to His6-PDEδ. Spectral
scans of His6-PDEδ in presence of farnesylated dns-GCVLS were obtained by exciting the
tryptophan residues in His6-PDEδ at 282 nm and monitoring dansyl group emission at 515 nm.
Negative controls consisted of His6-PDEδ with non-farnesylated dns-GCVLS, His6-PDEδ alone,
and both prenylated and non-prenylated dns-GCVLS alone. Emission spectral scans were carried
out following overnight incubation (see Materials and Methods). These scans did not provide a
consistent increase in fluorescence signal from the dansyl group in the peptide- His6-PDEδ
sample compared to negative control of His6-PDEδ only and/or His6-PDEδ with non-prenylated
dns-GCVLS peptide (Figure 4.6). Inconsistency in readings between wells makes interpreting
results more difficult. We failed to observe any consistent increase in fluorescence of the dansyl
group for the prenylated peptide in presence of His6-PDEδ, suggesting that PDEδ does not bind
the prenylated dns-GCVLS peptide under the conditions tested.
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These results are not overly surprising as studies have shown that PDEδ prefers binding
proteins that are processed post-prenylation, including a crystal structure of PDEδ bound to
KRas protein.26, 27 Specifically, PDEδ exhibits a greater affinity for proteins that are
carboxymethylated at their C-terminus following prenylation. In our assay, the dns-GCVLS
peptide used still has the three amino acids following the prenylated cysteine. In comparison, the
in vitro study performed by Zhang and co-workers utilized synthesized prenylated dansylcysteines with a carboxylmethyl moiety following the prenyl cysteine. Based on the crystal
structure and the Zhang study, we reasoned that the binding pocket of PDEδ may not be able to
accommodate the extra amino acids present in our tested peptide.
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Figure 4.5. Serial dilution of purified His6-PDEδ analyzed by SDS-PAGE Gel under nondenaturing conditions, MW = 17.4 kDa, as shown in white. His6-PDEδ was expressed and
purified as described in Materials and Methods.
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Figure 4.6. FRET measurements to determine binding interaction of PDEδ with
farnesylated and non-farnesylated dns-GCVLS via plate-reader. A)1 µM PDEδ incubated
with 500 nM prenylated or non-prenylated dns-GCVLS peptide overnight. B) 5 µM PDEδ
incubated with 500 nM prenylated or non-prenylated dns-GCVLS (two separate trials). Emission
spectral scans were obtained (ex = 282 nm, em = 400-600 nm) the following day as described in
Materials and Methods.

A)
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B)
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4.4 Investigating prenylation of non-canonical Cxx sequences in HEK293 cells via FLIMFRET using GRK1 protein construct
Note: FLIM-FRET microscopy and analysis was performed by Peter Calvert (Center for
Vision Research, Upstate Medical University). Cell maintenance and preparation was assisted
by Himanshu Malhotra from the Calvert Lab (Center for Vision Research, Upstate Medical
University).
Despite unsuccessful efforts towards the development of an in vitro FRET assay based on
mCherry-PDEδ or PDEδ binding prenylated eGFP or prenylated dansyl-peptides, respectively;
we explored FLIM-FRET studies using live cells to gauge the prenylation status of noncanonical Cxx sequences in the context of two mammalian fluorescent fusion proteins, mCherry
and eGFP. This work was based on an established study where the Bastaeins group used FLIMFRET to delineate the spatial organization of Ras proteins conferred by PDEδ activity.24
In collaboration with the Calvert Group (Upstate Medical University), we designed
FLIM-FRET experiments utilizing mCherry-PDEδ and an eGFP-GRK1 construct that was
modified at its C-terminus to contain prenylation motifs of interest. We chose the eGFP-GRK1
construct for this study for several reasons. First, numerous studies have reported that PDEδ
serves as a binding partner for GRK1, a rhodopsin kinase, for the proper localization of GRK1.28,
29

Second, as described in Chapter 1, prenylated protein usually require a secondary signal in

order to membrane associate. That signal can be an additional lipid modification, such as
palmitoylation, or it can be in the form of electrostatic interactions with the negatively charged
plasma membrane inner leaflet. The GRK1 sequence used in this study lacks multiple positively
charged residues that would aid its membrane localization and is not known to go under any
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further modifications once prenylated and processed, which makes this prenylated construct
more cytosolically available for binding interactions with PDEδ. It is also important to note,
however, that the Maza study utilized endogenously expressed PDEδ in rods of Xenopus laevis
in contrast to the human PDEδ sequence we utilized in this study,33 and that study used the
GRK1 sequence expressed in Xenopus laevis, which is also different from the human form.
For this study, the eGFP-GRK1 construct was modified to contain the following Cterminal sequences: -CVLS, -AVLS, and -CVL. These sequences were selected based on known
steady-state kinetic parameters (see section 2.6), representing the most active CaaX and Cxx
sequences tested.1 The alanine mutant serves as the negative control as it is not expected to be
prenylated or modified in any form, while -CVLS serves as the positive control as it is known to
be prenylated, processed, and bind to PDEδ.24
We initially expressed only the eGFP-GRK1-CVLS/-AVLS constructs in HEK293 cells
to establish a baseline FLIM-FRET signal that may result from the normal lifetime for eGFP or
homoFRET, i.e. eGFP to eGFP energy transfer. Robust expression of eGFP-GRK1 bearing CVLS and -AVLS sequences at their C-terminus was confirmed via fluorescence microscopy
and the resulting FLIM-FRET signals were analyzed to exhibit similar lifetimes for both eGFP
donor (Figure 4.7). Both eGFP-GRK1-CVLS and eGFP-GRK1-AVLS expressed proteins
showed lifetimes of approximately 2300-2400 ps. The fluorescence lifetimes observed are
shorter than the reported lifetime of eGFP at 2800 ± 70 ps (Mamontova), suggesting that
homoFRET might be playing a role in the values obtained (Figure 4.7). Moreover, eGFP-GRK1-

CVLS expression was found to be diffuse throughout the cell, making it available to bind with
mCherry-PDEδ.
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Figure 4.7. FLIM-FRET measurements in HEK293 cells expressing either eGFP-GRK1CVLS or eGFP-GRK1-AVLS. Left panel: HEK293 cells transfected with eGFP-GRK1-CVLS
or eGFP-GRK1-AVLS demonstrating diffuse fluorescence. Right panel: Mean florescence
lifetime plots of each respective sample.
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Following FLIM-FRET measurements of eGFP-GRK1 constructs alone, co-expression of
mCherry-PDEδ and eGFP-GRK1 constructs was performed in HEK293 cell with protein
expression verified by fluorescence microscopy. FLIM-FRET studies of co-transfected cells
were then performed and analyzed. In these experiments, a successful binding interactions would
be indicated by a larger reduction in the fluorescence lifetime of eGFP-GRK1-CVLS (presumed
prenylated) with mCherry-PDEδ than any changes observed with eGFP-GRK1-AVLS which is
expected to not be prenylated. In our experimental analysis, eGFP-GRK1-AVLS co-expressed
with mCherry-PDEδ exhibited a lower lifetime compared to eGFP-GRK1-AVLS alone (Figure
4.8). The lifetime of eGFP-GRK1-CVLS in presence of mCherry-PDEδ was similarly lower in
comparison to eGFP-GRK1-CVLS by itself. Moreover, we detected small peaks at a lower
fluorescence lifetime in the FLIM plot which correspond to a small proportion of the expressed
eGFP-GRK1-CVLS population in presence of mCherry-PDEδ (Figure 4.8), suggesting binding
of fraction of eGFP-GRK1-CVLS by mCherry-PDEδ likely due to prenylation. However, the
majority of the FLIM signal from eGFP-GRK1-CVLS in presence of mCherry-PDEδ was
comparable with the signal generated by the co-expression of eGFP-GRK1-AVLS and mCherryPDEδ. This highlights that these results should be interpreted carefully and require further
control experimentation, such as the co-expression of the eGFP-GRK1 constructs with mCherry
only to examine the possibility for non-prenylation dependent interactions with PDEδ. In the
case of the eGFP-GRK1-CVL construct expressed with mCherry-PDEδ, the FLIM-FRET results
were comparable to the negative control involving only eGFP-GRK1 constructs, suggesting that
a significant binding event between eGFP-GRK1-CVL and mCherry-PDEδ did not occur (Figure
4.8). Again, a control experiment with the eGFP-GRK1 constructs and mCherry only will help
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interpret these results and provide a comprehensive assessment about the viability of this assay
for detection of prenylation on Cxx sequences.
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Figure 4.8. FLIM-FRET measurements in HEK293 cells co-expressing eGFP-GRK1-CVLS
or eGFP-GRK1-AVLS or eGFP-GRK1-CVL and mCherry-PDEδ. Left panel: HEK293 cells
co-transfected with eGFP-GRK1-CVLS or eGFP-GRK1-AVLS or eGFP-GRK1-CVL and
mCherry-PDEδ. Right panel: Mean fluorescence lifetime plots of each respective sample.
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4.5 Investigating prenylation of non-canonical Cxx sequences in HEK293 cells via FLIMFRET using modified eGFP-KRas protein constructs with mCherry-PDEδ
Note: FLIM-FRET microscopy and analysis was performed by Peter Calvert (Center for
Vision Research, Upstate Medical University). Cell maintenance and preparation was assisted
by Himanshu Malhotra from the Calvert Lab (Center for Vision Research, Upstate Medical
University).
As described, the results from the FLIM-FRET analysis of live HEK293 cells coexpressing the modified eGFP-GRK1 constructs and mCherry-PDEδ did not provide a clear
representation regarding PDEδ binding the GRK1 constructs that is dependent on prenylation. It
is also important to note that the GRK1 construct utilized in that study was based on the Xenopus
Laevis GRK1 protein’s C-terminal amino acid sequence, which differ from the human version,
while the PDEδ protein expressed in live cells is of human origin. Therefore, it is conceivable
that these two proteins do not bind or bind as well as their respective human orthologs. To
mitigate the possibility that the observed lack of significant difference in FLIM signal between
the positive and negative controls is due to the utilization of cross-species proteins, we employed
a known binding partner of human PDEδ, human KRas protein.24, 27, 30
For this study, only an initial test with eGFP-KRas that has a canonical -CVIM motif was
carried out in the presence and absence of mCherry-PDEδ. Using live cells, completely
processed prenylated eGFP-KRas with its canonical C-terminus motif is expected to membrane
localize and bind PDEδ.27, 31 PDEδ is proposed to play a role in continuously sequestering
mislocalized KRas from endomembranes to ultimately restore KRas enrichment on the plasma
membrane.32 Consequently, the cytosolic fraction of prenylated KRas available to bind with
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mCherry-PDEδ is minimal compared to the GRK1 construct tested in section 4.4.24 Therefore, it
is not surprising that the FLIM-FRET results observed from the co-expression of eGFP-KRas
and mCherry-PDEδ in live HEK293 cells do not provide evidence for any binding interactions.
As shown in Figure 4.9, membrane localization of eGFP-KRas at the plasma membrane and the
lifetime of eGFP-KRas in presence of mCherry-PDEδ was comparable to the lifetime of eGFPKRas by itself. This result was expected and is in agreement with prior reports.24
While the results from this experiment do not provide evidence for PDEδ binding due to
the aforementioned reason, this system might still prove useful for detecting prenylation of noncanonical Cxx sequences. This is because KRas membrane localization is not only dependent on
farnesylation, but the polybasic residues upstream of the prenylated cysteine that utilize
electrostatic interactions to membrane associate with the negatively charged inner leaflet.31
Chandra and co-workers were able to increase the cytosolic fraction of KRas by mutating the
polybasic lysine residues to negatively charged glutamate residues and demonstrated a lower
lifetime for the mutated mCitrine-KRas construct in presence of mCherry-PDEδ, suggestive of
binding interactions.24 Therefore, future work should aim to utilize a KRas construct that is more
available in the cytosol for assessing binding with PDEδ.
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Figure 4.9. FLIM-FRET measurements in HEK293 cells co-expressing eGFP-KRas and
mCherry-PDEδ. Left panel: HEK293 cells transfected with eGFP-KRas or co-transfected with
eGFP-KRas and mCherry-PDEδ. Right panel: Mean fluorescence lifetime plots of each
respective sample.
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4.6 Conclusions
In this study, both in vitro and in vivo FRET-based techniques were explored to
investigate prenylation of non-canonical Cxx sequences. In vitro FRET assays to evaluate
binding of the prenylated protein/peptide to PDEδ using mCherry-PDEδ with prenylated eGFPCVIA and PDEδ alone with prenylated dns-GCVLS did not yield consistent FRET behavior
indicative of any binding events. We suggest that these negative results may arise from the
presence of unprocessed prenylated protein/peptide. Specifically, PDEδ exhibits a higher affinity
for prenylated substrates that have a carboxymethyl moiety following the prenylated cysteine
compared to prenylated substrates that still have an intact CaaX motif.26
In a more biologically relevant context, FLIM-FRET was utilized to assess binding of
fluorescent protein constructs by mCherry-PDEδ that is dependent on prenylation of the
fluorescent protein construct. FLIM-FRET provides a powerful avenue for quantifying binding
interactions. Two different fluorescent constructs were used in this study including the Cterminal 18 amino acid sequence of rhodopsin kinase (GRK1) protein, and full-length KRas. It is
important to note that the modified eGFP-GRK1C18 constructs were based on the GRK1 protein
expressed in Xenopus Laevis and are expected to be cytosolic when prenylated, while the eGFPKRas construct is based on human KRas protein and is expected to membrane associate
following prenylation and processing. PDEδ has been reported to bind both prenylated
proteins.20-24
For the eGFP-GRK1 constructs expressed with mCherry-PDEδ, the FLIM-FRET analysis
provided some evidence for the binding of eGFP-GRK1-CVLS by mCherry-PDEδ through the
presence of eGFP subpopulations with markedly reduced fluorescence lifetimes. However, the
test construct of eGFP-GRK1-CVL with mCherry-PDEδ provided results similar to the negative
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control. Overall, these initial results are not conclusive and do not completely rule out the
utilization of this assay for detecting Cxx prenylation, but would be aided by the addition of a
negative control in which the eGFP-GRK1 constructs are co-expressed with mCherry only to
fully evaluate their lifetimes and binding potential. Further, utilization of the human GRK1
protein sequence is recommended to assuage any discriminatory behavior human PDEδ might
exhibit towards the Xenopus Laevis GRK1.
Leveraging human KRas, a known binding partner for PDEδ, also proved unfruitful in
this FLIM-FRET based study. The results indicated a clear membrane associative behavior for
eGFP-KRas, demonstrating the lack of cytosolic KRas available to bind PDEδ and produce a
FRET signal. Increasing the cytosolic fraction of prenylated KRas by mutating the lysine rich
area of KRas to glutamate residues would provide a better system for evaluating the viability of
this assay for detecting prenylation of non-canonical 3mer sequences.
Lastly, it is important to mention PDEδ’s binding preference again and how that may
influence the utility of this proposed assay. As described in section 4.3, PDEδ exhibits a higher
affinity for farnesylated proteins that are processed compared to their unprocessed
counterparts.26, 27 Therefore, it is important to consider if PDEδ can serve as a potential binding
partner for non-canonical sequences that are longer compared to processed farnesylated
canonical sequences. Future work towards the development of this detection method should take
this into account and aim to employ a mutagenesis strategy based on the proteins crystal
structure that would facilitate binding of longer PDEδ substrates.
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4.7 Materials and Methods

4.7.1 Construction of pET28a-mCherry-PDEδ bacterial vector: The mammalian vector for
mCherry-PDEδ obtained from Bastiaens Group (Max Planck Institute of Molecular Physiology)
was sequence verified to confirm the presence of both EcoR1 and Nhe1 restrictions sites
(Genewiz). Both the mammalian inserts and the pET28a vectors were double digested using
EcoR1 and Nhe1-HF restriction enzymes in a reaction containing 1 µg DNA, 2 µL 10x Buffer, 1
µL of each restriction enzyme in 20 µL total volume. The double digest reaction was incubated
for 2 hours at RT and then ran on a 0.8 % agarose gel to confirm successful digestion. The
digested products were purified from the gel using EZ-10 Spin Column DNA Gel Extraction kit
(BioBasic) per the manufacturer’s protocol. 1 µg of the double digested pET28a vector was
ligated with a 3-fold molar excess of the mCherry-PDEδ insert to get the pET28a-mCherryPDEδ vector. The ligation reaction was carried out as follows: 50 ng double digested pET28a
vector, 33.8 ng mCherry-PDEδ insert, 2X QuickLigase buffer (10 µL), and 1 µL of Quick ligase
enzyme (NEB) were added in a total reaction volume of 20 µL. A negative control reaction
without the mCherry-PDEδ insert was also carried out. The reactions were incubated at RT for 5
min before chilling them on ice and adding 2 µL of each the ligation reaction and the negative
control into separate tubes with 100 µL of DH5 cells. After transformation, DH5 cells were
incubated for 30 min on ice. 250 µL 1X LB Media was added to each transformed cell tube and
shaken for 1 hour at 37°C before plating the cells on LB-Kan plates and incubating overnight at
37°C. Colonies from the ligation reaction plate were inoculated into 5 mL of LB containing 50
µg/mL kanamycin and incubated overnight at 37°C with shaking at 225 rpm. The plasmids from
the overnight cultures were purified using the EZ-10 spin column plasmid purification kit
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(BioBasic) per manufacturer’s protocol and sequenced (Genewiz) to confirm the presence of
mCherry-PDEδ insert in the pET28a vector.

4.7.2 Expression and purification of pET28a-mCherry-PDEδ protein: Chemically competent
BL21 (DE3) E. coli were transformed with pET28a-mCherry-PDEδ vector. Following
transformation and antibiotic selection, a colony from the transformation plate was inoculated
into LB media (5 mL) containing 50 µg/mL kanamycin. Cultures were incubated and shaken at
225 rpm for 4 h at 37°C and then transferred to 0.5 liter of prewarmed auto-induction media (5 g
tryptone, 2.5 g yeast extract, 10 mL 50X 5052 media [25% glycerol, 10% lactose, 2.5% glucose],
25 mM Na2HPO4, 25 mM KH2PO4, 50 mM NH4Cl, 5 mM Na2SO4, 2 mM MgSO4, 100 µL
trace metals [50 µM FeCl2, 20 µM CaCl2, 10 µM MnCl2, 10 µM ZnCl2], 50 µg/mL kanamycin.
Expression cultures were incubated for 19 h at 37˚C with shaking. Cells were harvested by
centrifugation and resuspended in 50 mL resuspension buffer (20 mM NaH2PO4, 300 mM NaCl,
and 10 mM imidazole). Bacterial cell suspensions were lysed by sonication, clarified by
centrifugation, and purified by affinity chromatography using a Ni-NTA HisTrap column (GE S4
Healthcare). Fractions containing the fluorescent protein were combined and concentrated using
a centrifugal concentrator. Concentrated samples were buffer exchanged to 50 mM Tris buffer
(pH 7.5), divided into 20 µL aliquots, and flash frozen with liquid nitrogen for storage at −80°C.
Protein concentration was determined using the molar absorption of mCherry at 587 nm.

4.7.3 Construction of pET28a-PDEδ bacterial vector: The vector plasmid encoding for PDEδ
was prepared by PCR using the pET28a-mCherry-PDEδ vector with a 5’ primer containing the
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BamHI restriction site and a 3’ primer containing the HindIII restriction site (synthesized by
IDT, Inc.). The PCR reaction (50 μL) consisted of 1x Standard OneTaq buffer, 10 mM dNTPs,
125 ng reverse and forward primers each, 10 ng template plasmid, and OneTaq DNA polymerase
(0.25 µL, 5U/µL). The PCR reactions were performed in a BioRad Mycycler thermal cycler
using the following program: Initial denaturation (94°C, 1 min); thirty cycles of denaturation
(94°C, 30 sec), annealing (56°C, 1 min), and extension (68°C, 2 min); final extension (68°C, 5
min); and a final hold (10°C, ∞). PCR products were purified using BIO Basic Inc. EZ-10 Spin
Column PCR purification Kit following the manufacturer’s protocol. Following digestion by
BamHI and HindIII of the amplified product and pET28a, the PDEδ insert was ligated into the
pET28a plasmid using the Quick Ligase kit (NEB), following the manufacturer’s instructions.
Insert ligation was verified by analytical restriction digest and gene sequencing (Genewiz).

4.7.4 Expression and purification of pET28a-PDEδ: Chemically competent BL21 (DE3) E.
coli were transformed with pET28a-PDEδ vector. Following transformation and antibiotic
selection, a colony from the transformation plate was inoculated into LB media (5 mL)
containing 50 µg/mL kanamycin. Cultures were incubated and shaken at 225 rpm for 4 h at 37°C
and then transferred to 0.5 liter of prewarmed auto-induction media (5 g tryptone, 2.5 g yeast
extract, 10 mL 50X 5052 media [25% glycerol, 10% lactose, 2.5% glucose], 25 mM Na2HPO4,
25 mM KH2PO4, 50 mM NH4Cl, 5 mM Na2SO4, 2 mM MgSO4, 100 µL trace metals [50 µM
FeCl2, 20 µM CaCl2, 10 µM MnCl2, 10 µM ZnCl2], 50 µg/mL kanamycin. Expression cultures
were incubated for 19 h at 37˚C with shaking. Cells were harvested by centrifugation and
resuspended in 50 mL resuspension buffer (20 mM NaH2PO4, 300 mM NaCl, and 10 mM
imidazole). Bacterial cell suspensions were lysed by sonication, clarified by centrifugation, and
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purified by affinity chromatography using a Ni-NTA HisTrap column (GE S4 Healthcare).
Fractions containing the protein were combined and concentrated using a centrifugal
concentrator. Concentrated samples were buffer exchanged to 50 mM Tris buffer (pH 7.8),
divided into 20 µL aliquots, and stored at −20°C. Protein concentration was determined using the
molar absorption of PDEδ at 280 nm.

4.7.5 Farnesylation of purified eGFP-CVIA: Purified eGFP-CVIA was provided by Elizabeth
Cleverdon, Hougland Laboratory. 5 µM eGFP-CVIA was incubated with both 1X reaction buffer
(50 mM HEPPSO-NaOH, pH7.8, 5 mM TCEP) and 5 mM MgCl2 (.5 mL total) for 20 minutes in
1.5 mL low-adhesion eppendorf tube. Farnesylation reaction was initiated by adding an enzyme
mix (.5 mL) containing 100 nM FTase, 5 mM MgCl2, 1X reaction buffer, and 10 µM FPP.
Reaction was incubated at RT for 16 hours under foil before removing excess FPP through use of
a 0.5 mL illustra NAP-5 column (GE Healthcare). NAP-5 column was equilibrated with 50 mM
Tris-HCl (10 mL, pH7.8) before application of the 1 mL reaction sample. Elution followed with
50 mM Trish-HCl (1.0 mL, pH 7.8) into a low-adhesion eppendorf tube. Concentration of the
protein was calculated using UV-Vis absorbance of the eluent at 488 nm.

4.7.6 FRET assay to probe mCherry-PDEδ binding prenylated eGFP-CVIA: 300 nM
mCherry-PDEδ was incubated in 50 mM Tris-HCl (pH 7.8) at RT for 20 mins under foil before
adding prenylated eGFP-CVIA at various concentration, including, 25 nM, 50 nM, 100 nM, 200
nM, and 500 nM in a 96-well plate (Corning). Fluorescence measurements were obtained 15and 60-mins post-incubation in the BioTek H1 Synergy plate reader (ex 488 nm, em 610 nm).
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Relative fluorescence units were plotted against eGFP-CVIA concentrations. Controls consisted
of a non-prenylated eGFP-CVIA negative control.

4.7.7 Farnesylation and purification of dns-GCVLS: 3 µM dns-GCVLS was incubated with
both 1X reaction buffer (50 mM HEPPSO-NaOH, pH7.8, 5 mM TCEP) and 5 mM MgCl2 (.5 mL
total) for 20 minutes in 1.5 mL low-adhesion eppendorf tube. Farnesylation reaction was
initiated by adding an enzyme mix (.5 mL) containing 100 nM FTase, 5 mM MgCl2, 1X reaction
buffer, and 10 µM FPP. Reaction was incubated at RT for 16 hours under foil. Following
overnight incubation, the peptide reaction was purified by semi-preparative reverse phase HPLC
(Zorbax Eclipse XDB column, 9.4 x 250 mm) using a gradient mobile phase of 30%-100%
acetonitrile in aqueous 0.05 % trifluoroacetic acid (TFA) over 30.2 minutes, at a flow rate of 4.2
mL/min. Prenylated dansyl peptide elution was detected by fluorescence (ex 340 nm, em 496
nm), and fractions containing the prenylated peptide were collected and dried under vacuum at
room temperature and resuspended in 1:1 H2O: acetonitrile. Concentration of the protein was
calculated using UV-Vis absorbance of the eluent at 340 nm.

4.7.8 FRET assay to probe PDEδ binding prenylated dns-GCVLS: 500 nM or 1 µM
prenylated or non-prenylated dns-GCVLS were incubated in 1X reaction buffer (50 mM
HEPPSO-NaOH, pH7.8, 5 mM TCEP) at RT for 20 mins under foil before adding 3 or 5 µM
PDEδ in a 96-well plate (Corning). Spectral scans were obtained post-overnight incubation in the
BioTek H1 Synergy plate reader (ex 282 nm, em 320-550 nm). Relative fluorescence units were
plotted against emission wavelengths. Controls consisted of a non-prenylated dns-GCVLS and
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PDEδ only negative controls.

4.7.9 Generation of pCDNA-eGFP-GRK1ct18 mammalian vectors: The vector plasmids
encoding for eGFP-GRK1ct18-C/Axx(x) were prepared by PCR using the XOP-eGFPGRK1ct18 vector obtained for the Calvert Lab, Upstate Medical University serving as a
template. 5’ primer containing the BamHI restriction site and 3’ primers containing -CVLS, AVLS, -CVL, and -AVL C-terminal sequences and NotI restriction site were designed (IDT,
Inc.). The PCR reaction (50 μL) consisted of 1x Standard OneTaq buffer, 10 mM dNTPs, 125 ng
reverse and forward primers each, 10 ng template plasmid, and OneTaq DNA polymerase (0.25
µL, 5U/µL). The PCR reactions were performed in a BioRad Mycycler thermal cycler using the
following program: Initial denaturation (94°C, 1 min); thirty cycles of denaturation (94°C, 30
sec), annealing (56°C, 1 min), and extension (68°C, 2 min); final extension (68°C, 5 min); and a
final hold (10°C, ∞). PCR products were purified using BIO Basic Inc. EZ-10 Spin Column PCR
purification Kit following the manufacturer’s protocol. Following digestion by BamHI and NotI,
the eGFP-GRK1ct18-C/Axx(x) inserts were ligated into the pCDNA plasmid using the Quick
Ligase kit (NEB), following the manufacturer’s instructions. Insert ligation was verified by
analytical restriction digest and gene sequencing (Genewiz).

4.7.10 Transfection and FLIM-FRET analysis of various eGFP-GRK1ct18 and eGFP-KRas
fusion proteins in HEK293 cells: HEK293 cells were maintained in 75 mL vented tissue culture
flasks (Celltreat) and were split once reaching 80% confluency. Cells were grown in complete
DMEM (DMEM supplemented with 10% fetal bovine serum (FBS) and 1 % (v/v) penicillin207

streptomycin (MediaTech) in 5% CO2 at 37°C. For co-expression of the eGFP-GRK1ct18 and
eGFP-KRas constructs and mCherry-PDEδ, 2 x 105 cells were placed in 2 mL of complete
DMEM per well of a tissue culture treated 6-well plate (Corning), each containing a 25 mm glass
coverslip #1.5 thickness (Celltreat). The cells were incubated 24-28 hours prior to transfection.
The DNA-transfection reagent complex was prepared by incubating 4 µg each of eGFPGRK1ct18 and eGFP-KRas (provided by Casey Lab, Duke University) and mCherry-PDEδ and
6 µL of the Turbofect transfection reagent (Thermo Scientific) in a total volume of 500 µL
supplement free DMEM for 20 minutes at room temperature. The cells were then transfected
with the prepared DNA-transfection reagent complex by drop wise addition into the wells of a 6well tissue culture plate. Following transfection for 24-28 h, glass coverslips were prepared for
imaging by washing with 1X PBS and placing them in an imaging chamber. FLIM-FRET
microscopy and analysis was performed by Peter Calvert (Center for Vision Research, Upstate
Medical University).
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Chapter 5: Conclusions and Future Work
5.1 Summary
Prenylation is a form of post-translational lipidation that is involved in cell signaling and
growth, influencing protein structure, localization, and function.1-5 For the past 30 years, the
four-amino-acid, C-terminal “CaaX” box motif has served as the defining paradigm for
prenyltransferase substrate recognition, as first identified through study of yeast mating factors
and lamins.1, 3-11 Consequently, studies of prenylation targets for FTase and GGTase-I have
mainly focused on amino acid selectivity within the CaaX motif. Numerous biochemical,
crystallographic, and computational works have led to the development of general rules for
selectivity based on the four amino acids and have greatly enhanced our understanding of these
prenyltransferase substrate targets.7, 12-26
Recently, yeast genetic screening utilizing the Hsp40 co-chaperone Ydj1p revealed that
yeast FTase could efficiently prenylated shorter Cxx sequences.27 This finding motivated
fluorescent-based biochemical and cell-based studies at both the short peptide and full-length
protein level. These determined that mammalian FTase can recognize and prenylate a three
amino acid recognition motif in an in vitro context, as described. In addition, the recent finding
that FTase can target longer C(x)3X sequences has expanded the potential substrate scope for this
enzyme.28 A search of the human genome (as of May 2020) using Prosite results in 1074 proteins
ending in a Cxx sequence with the potential to undergo prenylation, expanding the number of
proteins that can be explored not only in humans but other organisms such as yeast. With
previous studies and current computational prediction models restricted to four amino acids,
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innovative approaches to determining the role of this novel selectivity will need to be addressed
for such a large scale of potential prenylated proteins.
This finding suggests a broader impact for prenylation in a biological context and raises
many new questions regarding the role of these Cxx proteins. With FTase and GGTase-I
showing a stark contrast in their acceptance of these shorter sequences, it is sensible to question
why these “sister” enzymes exhibit such a discrepancy in their flexibility for substrates. It is also
important to question how FTase recognizes these shorter sequences, and to determine the
biological role of potential Cxx proteins with both FPP and GGPP prenyl donors. Lastly, the
work herein failed to capture any membrane localization behavior of potentially prenylated Cxx
sequences in cells. This result suggests the potential for a shunt pathway in mammals, as seen
with yeast, which would define a new cytosolic role for prenylation in mammalian systems.29
The FLIM-FRET based system discussed in this work may prove useful in studying
lipidation for these new Cxx sequences in cells. The ability of FLIM-FRET to provide
quantitative information concerning potentially prenylated Cxx sequences as binding partners for
PDE gives an opportunity to identify endogenous Cxx substrates and explore the
aforementioned potential cytosolic function for prenylated Cxx substrates. However, this system
requires further refinement as our studies to date have not provided evidence for binding of
unprocessed prenylated substrates.
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5.2 Future directions
5.2.1 Investigation of FTase vs. GGTase-I in Cxx substrate selectivity
One of the most surprising findings, after determining the ability of FTase to prenylate
Cxx sequences using either FPP or GGPP prenyl donors, is the inability of GGTase-I to accept
any of the sequences tested.27 These two enzymes recognize the same classic CaaX motif with
variations in the amino acids they accept and the type of isoprenoid group they select to attach to
their respective substrates.3, 30, 31 FTase and GGTase-I exhibit distinct amino acid preference in
the “X” position of the CaaX prenylation motif with FTase accepting X = M, Q, S, T, and A and
GGTase-I most efficiently prenylating sequences of X = I or L.1 These closely related enzymes
have the ability to cross-talk in cells, with one enzyme rescuing prenylation of certain sequences
when the other is inhibited.32 For example, KRas has been shown to be geranylgeranylated in the
presence of FTase inhibitors. Despite the overlapping substrate selectivity of these two enzymes,
not a single Cxx sequence tested was found to be accepted by GGTase-I.
With the aim of understanding the difference between the enzymes, one of the next steps
is to determine the crystal structures of FTase interacting with Cxx motifs using both prenyl
donors. The ability to prenylate these short sequences with both prenyl donors suggests a
flexibility within the FTase active site not currently predicted through computational studies, and
also not present in GGTase-I. Understanding the contact points and spacing of amino acids
within the FTase binding site will provide valuable insight into why GGTase-I is much stricter in
its substrate selectivity and moreover, how FTase is able to incorporate both prenyl groups on
Cxx substrate targets.
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5.2.2 Utilizing metabolic labeling to investigate prenylation of Cxx sequences in cells
One approach not yet utilized in this work for investigating prenylation of Cxx sequences
inside cells is metabolic labeling. To provide definitive evidence for the prenylation of shortened
sequences within human cells, the protein can be enriched through metabolic labeling with an
alkyne-modified FPP analogue allowing subsequent conjugation with an affinity handle.33 This
approach was successfully employed in confirming the prenylation of a reporter protein bearing
a longer C(x)3X sequence.28
In this approach, following transfection with a reporter protein bearing the sequence of
interest, cells are incubated with the alkyne-modified FPP analogue for alkyne functionalization
of the expressed protein. Subsequent derivatization with TAMRA-N3 followed by in-gel imaging
of TAMRA fluorescence allows for the visualization of the potentially prenylated Cxx target.28,
33

Such an approach could prove fruitful in providing evidence for prenylation of non-canonical

Cxx sequences inside cells.

5.2.3 Identification of endogenous Cxx proteins and the potential of a human shunt
pathway
In light of the results presented in this work, this newly discovered activity of noncanonical Cxx sequences nearly doubles the number of proteins that can be potentially
prenylated, even after rejecting sequences containing other cysteines within the motif. Through a
Prosite search it was found that 1074 human proteins (accessed May 2020) follow a C-terminal
Cxx sequence, with 847 of those sequences containing no other cysteine other than that required
for prenylation (see Table 2.1). This is comparable to the 1208 potential Cxxx proteins in the
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human proteome. These numbers underscore the importance of exploring and characterizing
more Cxx proteins, to determine their prenylation state within the cell.
The Cxx sequences identified for analysis in this work from yeast used a screening tool
that discriminates for proteins that are prenylated but not proteolyzed. This raises the question as
to whether all Cxx sequences that serve as prenyltransferase substrates are unable or resistant to
undergoing subsequent processing. This possibility makes identifying prenylated Cxx sequences
through fluorescence microscopy difficult, as membrane localization can no longer be used as a
proxy for prenylation. Despite this challenge, implications of this newly discovered Cxx
sequence reactivity call for reassessing the role prenyl groups play beyond serving as a
membranous anchor, with the possible existence and role of a “shunt pathway” in mammalian
cells.29
An ultimate goal in examining human Cxx proteins is to identify one such protein that
undergoes endogenous prenylation. Due to the high number of potential proteins to test, this
objective presents a “needle in the haystack” obstacle. However, while there are 1074 human
proteins with a C-terminal Cxx sequence, the number of proteins with a unique Cxx sequence is
400, 85 of which have been tested in this work. While screening peptides via HPLC analysis can
be performed quickly, production of the peptides required to test all 315 remaining sequences
may prove to be a costly and time-consuming endeavor. This is even more true in testing
potential Cxx prenylation substrates in a biological context; steps of cloning, transfection,
imaging, and metabolic labeling of the proteins whose sequences produce a product peak on
HPLC is even more of a financial and time-insensitive effort than the initial screening.
One reasonable approach to tackle the number of potential sequences is to employ a tactic
similar to that used in this work to select peptides for an initial screening (see section 2.3). The
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requirements used to select potential substrates could be further refined to exclude proteins with
a C-terminal Cxx motif that results upon gene splicing. Protein splice variants are produced
during regulation of gene expression and allow for a single gene to produce several functional
proteins. By excluding such proteins, the complexity of proteins being examined can be reduced.
Moving towards yeast (and eventually other species), its smaller proteome makes for an
easier target to finding potentially prenylated Cxx proteins. Future work could also include
pathogenic organisms that employ either endogenous or host-mediated farnesylation, such as
Plasmodium falciparum, Candida albicans, and Legionella pneumophila, all of which have a
significantly lower number of potential targets.20, 33-39
Overall, this work lays the foundation to examine Cxx sequence prenylation by yeast and
mammalian FTase in biological systems. Moreover, we provide the first reported example of
wild type FTase catalyzing peptide geranylgeranylation with comparable efficiency to
farnesylation of the same sequences. This work expands both the peptide and prenyl donor
substrate pools for FTase, which further highlights the truly remarkable degree of substrate
flexibility exhibited by this enzyme. It supports further investigation of proteins terminating in
Cxx sequences in cellular systems to determine their prenylation status and impact of such
modification on the biological activities of Cxx proteins.
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